{
  "originUrl": "https://www.astrazeneca.com",
  "aborted": false,
  "lastCrawled": "https://www.astrazeneca.com/",
  "urls": [
    {
      "url": "https://www.astrazeneca.com/",
      "source": "SITEMAPS",
      "targetPath": "/",
      "id": "ecda591b69347eb7a8a22676c8ef671a2a80646c"
    },
    {
      "url": "https://www.astrazeneca.com/astrazeneca-exchange.html",
      "source": "SITEMAPS",
      "targetPath": "/astrazeneca-exchange",
      "id": "31ef1b2f96cec4c9eba7a188f2e86d5072275270"
    },
    {
      "url": "https://www.astrazeneca.com/az-suppliers/az-coupa-supplier.html",
      "source": "SITEMAPS",
      "targetPath": "/az-suppliers/az-coupa-supplier",
      "id": "3ead70c0c95ff959e114278689c39ca6855a0cf2"
    },
    {
      "url": "https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/brazil-suppliers.html",
      "source": "SITEMAPS",
      "targetPath": "/az-suppliers/az-coupa-supplier/brazil-suppliers",
      "id": "4633a81a5131edb665f2750b29e0f1d242bcdfd3"
    },
    {
      "url": "https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/CSP.html",
      "source": "SITEMAPS",
      "targetPath": "/az-suppliers/az-coupa-supplier/csp",
      "id": "854c183ac58ae40dd866a625dc940c4233951f4c"
    },
    {
      "url": "https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/faq.html",
      "source": "SITEMAPS",
      "targetPath": "/az-suppliers/az-coupa-supplier/faq",
      "id": "9cb84bedb5f7f08acb4e4b6483163e64d80a3d06"
    },
    {
      "url": "https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/faq/coupa-supplier-portal.html",
      "source": "SITEMAPS",
      "targetPath": "/az-suppliers/az-coupa-supplier/faq/coupa-supplier-portal",
      "id": "39a7a38c3bbd5437f1ccd405f165a3eb35dd9d71"
    },
    {
      "url": "https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/faq/CSP-linked.html",
      "source": "SITEMAPS",
      "targetPath": "/az-suppliers/az-coupa-supplier/faq/csp-linked",
      "id": "758da2ada74e200e6223ca13f42cf3abedf1e3cd"
    },
    {
      "url": "https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/faq/CSP.html",
      "source": "SITEMAPS",
      "targetPath": "/az-suppliers/az-coupa-supplier/faq/csp",
      "id": "e135fcaf84169608cad6f61441b72d9586ad1a34"
    },
    {
      "url": "https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/faq/cXML-invoices.html",
      "source": "SITEMAPS",
      "targetPath": "/az-suppliers/az-coupa-supplier/faq/cxml-invoices",
      "id": "70cf3362c34adf04d63986e73d755c78d2a37326"
    },
    {
      "url": "https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/faq/SAN.html",
      "source": "SITEMAPS",
      "targetPath": "/az-suppliers/az-coupa-supplier/faq/san",
      "id": "2668d0514c90ffc63191725a7390fbe49861fa02"
    },
    {
      "url": "https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/faq/Supplier-Actionable-Notification.html",
      "source": "SITEMAPS",
      "targetPath": "/az-suppliers/az-coupa-supplier/faq/supplier-actionable-notification",
      "id": "21a939aae4788da274ca0389a59a91dd707ac365"
    },
    {
      "url": "https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/french-suppliers.html",
      "source": "SITEMAPS",
      "targetPath": "/az-suppliers/az-coupa-supplier/french-suppliers",
      "id": "989610efeb6c3f7fd52497ef293fbc8b9684dfb1"
    },
    {
      "url": "https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/german-suppliers.html",
      "source": "SITEMAPS",
      "targetPath": "/az-suppliers/az-coupa-supplier/german-suppliers",
      "id": "a626a53e669fad26205d3028517d30bf8530ad67"
    },
    {
      "url": "https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/japanese-suppliers.html",
      "source": "SITEMAPS",
      "targetPath": "/az-suppliers/az-coupa-supplier/japanese-suppliers",
      "id": "9ba41056902fad3198db2b04711be651d4f797c5"
    },
    {
      "url": "https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/latest-update.html",
      "source": "SITEMAPS",
      "targetPath": "/az-suppliers/az-coupa-supplier/latest-update",
      "id": "f3a8e77830b71c2297944a6e847792b1060ec1b1"
    },
    {
      "url": "https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/mexican-suppliers.html",
      "source": "SITEMAPS",
      "targetPath": "/az-suppliers/az-coupa-supplier/mexican-suppliers",
      "id": "5c3afd777db36b32d20c4b22b02495256a9f15a3"
    },
    {
      "url": "https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/selected-suppliers-page.html",
      "source": "SITEMAPS",
      "targetPath": "/az-suppliers/az-coupa-supplier/selected-suppliers-page",
      "id": "25dbefeb7754e1d5f8754f4a0ea6fb18131e40cd"
    },
    {
      "url": "https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/spanish-suppliers.html",
      "source": "SITEMAPS",
      "targetPath": "/az-suppliers/az-coupa-supplier/spanish-suppliers",
      "id": "04568bc00b8628fa582da0ffc3a3d0614db3fa96"
    },
    {
      "url": "https://www.astrazeneca.com/az-suppliers/az-coupa-supplier/sweden-suppliers.html",
      "source": "SITEMAPS",
      "targetPath": "/az-suppliers/az-coupa-supplier/sweden-suppliers",
      "id": "764a0541aec05a51eebeb1b2241cdadffb8ce639"
    },
    {
      "url": "https://www.astrazeneca.com/az-suppliers/supplier-contact-information.html",
      "source": "SITEMAPS",
      "targetPath": "/az-suppliers/supplier-contact-information",
      "id": "dbb14d23ae12ac40612761d2c6bef72eceb52aa1"
    },
    {
      "url": "https://www.astrazeneca.com/government-contract-t-cs.html",
      "source": "SITEMAPS",
      "targetPath": "/government-contract-t-cs",
      "id": "aaa404414debc656b470e7b38212cdc457aba6ff"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre",
      "id": "024dc5b113f46af863f9dcf3e8afcbe78cdb7723"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases",
      "id": "01a858e31b0acf8293e431cec7c2430cf654e5a2"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2017.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2017",
      "id": "704628fce61802d979da74b5b45539479b627bd6"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-pieris-pharmaceuticals-collaborate-to-develop-and-commercialise-anticalin-based-inhaled-treatments-for-respiratory-diseases-03052017.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2017/astrazeneca-and-pieris-pharmaceuticals-collaborate-to-develop-and-commercialise-anticalin-based-inhaled-treatments-for-respiratory-diseases-03052017",
      "id": "157c8d9f406a9336168e4659e291e536a9d74f39"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-expands-1st-line-lung-cancer-immuno-oncology-programme-opportunities-17012017.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2017/astrazeneca-expands-1st-line-lung-cancer-immuno-oncology-programme-opportunities-17012017",
      "id": "867004883e8e9bda715ccf03bb8a6bd2f55d3300"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2017/full-year-and-q4-2016-results-02022017.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2017/full-year-and-q4-2016-results-02022017",
      "id": "a603073728f6db174645723301e7f19a81bc7434"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2017/Siliq-brodalumab-approved-by-the-US-FDA-for-adult-patients-with-moderate-to-severe-plaque-psoriasis-160220170.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2017/siliq-brodalumab-approved-by-the-us-fda-for-adult-patients-with-moderate-to-severe-plaque-psoriasis-160220170",
      "id": "b62b80271b53bda7e5b6fffba8986d5a006154dc"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2017/symbicort-granted-paediatric-exclusivity-in-the-us-26012017.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2017/symbicort-granted-paediatric-exclusivity-in-the-us-26012017",
      "id": "3ac7383d696656e93d772d7b3ae4b660472d9c98"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018",
      "id": "f21720ef1cfad782a153f8da4e5b4163c2884ee0"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/1st-line-tagrisso-demonstrates-sustained-benefit-post-progression-in-patients-with-egfr-mutated-non-small-cell-lung-cancer-13042018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/1st-line-tagrisso-demonstrates-sustained-benefit-post-progression-in-patients-with-egfr-mutated-non-small-cell-lung-cancer-13042018",
      "id": "cb15803b7f32c7513c1483368f1fa02417166b0b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/agreement-with-grunenthal-for-rights-to-nexium-in-europe-and-vimovo-worldwide-ex-us-30102018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/agreement-with-grunenthal-for-rights-to-nexium-in-europe-and-vimovo-worldwide-ex-us-30102018",
      "id": "b1ec6690bf36c52abc342885cb4d7056ea5c80e2"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-aims-to-advance-clinical-practice-in-cv-risk-management-with-new-data-at-acc-2018-05032018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/astrazeneca-aims-to-advance-clinical-practice-in-cv-risk-management-with-new-data-at-acc-2018-05032018",
      "id": "7904c3915b84eb91e9f58a2eed8e8371586b7ba1"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-and-cancer-research-uk-launch-functional-genomics-centre-to-accelerate-the-discovery-of-new-medicines-10122018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/astrazeneca-and-cancer-research-uk-launch-functional-genomics-centre-to-accelerate-the-discovery-of-new-medicines-10122018",
      "id": "274f88171a4a9e3b8ddc30d34a6becb4ab901bd7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-and-luye-pharma-group-enter-agreement-for-rights-to-seroquel-and-seroquel-xr-in-the-uk-china-and-other-international-markets.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/astrazeneca-and-luye-pharma-group-enter-agreement-for-rights-to-seroquel-and-seroquel-xr-in-the-uk-china-and-other-international-markets",
      "id": "13ae20d6040c3da14bad52a433335da7a1c3c7e7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-heads-to-2018-asco-annual-meeting-with-its-diversified-oncology-portfolio-and-next-generation-pipeline24052018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/astrazeneca-heads-to-2018-asco-annual-meeting-with-its-diversified-oncology-portfolio-and-next-generation-pipeline24052018",
      "id": "9fb6c394531436eaeb3992ec6525154d19ce8f2f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-is-advancing-clinical-practice-in-respiratory-medicine-with-new-data-at-the-american-thoracic-society-2018-international-congress.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/astrazeneca-is-advancing-clinical-practice-in-respiratory-medicine-with-new-data-at-the-american-thoracic-society-2018-international-congress",
      "id": "70b4e69aeb9ff3605a5bf5862b293046477043ef"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-is-advancing-understanding-of-cardio-renal-metabolic-interconnectivity-with-new-evidence-at-esc-2018-20082018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/astrazeneca-is-advancing-understanding-of-cardio-renal-metabolic-interconnectivity-with-new-evidence-at-esc-2018-20082018",
      "id": "2f443c92b56df04dfc9946a2ac87edbb5d08a0e4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-listed-as-one-of-the-worlds-top-100-most-sustainable-companies-and-recognised-for-its-three-fold-increase-in-renewable-energy-usage-23012018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/astrazeneca-listed-as-one-of-the-worlds-top-100-most-sustainable-companies-and-recognised-for-its-three-fold-increase-in-renewable-energy-usage-23012018",
      "id": "b9478f7bfbbae37b981884c05c847ea1be6093a7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-presents-advances-in-improving-treatment-options-for-ovarian-and-lung-cancer-patients-at-esmo-2018-09102018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/astrazeneca-presents-advances-in-improving-treatment-options-for-ovarian-and-lung-cancer-patients-at-esmo-2018-09102018",
      "id": "f8f45311f87ba46d0f4e6190157475cfec4d9a69"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-presents-clinical-research-advances-for-blood-cancer-patients-at-2018-american-society-of-hematology-annual-meeting-27112018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/astrazeneca-presents-clinical-research-advances-for-blood-cancer-patients-at-2018-american-society-of-hematology-annual-meeting-27112018",
      "id": "ee8577fca7d549c04389f7187182a793fb461e60"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-presents-further-data-showing-the-interconnectivity-between-cardiovascular-and-renal-risks-in-diabetes-at-easd-2018-20092018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/astrazeneca-presents-further-data-showing-the-interconnectivity-between-cardiovascular-and-renal-risks-in-diabetes-at-easd-2018-20092018",
      "id": "1c742203cf1f2a136891a8b7305e2f16a699ee18"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-provides-update-on-aeristo-phase-iiib-trial-for-bevespi-aerosphere-in-chronic-obstructive-pulmonary-disease23082018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/astrazeneca-provides-update-on-aeristo-phase-iiib-trial-for-bevespi-aerosphere-in-chronic-obstructive-pulmonary-disease23082018",
      "id": "1af31ac87cd57054569986d717460814eb814334"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-provides-update-on-galathea-phase-iii-trial-for-fasenra-in-chronic-obstructive-pulmonary-disease-11052018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/astrazeneca-provides-update-on-galathea-phase-iii-trial-for-fasenra-in-chronic-obstructive-pulmonary-disease-11052018",
      "id": "94f3d6ba88f85fa29013514d5cf5954c653755dc"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-provides-update-on-mystic-trial-timeline-12032018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/astrazeneca-provides-update-on-mystic-trial-timeline-12032018",
      "id": "ea0da1a13eab0dda2250f1b1bce6290047dc43de"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-provides-update-on-the-phase-iii-mystic-trial-of-imfinzi-and-tremelimumab-in-stage-iv-non-small-cell-lung-cancer16112018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/astrazeneca-provides-update-on-the-phase-iii-mystic-trial-of-imfinzi-and-tremelimumab-in-stage-iv-non-small-cell-lung-cancer16112018",
      "id": "d77434ac76c86c5e1c3e8a2477f191422fb8b97a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-receives-eu-approval-of-fasenra-for-severe-eosinophilic-asthma-10012018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/astrazeneca-receives-eu-approval-of-fasenra-for-severe-eosinophilic-asthma-10012018",
      "id": "cc58f10f5a003922184aceb4a4d3eaad1668bdad"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-reports-results-from-the-arctic-trial-in-third-line-non-small-cell-lung-cancer-24042018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/astrazeneca-reports-results-from-the-arctic-trial-in-third-line-non-small-cell-lung-cancer-24042018",
      "id": "6c7918e4d98472c038848af2112cc908ff459dab"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-reports-top-line-phase-iii-kronos-trial-results-for-pt010-triple-combination-therapy-in-chronic-obstructive-pulmonary-disease-26102018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/astrazeneca-reports-top-line-phase-iii-kronos-trial-results-for-pt010-triple-combination-therapy-in-chronic-obstructive-pulmonary-disease-26102018",
      "id": "090e8857d2a8a20ce2a6b1ce2935fbe37ee82562"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-strengthens-and-expands-oncology-development-and-commercialisation-collaboration-with-innate-pharma23102018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/astrazeneca-strengthens-and-expands-oncology-development-and-commercialisation-collaboration-with-innate-pharma23102018",
      "id": "e47f441965e2076ca6bc29439bf3e7a4f9e51e4e"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-to-divest-us-synagis-rights-to-sobi131120180.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/astrazeneca-to-divest-us-synagis-rights-to-sobi131120180",
      "id": "5bfbdca9835fab5454446f08a98824315772d2f6"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-to-present-fasenra-long-term-safety-and-efficacy-data-at-european-respiratory-society-international-congress-2018-13092018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/astrazeneca-to-present-fasenra-long-term-safety-and-efficacy-data-at-european-respiratory-society-international-congress-2018-13092018",
      "id": "a7c684931b08e0e58107d6b887f757f9197f1ec4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-to-present-new-data-demonstrating-breadth-of-research-portfolio-in-renal-disease-at-asn-kidney-week-22102018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/astrazeneca-to-present-new-data-demonstrating-breadth-of-research-portfolio-in-renal-disease-at-asn-kidney-week-22102018",
      "id": "b4d513569fedd6fa716ee59d56aca4ddf72d2b84"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-to-share-latest-data-from-an-industry-leading-portfolio-that-aims-to-advance-clinical-understanding-of-diabetes-and-cv-risk-management-at-ada-2018-19062018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/astrazeneca-to-share-latest-data-from-an-industry-leading-portfolio-that-aims-to-advance-clinical-understanding-of-diabetes-and-cv-risk-management-at-ada-2018-19062018",
      "id": "516984d5bd43b59f7196bb1a80c0586fe2a6585c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/astrazenecas-early-and-late-stage-oncology-portfolio-showcased-at-aacr-annual-meeting-and-elcc-04042018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/astrazenecas-early-and-late-stage-oncology-portfolio-showcased-at-aacr-annual-meeting-and-elcc-04042018",
      "id": "5d337d3e10d17d8b22dede998879068c94e52eea"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/Atacand-to-be-divested-to-Cheplapharm-in-Europe24072018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/atacand-to-be-divested-to-cheplapharm-in-europe24072018",
      "id": "5d4676bd57ec7d8e983de121e66d02706f244eec"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/bevespi-aerosphere-approved-in-the-eu-for-chronic-obstructive-pulmonary-disease-20122018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/bevespi-aerosphere-approved-in-the-eu-for-chronic-obstructive-pulmonary-disease-20122018",
      "id": "abf5476f73fc2648a0780a4f8d62dcd66497ea54"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/brilinta-significantly-reduces-cv-events-and-coronary-death-beyond-one-year-in-heart-attack-survivors-with-multi-vessel-disease-07022018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/brilinta-significantly-reduces-cv-events-and-coronary-death-beyond-one-year-in-heart-attack-survivors-with-multi-vessel-disease-07022018",
      "id": "a703a47573601611a351dc57ea3ccfbe0c3568f4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/bydureon-receives-positive-eu-chmp-opinion-for-exscel-cardiovascular-outcomes-data-25092018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/bydureon-receives-positive-eu-chmp-opinion-for-exscel-cardiovascular-outcomes-data-25092018",
      "id": "48a5d69d28e5af534564dfc337ad69aa6af4fbf3"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/bydureon-receives-positive-eu-chmp-opinion-for-new-bcise-device-for-patients-with-type-2-diabetes-29062018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/bydureon-receives-positive-eu-chmp-opinion-for-new-bcise-device-for-patients-with-type-2-diabetes-29062018",
      "id": "ff61c7172b2fe0d9f887d29df5511b84a681ce13"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/chmp-issues-a-positive-opinion-for-bevespi-aerosphere-for-the-treatment-of-chronic-obstructive-pulmonary-disease-19102018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/chmp-issues-a-positive-opinion-for-bevespi-aerosphere-for-the-treatment-of-chronic-obstructive-pulmonary-disease-19102018",
      "id": "21060024a43adfc793269453a3a1b9becccaaae4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/divestment-of-rights-to-alvescoomnaris-and-zetonna-to-covis-pharma06112018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/divestment-of-rights-to-alvescoomnaris-and-zetonna-to-covis-pharma06112018",
      "id": "a15730008cedfb8c9969368a42d89e01f27b298c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/european-commission-approves-imfinzi-for-locally-advanced-unresectable-nsclc-24092018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/european-commission-approves-imfinzi-for-locally-advanced-unresectable-nsclc-24092018",
      "id": "37fa26a00b1accaa2bc1fb35dcb53c9a6d4fd2c9"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/european-commission-approves-new-easy-to-use-once-weekly-bydureon-bcise-device-for-patients-with-type-2-diabetes30082018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/european-commission-approves-new-easy-to-use-once-weekly-bydureon-bcise-device-for-patients-with-type-2-diabetes30082018",
      "id": "bfef485afc4e77115e746667d5a4b99047e2ec19"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/farxiga-achieved-a-positive-result-in-the-phase-iii-declare-timi-58-trial-a-large-cardiovascular-outcomes-trial-in-17000-patients-with-type-2-diabetes-24092018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/farxiga-achieved-a-positive-result-in-the-phase-iii-declare-timi-58-trial-a-large-cardiovascular-outcomes-trial-in-17000-patients-with-type-2-diabetes-24092018",
      "id": "665881fb6df5064f38bf0ecdac41cf65797def2c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/farxiga-significantly-reduced-hospitalisation-for-heart-failure-or-cv-death-in-a-broad-patient-population-with-type-2-diabetes-in-the-landmark-declare-timi-58-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/farxiga-significantly-reduced-hospitalisation-for-heart-failure-or-cv-death-in-a-broad-patient-population-with-type-2-diabetes-in-the-landmark-declare-timi-58-trial",
      "id": "06c63ce176eb041ee26989051e36dfaf171c72ab"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/fasenra-recieves-approval-in-japan-19012018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/fasenra-recieves-approval-in-japan-19012018",
      "id": "6e3c3c1a89a37f4141a99b5a54719eb4cd939774"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/fasenra-shows-consistent-safety-and-sustained-efficacy-in-long-term-phase-iii-bora-trial-in-severe-eosinophilic-asthma-18092018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/fasenra-shows-consistent-safety-and-sustained-efficacy-in-long-term-phase-iii-bora-trial-in-severe-eosinophilic-asthma-18092018",
      "id": "4e094300d0bd2c0fab90cda3b59d0d16d004bb3c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/full-year-2017-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/full-year-2017-results",
      "id": "d88e3b9a25a2f1a6a762335f64a8bc93954f66d8"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/h1-2018-results-25072018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/h1-2018-results-25072018",
      "id": "152ad7fc66011a17b10a95bc749c98e67019fb7d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/imfinzi-approved-in-japan-for-unresectable-stage-iii-non-small-cell-lung-cancer-02072018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/imfinzi-approved-in-japan-for-unresectable-stage-iii-non-small-cell-lung-cancer-02072018",
      "id": "5182ac267337fd6031cf5d9687324d66410530db"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/imfinzi-is-the-first-immunotherapy-to-demonstrate-significant-overall-survival-benefit-in-unresectable-stage-iii-lung-cancer25092018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/imfinzi-is-the-first-immunotherapy-to-demonstrate-significant-overall-survival-benefit-in-unresectable-stage-iii-lung-cancer25092018",
      "id": "1f024db6b0a4ac04cc6512c9daaef37bd7bf8cf1"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/imfinzi-receives-positive-eu-chmp-opinion-for-locally-advanced-unresectable-non-small-cell-lung-cancer-27072018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/imfinzi-receives-positive-eu-chmp-opinion-for-locally-advanced-unresectable-non-small-cell-lung-cancer-27072018",
      "id": "62e85755b9f318b5c9de4cbf0ff0d82f2518bbc7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/imfinzi-significantly-improves-overall-survival-in-the-phase-iii-pacific-trial-for-unresectable-stage-iii-non-small-cell-lung-cancer-25052018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/imfinzi-significantly-improves-overall-survival-in-the-phase-iii-pacific-trial-for-unresectable-stage-iii-non-small-cell-lung-cancer-25052018",
      "id": "acfdfa086f199d27df983ca1a71423f0c364bd29"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/lokelma-approved-in-the-eu-for-the-treatment-of-adults-with-hyperkalaemia-22032018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/lokelma-approved-in-the-eu-for-the-treatment-of-adults-with-hyperkalaemia-22032018",
      "id": "e16d0ad58ac4e29bdcf7ef49b1597cc7676249d2"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/lokelma-approved-in-the-us-for-the-treatment-of-adults-with-hyperkalaemia-21052018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/lokelma-approved-in-the-us-for-the-treatment-of-adults-with-hyperkalaemia-21052018",
      "id": "68d3b04cd43365a7495f5f10ab918478da00624f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-approved-by-us-fda-for-1st-line-maintenance-therapy-in-brca-mutated-advanced-ovarian-cancer19122018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/lynparza-approved-by-us-fda-for-1st-line-maintenance-therapy-in-brca-mutated-advanced-ovarian-cancer19122018",
      "id": "bb7c3b9fe6e832605cc511ab8063f50de9e99bb5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-approved-by-us-fda-in-germline-brca-mutated-metastatic-breast-cancer-12012018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/lynparza-approved-by-us-fda-in-germline-brca-mutated-metastatic-breast-cancer-12012018",
      "id": "43f499da293b82ba600f14f53aa2a6e3baf5c3c8"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-approved-in-japan-for-brca-mutated-metastatic-breast-cancer-02072018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/lynparza-approved-in-japan-for-brca-mutated-metastatic-breast-cancer-02072018",
      "id": "9229dcc27310cbc072b92fd283b320702c80e4c1"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-in-combination-with-abiraterone-delayed-disease-progression-in-metastatic-castration-resistant-prostate-cancer-04062018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/lynparza-in-combination-with-abiraterone-delayed-disease-progression-in-metastatic-castration-resistant-prostate-cancer-04062018",
      "id": "5cf2111cbceb3d42eb87e60c86926081645cbdeb"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-meets-primary-endpoint-in-phase-iii-solo-3-trial-for-the-treatment-of-relapsed-brca-mutated-advanced-ovarian-cancer20122018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/lynparza-meets-primary-endpoint-in-phase-iii-solo-3-trial-for-the-treatment-of-relapsed-brca-mutated-advanced-ovarian-cancer20122018",
      "id": "622f72a0b0f6518242ca9c212b36b5ab9da93f8b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-receives-approval-in-japan-for-the-treatment-of-advanced-ovarian-cancer-19012018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/lynparza-receives-approval-in-japan-for-the-treatment-of-advanced-ovarian-cancer-19012018",
      "id": "38d695b5deffb24d59722a7c6f32c3bcd0b40709"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-receives-positive-eu-chmp-opinion-in-platinum-sensitive-relapsed-ovarian-cancer-23022018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/lynparza-receives-positive-eu-chmp-opinion-in-platinum-sensitive-relapsed-ovarian-cancer-23022018",
      "id": "ecc64eafbc1fdcca65f08de1b978116ea38c87a6"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-significantly-delays-disease-progression-in-phase-iii-1st-line-solo-1-trial-for-ovarian-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/lynparza-significantly-delays-disease-progression-in-phase-iii-1st-line-solo-1-trial-for-ovarian-cancer",
      "id": "96a6e6cde7757bff38a8364147ddf5510b76ccff"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/lynparza-tablets-receive-eu-approval-for-the-treatment-of-platinum-sensitive-relapsed-ovarian-cancer08052018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/lynparza-tablets-receive-eu-approval-for-the-treatment-of-platinum-sensitive-relapsed-ovarian-cancer08052018",
      "id": "15dedf729de4b1c93f4651b745a016596e347584"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/medimmune-to-create-stand-alone-company-for-early-stage-inflammation-and-autoimmunity-biologics-28022018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/medimmune-to-create-stand-alone-company-for-early-stage-inflammation-and-autoimmunity-biologics-28022018",
      "id": "5a8abe87900a5deae7ff9b005426bf6f45d80455"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/moxetumomab-pasudotox-pivotal-data-in-patients-with-previously-treated-hairy-cell-leukaemia-presented-at-the-2018-asco-meeting-04062018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/moxetumomab-pasudotox-pivotal-data-in-patients-with-previously-treated-hairy-cell-leukaemia-presented-at-the-2018-asco-meeting-04062018",
      "id": "c1903fa957d157101ee273f5b0a66908edacc757"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/new-data-from-landmark-cvd-real-study-of-patients-with-type-2-diabetes-confirms-cv-benefits-associated-with-sglt-2-inhibitors-12032018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/new-data-from-landmark-cvd-real-study-of-patients-with-type-2-diabetes-confirms-cv-benefits-associated-with-sglt-2-inhibitors-12032018",
      "id": "32185527cb9bb946bc2eea115aa102763b7f9e80"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/new-data-on-mechanisms-of-acquired-resistance-after-1st-line-tagrisso-in-nsclc-support-initiation-of-orchard-trial-to-explore-post-progression-treatment-options-19102018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/new-data-on-mechanisms-of-acquired-resistance-after-1st-line-tagrisso-in-nsclc-support-initiation-of-orchard-trial-to-explore-post-progression-treatment-options-19102018",
      "id": "f2b9d879bdb59dec5d5359b04941c57f0f395ecc"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/new-england-journal-of-medicine-publishes-two-trials-for-symbicort-as-an-anti-inflammatory-reliever-therapy-as-needed-in-mild-asthma16052018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/new-england-journal-of-medicine-publishes-two-trials-for-symbicort-as-an-anti-inflammatory-reliever-therapy-as-needed-in-mild-asthma16052018",
      "id": "d4eb9f54686c35b453166da360c7640a267b14b1"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/new-long-term-data-on-calquence-presented-at-ash-2018-03122018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/new-long-term-data-on-calquence-presented-at-ash-2018-03122018",
      "id": "2ed11886889634b19dc5b9b500458883df71d624"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/phase-iii-harmonize-global-trial-of-lokelma-confirms-efficacy-in-maintaining-normal-potassium-levels-in-asian-patients-with-hyperkalaemia-25102018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/phase-iii-harmonize-global-trial-of-lokelma-confirms-efficacy-in-maintaining-normal-potassium-levels-in-asian-patients-with-hyperkalaemia-25102018",
      "id": "e4dc66b80cb14dc52569e665e5d9daaa2e6da6d1"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/phase-iii-olympus-and-rockies-trials-for-roxadustat-met-their-primary-endpoints-in-chronic-kidney-disease-patients-with-anaemia20122018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/phase-iii-olympus-and-rockies-trials-for-roxadustat-met-their-primary-endpoints-in-chronic-kidney-disease-patients-with-anaemia20122018",
      "id": "1690dc4e07c59221a1dac459e1aed148b928e544"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/q1-2018-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/q1-2018-results",
      "id": "9a6e93e8068038961ef4f048643d1603ff765192"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/regulatory-submission-in-japan-for-forxiga-in-type-1-diabetes-21052018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/regulatory-submission-in-japan-for-forxiga-in-type-1-diabetes-21052018",
      "id": "c4d11336b247fc6520eba5dc5f8f951580a56990"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/roxadustat-approved-in-china-for-the-treatment-of-anaemia-in-chronic-kidney-disease-patients-on-dialysis18122018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/roxadustat-approved-in-china-for-the-treatment-of-anaemia-in-chronic-kidney-disease-patients-on-dialysis18122018",
      "id": "f8745304d7d2a4d2c22492c675e627225bd52656"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/selumetinib-granted-orphan-designation-in-europe-for-neurofibromatosis-type-1-03082018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/selumetinib-granted-orphan-designation-in-europe-for-neurofibromatosis-type-1-03082018",
      "id": "87759165e7e835f65d6c3c874e30758d8a28056f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/selumetinib-granted-orphan-drug-designation-by-the-us-fda-for-neurofibromatosis-type-1-15022018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/selumetinib-granted-orphan-drug-designation-by-the-us-fda-for-neurofibromatosis-type-1-15022018",
      "id": "e16fdd15cf78152c2f80d1db80bddc8379c7015b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/solo-1-phase-III-trial-demonstrates-lynparza-maintenance-therapy-cut-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovarian-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/solo-1-phase-iii-trial-demonstrates-lynparza-maintenance-therapy-cut-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovarian-cancer",
      "id": "4674472a2ea7e2cd93d07b573510e40f0f0d33a2"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/tagrisso-approved-in-japan-for-1st-line-treatment-of-egfr-mutated-non-small-cell-lung-cancer-21082018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/tagrisso-approved-in-japan-for-1st-line-treatment-of-egfr-mutated-non-small-cell-lung-cancer-21082018",
      "id": "afd55df6896a6aca5560b3ff90c376ddb9187a72"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/tagrisso-receives-positive-eu-chmp-opinion-for-1st-line-treatment-of-egfr-mutated-non-small-cell-lung-cancer27042018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/tagrisso-receives-positive-eu-chmp-opinion-for-1st-line-treatment-of-egfr-mutated-non-small-cell-lung-cancer27042018",
      "id": "9a042ffc801a14a92454cae337bcb770dd0506e1"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/tezepelumab-granted-breakthrough-therapy-designation-by-us-fda-07092018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/tezepelumab-granted-breakthrough-therapy-designation-by-us-fda-07092018",
      "id": "8c1242ff996ad5ddfd164b3c8a44e120d2ffb657"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/the-eu-approves-tagrisso-for-1st-line-treatment-of-egfr-mutated-non-small-cell-lung-cancer-08062018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/the-eu-approves-tagrisso-for-1st-line-treatment-of-egfr-mutated-non-small-cell-lung-cancer-08062018",
      "id": "a503ab26c400b6b3252f1bfc855d3e8b8733588d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/the-european-medicines-agency-accepts-regulatory-submission-for-forxiga-in-adults-with-type-1-diabetes-05032018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/the-european-medicines-agency-accepts-regulatory-submission-for-forxiga-in-adults-with-type-1-diabetes-05032018",
      "id": "ad7c188d8c75ce75aa1bd677fc599cf0d3a3b284"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-in-brca-mutated-her2-negative-metastatic-breast-cancer-03042018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/the-european-medicines-agency-accepts-regulatory-submission-for-lynparza-in-brca-mutated-her2-negative-metastatic-breast-cancer-03042018",
      "id": "c88336230fb97abbd9992e0ed76b8833631fc9c7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/the-lancet-respiratory-medicine-publishes-first-phase-iii-trial-for-pt010-triple-combination-therapy-in-moderate-to-very-severe-chronic-obstructive-pulmonary-disease-16092018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/the-lancet-respiratory-medicine-publishes-first-phase-iii-trial-for-pt010-triple-combination-therapy-in-moderate-to-very-severe-chronic-obstructive-pulmonary-disease-16092018",
      "id": "09f3e1a436cb3ae0b9b92972822b10da98717b8c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/the-landmark-declare-timi-58-cardiovascular-outcomes-trial-of-farxiga-in-patients-with-type-2-diabetes-to-be-featured-at-aha-01112018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/the-landmark-declare-timi-58-cardiovascular-outcomes-trial-of-farxiga-in-patients-with-type-2-diabetes-to-be-featured-at-aha-01112018",
      "id": "bdb5165512b3068e55f1c52eb3d53d9a531b1720"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-phase-iii-clinical-trials-of-lanabecestat-for-alzheimers-disease-12062018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/update-on-phase-iii-clinical-trials-of-lanabecestat-for-alzheimers-disease-12062018",
      "id": "87ed06c45afacfed72708c37c7b96bd48280b304"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-terranova-phase-iii-trial-for-fasenra-in-chronic-obstructive-pulmonary-disease-30052018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/update-on-terranova-phase-iii-trial-for-fasenra-in-chronic-obstructive-pulmonary-disease-30052018",
      "id": "7b232b9080911d21982cbfbfa83a4a9d781aa98b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-the-phase-iii-eagle-trial-of-imfinzi-and-tremelimumab-in-advanced-head-and-neck-cancer-07122018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/update-on-the-phase-iii-eagle-trial-of-imfinzi-and-tremelimumab-in-advanced-head-and-neck-cancer-07122018",
      "id": "97997210c2a2423d264bf9b06f23e201e6039a13"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-tulip-1-phase-iii-trial-for-anifrolumab-in-systemic-lupus-erythematosus-31082018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/update-on-tulip-1-phase-iii-trial-for-anifrolumab-in-systemic-lupus-erythematosus-31082018",
      "id": "6af9780fa012b42151088901cac8b7ecab144b7f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/updated-overall-survival-data-for-lynparza-in-brca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr-16042018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/updated-overall-survival-data-for-lynparza-in-brca-mutated-her2-negative-metastatic-breast-cancer-presented-at-aacr-16042018",
      "id": "90d533c950d0159d1e06760700f4fffeb485ce1a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-accepts-biologics-license-application-for-moxetumomab-pasudotox-in-hairy-cell-leukaemia-03042018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/us-fda-accepts-biologics-license-application-for-moxetumomab-pasudotox-in-hairy-cell-leukaemia-03042018",
      "id": "89bc847f54085fe8754fd567e3caad839f75d9a7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-accepts-regulatory-submission-for-lynparza-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review-12112018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/us-fda-accepts-regulatory-submission-for-lynparza-maintenance-therapy-in-newly-diagnosed-brca-mutated-advanced-ovarian-cancer-and-grants-priority-review-12112018",
      "id": "961bccef61a3e2700b69d917b6f56b0a3dda1842"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-approves-imfinzi-for-unresectable-stage-iii-non-small-cell-lung-cancer-180202018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/us-fda-approves-imfinzi-for-unresectable-stage-iii-non-small-cell-lung-cancer-180202018",
      "id": "402e08d46fecab141659e832722eb9b642e3c6b0"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-approves-lumoxiti-moxetumomab-pasudotox-tdfk-for-certain-patients-with-relapsed-or-refractory-hairy-cell-leukaemia.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/us-fda-approves-lumoxiti-moxetumomab-pasudotox-tdfk-for-certain-patients-with-relapsed-or-refractory-hairy-cell-leukaemia",
      "id": "f81e28f9f928d93806f958dfea4fee51a5931b9d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-approves-tagrisso-as-1st-line-treatment-for-EGFR-mutated-non-small-cell-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/us-fda-approves-tagrisso-as-1st-line-treatment-for-egfr-mutated-non-small-cell-lung-cancer",
      "id": "65df85c154d1ad575f7c39ed7a097801d908cab7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-grants-fasenra-orphan-drug-designation-for-eosinophilic-granulomatosis-with-polyangiitis-26112018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/us-fda-grants-fasenra-orphan-drug-designation-for-eosinophilic-granulomatosis-with-polyangiitis-26112018",
      "id": "6dcac0f2d1413a417742346dfffe4e6b1d47deb7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/us-fda-grants-lynparza-orphan-drug-designation-for-pancreatic-cancer-16102018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/us-fda-grants-lynparza-orphan-drug-designation-for-pancreatic-cancer-16102018",
      "id": "6d31397dd27dc830642d86248802037030b04fe9"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2018/year-to-date-and-q3-2018-results-08112018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2018/year-to-date-and-q3-2018-results-08112018",
      "id": "5bc6905ddb1e95c2eadaff040431c3e2ed9a74ae"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019",
      "id": "9cff4e41d819eb6a03554c71e3a6d9d8a626a42f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/agreement-with-cheplapharm-for-rights-to-seroquel-and-seroquel-xr-in-europe-and-russia-completed-16122019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/agreement-with-cheplapharm-for-rights-to-seroquel-and-seroquel-xr-in-europe-and-russia-completed-16122019",
      "id": "433733722b4ed2a1a8c520bdc26f0e74c4b8f7de"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/anifrolumab-demonstrated-superiority-across-multiple-efficacy-endpoints-in-patients-with-systemic-lupus-erythematosus-in-phase-iii-tulip-2-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/anifrolumab-demonstrated-superiority-across-multiple-efficacy-endpoints-in-patients-with-systemic-lupus-erythematosus-in-phase-iii-tulip-2-trial",
      "id": "d164574dc29fb7c693226e9a584d0fae20c8864b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/anifrolumab-phase-iii-trial-meets-primary-endpoint-in-systemic-lupus-erythematosus-29082019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/anifrolumab-phase-iii-trial-meets-primary-endpoint-in-systemic-lupus-erythematosus-29082019",
      "id": "a25144f7b05c56b66ab1777e70f75d0146aef512"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-agrees-to-buy-us-fda-priority-review-voucher-from-sobi-22082019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/astrazeneca-agrees-to-buy-us-fda-priority-review-voucher-from-sobi-22082019",
      "id": "1dd8bbcc2f19748b462166474832bed0f5245247"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-amends-collaboration-with-ironwood-for-linzess-in-china.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/astrazeneca-amends-collaboration-with-ironwood-for-linzess-in-china",
      "id": "673d20ae4863cdd41b0efa854c3ebda021b21198"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-and-daiichi-sankyo-enter-collaboration-for-novel-her-2-targeting-antibody-drug-conjugate.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/astrazeneca-and-daiichi-sankyo-enter-collaboration-for-novel-her-2-targeting-antibody-drug-conjugate",
      "id": "6f160b408f8fa3f653280e7b9bb4b0ff9899e277"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-announces-organisational-changes.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/astrazeneca-announces-organisational-changes",
      "id": "149d0293bb7e3504902deb6268838ffe36e5ae53"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-announces-three-large-scale-initiatives-in-china-to-advance-global-medicine-research-and-development-061120119.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/astrazeneca-announces-three-large-scale-initiatives-in-china-to-advance-global-medicine-research-and-development-061120119",
      "id": "abe23f19a728d756509cdeb5384147f98f772856"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-commits-35m-to-help-young-people-tackle-the-threat-of-non-communicable-diseases-22102019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/astrazeneca-commits-35m-to-help-young-people-tackle-the-threat-of-non-communicable-diseases-22102019",
      "id": "1033192c9f32b9ad842f71e3b251176d519e1956"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-continues-to-redefine-cancer-treatment-at-the-2019-asco-annual-meeting-16052019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/astrazeneca-continues-to-redefine-cancer-treatment-at-the-2019-asco-annual-meeting-16052019",
      "id": "2b6d19559a2f7bd8b04df0f47de563f70a89dfd1"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-divests-rights-for-losec-to-cheplapharm-01102019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/astrazeneca-divests-rights-for-losec-to-cheplapharm-01102019",
      "id": "e66ea16aab780e7ff09e3e4e28c58303631835df"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-divests-rights-to-arimidex-and-casodex-in-europe-and-certain-additional-countries-20122019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/astrazeneca-divests-rights-to-arimidex-and-casodex-in-europe-and-certain-additional-countries-20122019",
      "id": "da67c94fc484f2696cfb6171371f8c465d9a37a9"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-divests-rights-to-seroquel-and-seroquel-xr-in-europe-and-russia-30102019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/astrazeneca-divests-rights-to-seroquel-and-seroquel-xr-in-europe-and-russia-30102019",
      "id": "65126a7396bf811cda1a0565b6864d96fcf9bcb5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-divests-rights-to-seroquel-and-seroquel-xr-in-the-us-and-canada-03122019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/astrazeneca-divests-rights-to-seroquel-and-seroquel-xr-in-the-us-and-canada-03122019",
      "id": "0add524b541cd921094c6bac470d3fdc07bc89c8"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-redefines-cancer-treatment-with-practice-changing-data-at-esmo-2019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/astrazeneca-redefines-cancer-treatment-with-practice-changing-data-at-esmo-2019",
      "id": "cc548dbd7feef38feebae34f87d6f2ba55fb6dab"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/astraZeneca-showcases-next-generation-oncology-pipeline-addressing-unmet-patient-needs-at-aacr-annual-meeting.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/astrazeneca-showcases-next-generation-oncology-pipeline-addressing-unmet-patient-needs-at-aacr-annual-meeting",
      "id": "a8b6cf228dec5ec43e5f770f15edd9147d0493d2"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-starts-artificial-intelligence-collaboration-to-accelerate-drug-discovery-30042019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/astrazeneca-starts-artificial-intelligence-collaboration-to-accelerate-drug-discovery-30042019",
      "id": "4edd0cc5c8dc37e817db4758065a77f8d9e1b4bc"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-to-present-data-at-esc-congress-2019-that-potentially-redefines-the-treatment-of-heart-failure-29082019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/astrazeneca-to-present-data-at-esc-congress-2019-that-potentially-redefines-the-treatment-of-heart-failure-29082019",
      "id": "8346f675e705871ef48562533da2f6307e2e780c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-to-present-new-cardiovascular-data-on-farxiga-in-type-2-diabetes-at-acc-2019-11032019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/astrazeneca-to-present-new-cardiovascular-data-on-farxiga-in-type-2-diabetes-at-acc-2019-11032019",
      "id": "056cd08819f4a8baccfbca146ae4241aaf81e81f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-to-present-next-wave-of-science-in-respiratory-disease-at-ers-international-congress-25092019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/astrazeneca-to-present-next-wave-of-science-in-respiratory-disease-at-ers-international-congress-25092019",
      "id": "bfe4916210182f720ec63873f16197b33bd04d4c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-to-present-pivotal-roxadustat-phase-iii-data-at-the-american-society-of-nephrology-kidney-week-2019-30102019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/astrazeneca-to-present-pivotal-roxadustat-phase-iii-data-at-the-american-society-of-nephrology-kidney-week-2019-30102019",
      "id": "595384161bfbfaaf54fef8a37eea708b21d3da8f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/astrazenecas-mene-pangalos-awarded-knighthood-in-the-new-year-2020-honours-list-28122019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/astrazenecas-mene-pangalos-awarded-knighthood-in-the-new-year-2020-honours-list-28122019",
      "id": "8c05e8c0ffc0bbb11354ccbbdb346e482b6bd777"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/astrazenecas-triple-combination-therapy-approved-in-china-for-patients-with-copd-23122019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/astrazenecas-triple-combination-therapy-approved-in-china-for-patients-with-copd-23122019",
      "id": "3f9dd7089db478c83e549f91cfbf1619a667c3d2"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/bevespi-aerosphere-approved-by-the-japanese-ministry-of-health-labour-and-welfare-for-patients-with-chronic-obstructive-pulmonary-disease-19062019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/bevespi-aerosphere-approved-by-the-japanese-ministry-of-health-labour-and-welfare-for-patients-with-chronic-obstructive-pulmonary-disease-19062019",
      "id": "cc65b97dab689919c72b302228f6e41678e29380"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/breztri-aerosphere-phase-iii-ethos-trial-met-its-primary-endpoint-in-chronic-obstructive-pulmonary-disease-28082019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/breztri-aerosphere-phase-iii-ethos-trial-met-its-primary-endpoint-in-chronic-obstructive-pulmonary-disease-28082019",
      "id": "c7b22a7fdd3d8f6f0f7062d6b8b9d614527ac406"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/breztri-aerosphere-pt010-approved-in-japan-for-patients-with-chronic-obstructive-pulmonary-disease-19062019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/breztri-aerosphere-pt010-approved-in-japan-for-patients-with-chronic-obstructive-pulmonary-disease-19062019",
      "id": "012b4d151ceb84736b1e6e7ae9135b706fc0a6ab"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/brilinta-reduced-the-risk-of-cardiovascular-events-in-patients-with-coronary-artery-disease-and-type-2-diabetes-in-phase-iii-themis-trial-01092018.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/brilinta-reduced-the-risk-of-cardiovascular-events-in-patients-with-coronary-artery-disease-and-type-2-diabetes-in-phase-iii-themis-trial-01092018",
      "id": "0752b2fc54bbef41bc87d6443aac564614b131cf"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/brilintas-phase-iii-themis-trial-met-primary-endpoint-in-patients-with-established-coronary-artery-disease-and-type-2-diabetes-25022019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/brilintas-phase-iii-themis-trial-met-primary-endpoint-in-patients-with-established-coronary-artery-disease-and-type-2-diabetes-25022019",
      "id": "07195cb5251f4cd2d21ae10de4dd7401d8ac8ec3"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-approved-in-the-us-for-adult-patients-with-chronic-lymphocytic-leukaemia-21112019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/calquence-approved-in-the-us-for-adult-patients-with-chronic-lymphocytic-leukaemia-21112019",
      "id": "531693fd377657f60db58c2c820737af78920334"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-data-to-show-improved-progression-free-survival-in-phase-iii-front-line-chronic-lymphocytic-leukaemia-trial-at-ash-2019-annual-meeting.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/calquence-data-to-show-improved-progression-free-survival-in-phase-iii-front-line-chronic-lymphocytic-leukaemia-trial-at-ash-2019-annual-meeting",
      "id": "ac2d4916ae3dea03d58ed792c9bd66f63858b5ab"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-granted-us-breakthrough-therapy-designation-for-chronic-lymphocytic-leukaemia-14082019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/calquence-granted-us-breakthrough-therapy-designation-for-chronic-lymphocytic-leukaemia-14082019",
      "id": "6403916783e8deddbd74231302e6eac2bdf9db29"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-phase-iii-ascend-trial-met-primary-endpoint-at-interim-analysis-in-relapsed-or-refractory-chronic-lymphocytic-leukaemia-and-will-stop-early-07052019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/calquence-phase-iii-ascend-trial-met-primary-endpoint-at-interim-analysis-in-relapsed-or-refractory-chronic-lymphocytic-leukaemia-and-will-stop-early-07052019",
      "id": "540efd2253c92503f28f8602ce40af1542f0a13c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-phase-iii-elevate-tn-trial-met-primary-endpoint-at-interim-analysis-in-previously-untreated-chronic-lymphocytic-leukaemia06062019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/calquence-phase-iii-elevate-tn-trial-met-primary-endpoint-at-interim-analysis-in-previously-untreated-chronic-lymphocytic-leukaemia06062019",
      "id": "461fa5b4d9852da83722f6a7b9b8efc1fe0af777"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-significantly-prolonged-the-time-patients-lived-without-disease-progression-in-relapsed-or-refractory-chronic-lymphocytic-leukaemia15062019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/calquence-significantly-prolonged-the-time-patients-lived-without-disease-progression-in-relapsed-or-refractory-chronic-lymphocytic-leukaemia15062019",
      "id": "84aa912190fc2fbf7aa1a2e5af04c0f86df24da4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-significantly-prolonged-the-time-patients-lived-without-disease-progression-or-death-in-previously-untreated-chronic-lymphocytic-leukaemia.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/calquence-significantly-prolonged-the-time-patients-lived-without-disease-progression-or-death-in-previously-untreated-chronic-lymphocytic-leukaemia",
      "id": "6563645f67f898a70093806b4a5c53825e8c04f3"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/detailed-results-from-phase-iii-dapa-hf-trial-showed-farxiga-significantly-reduced-both-the-incidence-of-cardiovascular-death-and-the-worsening-of-heart-failure-01092019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/detailed-results-from-phase-iii-dapa-hf-trial-showed-farxiga-significantly-reduced-both-the-incidence-of-cardiovascular-death-and-the-worsening-of-heart-failure-01092019",
      "id": "0c5f2e243d0606da95f99b76168744e714200c5b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/ema-grants-prime-eligibility-for-potential-next-generation-rsv-medicine-medi8897-05022019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/ema-grants-prime-eligibility-for-potential-next-generation-rsv-medicine-medi8897-05022019",
      "id": "f3a99bd26d3bc3dfc94fec68d070812eede791f9"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/enhertu-trastuzumab-deruxtecan-approved-in-the-us-for-her2-positive-unresectable-or-metastatic-breast-cancer-following-2-or-more-prior-anti-her2-based-regimens.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/enhertu-trastuzumab-deruxtecan-approved-in-the-us-for-her2-positive-unresectable-or-metastatic-breast-cancer-following-2-or-more-prior-anti-her2-based-regimens",
      "id": "8d3d6699e39af108f1d9c9c067a6c61eca6eec77"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/farxiga-approved-in-the-us-to-reduce-the-risk-of-hospitalisation-for-heart-failure-in-patients-with-type-2-diabetes-21102019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/farxiga-approved-in-the-us-to-reduce-the-risk-of-hospitalisation-for-heart-failure-in-patients-with-type-2-diabetes-21102019",
      "id": "479a78de520838315c053f3a089d9bc7e3a844e8"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/farxiga-met-primary-endpoint-in-landmark-phase-iii-dapa-hf-trial-for-the-treatment-of-patients-with-heart-failure-20082019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/farxiga-met-primary-endpoint-in-landmark-phase-iii-dapa-hf-trial-for-the-treatment-of-patients-with-heart-failure-20082019",
      "id": "ee0e840c9615a5484424b5735880f1b6d28ef841"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/fasenra-approved-in-the-us-for-self-administration-in-a-new-pre-filled-auto-injector-the-fasenra-pen-04102019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/fasenra-approved-in-the-us-for-self-administration-in-a-new-pre-filled-auto-injector-the-fasenra-pen-04102019",
      "id": "e2f0fcd66a0139032ec108e364a905a887dc584b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/fasenra-granted-us-orphan-drug-designation-for-eosinophilic-oesophagitis-28082019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/fasenra-granted-us-orphan-drug-designation-for-eosinophilic-oesophagitis-28082019",
      "id": "8144330df61e66096bdfb9c3de35a37c85bb43c0"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/fasenra-receives-positive-eu-chmp-opinion-for-self-administration-and-the-new-fasenra-pen-a-pre-filled-single-use-auto-injector-01072019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/fasenra-receives-positive-eu-chmp-opinion-for-self-administration-and-the-new-fasenra-pen-a-pre-filled-single-use-auto-injector-01072019",
      "id": "e5f06b5f49a5fe9262c361022bea7831b0d05c9b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/fda-grants-fast-track-designation-for-farxiga-in-chronic-kidney-disease-27082019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/fda-grants-fast-track-designation-for-farxiga-in-chronic-kidney-disease-27082019",
      "id": "9a490d6cbc0c42f2e1b565193577793b29e26be0"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/fda-grants-fast-track-designation-for-farxiga-in-heart-failure.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/fda-grants-fast-track-designation-for-farxiga-in-heart-failure",
      "id": "38b98c285acdb8b95945deec85e7de66a1e02ecc"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/first-sub-analyses-from-the-declare-timi-58-trial-further-support-the-cardiovascular-effects-of-farxiga-in-type-2-diabetes-18032019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/first-sub-analyses-from-the-declare-timi-58-trial-further-support-the-cardiovascular-effects-of-farxiga-in-type-2-diabetes-18032019",
      "id": "17cb32f472b1536769a6c33f7d05bc82c643f5c5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/forxiga-approved-in-europe-for-type-1-diabetes22032019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/forxiga-approved-in-europe-for-type-1-diabetes22032019",
      "id": "09f76d451f25254315f6fde2ad3963770f9b74c7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/forxiga-approved-in-japan-for-type-1-diabetes-27032019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/forxiga-approved-in-japan-for-type-1-diabetes-27032019",
      "id": "192424f0bc9cce4e57d6ab482a34027a01a104ff"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/forxiga-label-updated-in-the-eu-in-type-2-diabetes.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/forxiga-label-updated-in-the-eu-in-type-2-diabetes",
      "id": "551d3dede739ae6d9b11555f30cde57b18e672a5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/forxiga-receives-positive-eu-chmp-opinion-for-declare-timi-58-cardiovascular-outcomes-data-01072019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/forxiga-receives-positive-eu-chmp-opinion-for-declare-timi-58-cardiovascular-outcomes-data-01072019",
      "id": "9be879b96305c2676f15a72a7cfabe633e1c9325"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/forxiga-receives-positive-eu-chmp-opinion-for-the-treatment-of-adults-with-type-1-diabetes.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/forxiga-receives-positive-eu-chmp-opinion-for-the-treatment-of-adults-with-type-1-diabetes",
      "id": "ebe480ac907d1d2424b1c626e40228bc13b0d716"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/full-year-2018-results-14022019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/full-year-2018-results-14022019",
      "id": "254b09ec3ee597b9f9cdb9d10fda2e32b837425b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/H1-2019-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/h1-2019-results",
      "id": "5956d5c5ba643f03545efbbd6748768801d4e4a4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/harvard-business-review-names-pascal-soriot-among-best-performing-top-100-ceos-in-the-world-2019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/harvard-business-review-names-pascal-soriot-among-best-performing-top-100-ceos-in-the-world-2019",
      "id": "b38c4d54f1449d3c5bc8a5932150987bbc10dcf4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/imfinzi-and-imfinzi-plus-tremelimumab-delayed-disease-progression-in-phase-iii-poseidon-trial-for-1st-line-treatment-of-stage-iv-non-small-cell-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/imfinzi-and-imfinzi-plus-tremelimumab-delayed-disease-progression-in-phase-iii-poseidon-trial-for-1st-line-treatment-of-stage-iv-non-small-cell-lung-cancer",
      "id": "8b17eabcc2bb0b0ba0431b2900030545f55d969a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/imfinzi-approved-in-china-for-the-treatment-of-unresectable-stage-iii-non-small-cell-lung-cancer-based-on-the-phase-iii-pacific-trial-12122019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/imfinzi-approved-in-china-for-the-treatment-of-unresectable-stage-iii-non-small-cell-lung-cancer-based-on-the-phase-iii-pacific-trial-12122019",
      "id": "b07f4ccd50d445b3286cefe94959b7625a32c49d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/imfinzi-granted-fda-priority-review-for-the-treatment-of-patients-with-extensive-stage-small-cell-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/imfinzi-granted-fda-priority-review-for-the-treatment-of-patients-with-extensive-stage-small-cell-lung-cancer",
      "id": "d050c26587c8f9eff293d135c3067975f56ca9b1"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/imfinzi-granted-us-orphan-drug-designation-for-small-cell-lung-cancer12072019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/imfinzi-granted-us-orphan-drug-designation-for-small-cell-lung-cancer12072019",
      "id": "905bbd800d6fa3e31ecc9ee41a043167ad0dd7f9"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/imfinzi-improves-overall-survival-at-interim-analysis-in-the-phase-iii-caspian-trial-in-1st-line-extensive-stage-small-cell-lung-cancer-27062019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/imfinzi-improves-overall-survival-at-interim-analysis-in-the-phase-iii-caspian-trial-in-1st-line-extensive-stage-small-cell-lung-cancer-27062019",
      "id": "e278580c0ad668ae69edfb3cda2ceeaccfad1956"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/imfinzi-is-the-only-immunotherapy-to-demonstrate-overall-survival-at-three-years-in-unresectable-stage-iii-non-small-cell-lung-cancer02062019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/imfinzi-is-the-only-immunotherapy-to-demonstrate-overall-survival-at-three-years-in-unresectable-stage-iii-non-small-cell-lung-cancer02062019",
      "id": "fd294fb388810d161b50cf6613865a8600710b59"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/linzess-linaclotide-approved-in-china-for-the-treatment-of-irritable-bowel-syndrome-with-constipation-18012019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/linzess-linaclotide-approved-in-china-for-the-treatment-of-irritable-bowel-syndrome-with-constipation-18012019",
      "id": "5f35164a03608400366b5c0ca0d68cd450a8c1a2"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/lokelma-demonstrated-efficacy-in-treating-hyperkalaemia-in-patients-with-end-stage-renal-disease-on-haemodialysis14062019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/lokelma-demonstrated-efficacy-in-treating-hyperkalaemia-in-patients-with-end-stage-renal-disease-on-haemodialysis14062019",
      "id": "8b338f2349e5d6c826b5ce4b579af0c99649895c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-achieved-a-72-objective-response-rate-in-patients-with-relapsed-germline-brca-mutated-advanced-ovarian-cancer-03062019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/lynparza-achieved-a-72-objective-response-rate-in-patients-with-relapsed-germline-brca-mutated-advanced-ovarian-cancer-03062019",
      "id": "97cf70bda570b8ef56217071c6538700ef09e345"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-approved-in-china-as-a-1st-line-maintenance-therapy-in-brca-mutated-advanced-ovarian-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/lynparza-approved-in-china-as-a-1st-line-maintenance-therapy-in-brca-mutated-advanced-ovarian-cancer",
      "id": "1ed822e23310e12120968b7afd0929884e4693e0"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer-10042019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/lynparza-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer-10042019",
      "id": "1d721fce89ab5ad1dd698e2644680a5184df38ab"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-approved-in-japan-for-1st-line-maintenance-therapy-in-brca-mutated-advanced-ovarian-cancer-19062019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/lynparza-approved-in-japan-for-1st-line-maintenance-therapy-in-brca-mutated-advanced-ovarian-cancer-19062019",
      "id": "daf484782a8f2a93de2a463706a92800ea9503b3"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-approved-in-the-eu-for-1st-line-maintenance-treatment-of-brca-mutated-advanced-ovarian-cancer-18062019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/lynparza-approved-in-the-eu-for-1st-line-maintenance-treatment-of-brca-mutated-advanced-ovarian-cancer-18062019",
      "id": "520dfb295eda3eb3874d636be256cd41b304ddd0"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-approved-in-the-us-as-a-1st-line-maintenance-treatment-of-germline-brca-mutated-metastatic-pancreatic-cancer-30122019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/lynparza-approved-in-the-us-as-a-1st-line-maintenance-treatment-of-germline-brca-mutated-metastatic-pancreatic-cancer-30122019",
      "id": "5248138b22857d948ebaf593a0fedd313d6ad35f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-improved-the-time-women-lived-without-disease-progression-to-22-months-in-the-broad-population-and-to-37-months-in-hrd-positive-patients.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/lynparza-improved-the-time-women-lived-without-disease-progression-to-22-months-in-the-broad-population-and-to-37-months-in-hrd-positive-patients",
      "id": "483c67a684aa1b9885645a8a5ebd0ed0ee874b58"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-more-than-doubled-the-time-without-disease-progression-in-patients-with-brca1-2-atm-mutated-metastatic-castration-resistant-prostate-cancer-30092019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/lynparza-more-than-doubled-the-time-without-disease-progression-in-patients-with-brca1-2-atm-mutated-metastatic-castration-resistant-prostate-cancer-30092019",
      "id": "7d57f06689d62f1eb384d55d2473d48e45cc8002"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-nearly-doubled-the-time-patients-lived-without-disease-progression-from-germline-brca-mutated-metastatic-pancreatic-cancer02062019-2.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/lynparza-nearly-doubled-the-time-patients-lived-without-disease-progression-from-germline-brca-mutated-metastatic-pancreatic-cancer02062019-2",
      "id": "274f6e37a3078b5eb4ffd98b2184e2e448704f01"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-nearly-doubled-the-time-patients-lived-without-disease-progression-from-germline-brca-mutated-metastatic-pancreatic-cancer02062019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/lynparza-nearly-doubled-the-time-patients-lived-without-disease-progression-from-germline-brca-mutated-metastatic-pancreatic-cancer02062019",
      "id": "d3a879141077c4694474da38a9608cf00b38bdf8"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-phase-iii-paola-1-trial-met-primary-endpoint-as-1st-line-maintenance-treatment-with-bevacizumab-for-advanced-ovarian-cancer-14082019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/lynparza-phase-iii-paola-1-trial-met-primary-endpoint-as-1st-line-maintenance-treatment-with-bevacizumab-for-advanced-ovarian-cancer-14082019",
      "id": "e9c7125551619ea8dcb9241dc1d8f0ca816fe3cc"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-phase-iii-profound-trial-in-hrr-mutation-selected-metastatic-castration-resistant-prostate-cancer-met-primary-endpoint-07082019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/lynparza-phase-iii-profound-trial-in-hrr-mutation-selected-metastatic-castration-resistant-prostate-cancer-met-primary-endpoint-07082019",
      "id": "71c28a7629a5a18d4545d36185ab37140a4c085b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-receives-positive-eu-chmp-opinion-for-1st-line-maintenance-treatment-of-brca-mutated-advanced-ovarian-cancer-26042019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/lynparza-receives-positive-eu-chmp-opinion-for-1st-line-maintenance-treatment-of-brca-mutated-advanced-ovarian-cancer-26042019",
      "id": "fbce3bf1d453067ef280848af37230a6d51aee2f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-receives-positive-eu-chmp-opinion-for-use-in-germline-brca-mutated-her2-negative-advanced-breast-cancer-01032019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/lynparza-receives-positive-eu-chmp-opinion-for-use-in-germline-brca-mutated-her2-negative-advanced-breast-cancer-01032019",
      "id": "d7e03fe382f944feaa6de89bdea318f2a8b7f03a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-recommended-by-fda-advisory-committee-for-1st-line-maintenance-treatment-of-germline-brca-mutated-metastatic-pancreatic-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/lynparza-recommended-by-fda-advisory-committee-for-1st-line-maintenance-treatment-of-germline-brca-mutated-metastatic-pancreatic-cancer",
      "id": "eb072a8e5af914597136009d58766cfb614c8cd3"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-significantly-delayed-disease-progression-as-1st-line-maintenance-treatment-in-germline-brca-mutated-metastatic-pancreatic-cancer-26022019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/lynparza-significantly-delayed-disease-progression-as-1st-line-maintenance-treatment-in-germline-brca-mutated-metastatic-pancreatic-cancer-26022019",
      "id": "54a4b47c7898b35162483c0a204b6fc0fc4bcb75"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/new-data-on-symbicort-as-a-potential-anti-inflammatory-reliever-in-mild-asthma-to-be-presented-at-ats-2019-16052019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/new-data-on-symbicort-as-a-potential-anti-inflammatory-reliever-in-mild-asthma-to-be-presented-at-ats-2019-16052019",
      "id": "40af77bd13bc39824083d93e6bd30aa33f195558"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/new-data-show-symbicort-reduces-attacks-in-mild-asthma-when-used-as-an-anti-inflammatory-reliever-20052019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/new-data-show-symbicort-reduces-attacks-in-mild-asthma-when-used-as-an-anti-inflammatory-reliever-20052019",
      "id": "01801fbec468416139844d3185ea7ba749c69724"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/pooled-analyses-of-the-roxadustat-global-phase-3-programme-confirmed-cardiovascular-safety.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/pooled-analyses-of-the-roxadustat-global-phase-3-programme-confirmed-cardiovascular-safety",
      "id": "3b8c2ccef6838e712f3d602abab7c67e926adf67"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/positive-results-from-fasenra-phase-ii-trial-in-hypereosinophilic-syndrome-published-in-new-england-journal-of-medicine-04042019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/positive-results-from-fasenra-phase-ii-trial-in-hypereosinophilic-syndrome-published-in-new-england-journal-of-medicine-04042019",
      "id": "35971761c47512b7caba03dacb92ee389b04c73f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/proposed-placing-of-new-ordinary-shares.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/proposed-placing-of-new-ordinary-shares",
      "id": "12ed92767e03b452d878afafa1e16982b46f00de"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/Q1-2019-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/q1-2019-results",
      "id": "725dddd223dda9f7219f5fb108d95a55d8639889"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/qternmet-xr-approved-in-the-us-for-the-treatment-of-type-2-diabetes-03052019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/qternmet-xr-approved-in-the-us-for-the-treatment-of-type-2-diabetes-03052019",
      "id": "18a3bd861b7d7cf4c76ebd3abc3b39f4d3b40ea4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/qtrilmet-approved-in-the-eu-for-the-treatment-of-type-2-diabetes-15112019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/qtrilmet-approved-in-the-eu-for-the-treatment-of-type-2-diabetes-15112019",
      "id": "c868b45a3c4ba94aa0bfbe503bcdcdafc534bf33"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/qtrilmet-recommended-for-approval-in-eu-by-chmp-for-the-treatment-of-type-2-diabetes-23092019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/qtrilmet-recommended-for-approval-in-eu-by-chmp-for-the-treatment-of-type-2-diabetes-23092019",
      "id": "e80fdcf692ff9f1e6e17aca75bd16ccb60449995"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/rns1.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/rns1",
      "id": "00ee198b058a83670e67965ba01df7a8ca4c71ae"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/roxadustat-approved-in-china-for-the-treatment-of-anaemia-in-non-dialysis-dependent-patients-with-chronic-kidney-disease-22082019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/roxadustat-approved-in-china-for-the-treatment-of-anaemia-in-non-dialysis-dependent-patients-with-chronic-kidney-disease-22082019",
      "id": "625cf07eb157e770edfbc6c9d1e7f50ac2fcd960"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/roxadustat-phase-iii-programme-pooled-analyses-showed-positive-efficacy-and-no-increased-cv-risk-in-patients-with-anaemia-from-chronic-kidney-disease.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/roxadustat-phase-iii-programme-pooled-analyses-showed-positive-efficacy-and-no-increased-cv-risk-in-patients-with-anaemia-from-chronic-kidney-disease",
      "id": "74c4554ed70aa012018cfcb9fbff5f5d31c10fd4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/roxadustat-significantly-increased-haemoglobin-levels-for-chronic-kidney-disease-patients-with-anaemia-in-phase-iii-olympus-and-rockies-trials.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/roxadustat-significantly-increased-haemoglobin-levels-for-chronic-kidney-disease-patients-with-anaemia-in-phase-iii-olympus-and-rockies-trials",
      "id": "0f69f46588812275fcee3117293b1d659fae3163"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/selumetinib-granted-us-breakthrough-therapy-designation-in-neurofibromatosis-type-1-01042019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/selumetinib-granted-us-breakthrough-therapy-designation-in-neurofibromatosis-type-1-01042019",
      "id": "96b02ccb78435d32e65c6441e8882a00fdd9fc6d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/tagrisso-approved-in-china-as-a-1st-line-treatment-for-egfr-mutated-non-small-cell-lung-cancer-04092019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/tagrisso-approved-in-china-as-a-1st-line-treatment-for-egfr-mutated-non-small-cell-lung-cancer-04092019",
      "id": "5a48bffb9afe77993288eb7e141569f7ad1877d2"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/tagrisso-is-the-only-1st-line-treatment-for-egfr-mutated-non-small-cell-lung-cancer-to-deliver-a-median-overall-survival-of-more-than-three-years.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/tagrisso-is-the-only-1st-line-treatment-for-egfr-mutated-non-small-cell-lung-cancer-to-deliver-a-median-overall-survival-of-more-than-three-years",
      "id": "c04cde26d7a87b434610416538118c3460834a1e"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/tagrisso-significantly-improves-overall-survival-in-the-phase-iii-flaura-trial-for-1st-line-egfr-mutated-non-small-cell-lung-cancer-09082019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/tagrisso-significantly-improves-overall-survival-in-the-phase-iii-flaura-trial-for-1st-line-egfr-mutated-non-small-cell-lung-cancer-09082019",
      "id": "336cfd964a4e837aaeb773af4ae27d89144a6e9d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/trastuzumab-deruxtecan-achieved-a-tumour-response-rate-of-60-in-pivotal-phase-ii-her2-positive-metastatic-breast-cancer-trial-11122019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/trastuzumab-deruxtecan-achieved-a-tumour-response-rate-of-60-in-pivotal-phase-ii-her2-positive-metastatic-breast-cancer-trial-11122019",
      "id": "3b9a5739f610f4f030c920009d3c088384fae34a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/trastuzumab-deruxtecan-demonstrated-clinically-meaningful-response-in-patients-with-refractory-her2-positive-metastatic-breast-cancer-a-population-with-high-unmet-need-08052019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/trastuzumab-deruxtecan-demonstrated-clinically-meaningful-response-in-patients-with-refractory-her2-positive-metastatic-breast-cancer-a-population-with-high-unmet-need-08052019",
      "id": "766b72f9455947ec33e73da2cd747c994c16ea6c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/trastuzumab-deruxtecan-granted-fda-priority-review-for-treatment-of-patients-with-her2-positive-metastatic-breast-cancer-17102019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/trastuzumab-deruxtecan-granted-fda-priority-review-for-treatment-of-patients-with-her2-positive-metastatic-breast-cancer-17102019",
      "id": "7457ed25ce58ab3d8e9797b2d73054740c05db8a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/update-on-the-phase-iii-neptune-trial-of-imfinzi-plus-tremelimumab-in-stage-iv-non-small-cell-lung-cancer-21082019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/update-on-the-phase-iii-neptune-trial-of-imfinzi-plus-tremelimumab-in-stage-iv-non-small-cell-lung-cancer-21082019",
      "id": "77f1bffd87ae90311aaaa30e16d24a457aeb4300"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/update-on-us-regulatory-decision-for-farxiga-in-type-1-diabetes-15072019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/update-on-us-regulatory-decision-for-farxiga-in-type-1-diabetes-15072019",
      "id": "e9699ab4314ac4f46f7a833ea0afcdb804623dff"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/update-on-us-regulatory-review-of-pt010-in-copd-01102019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/update-on-us-regulatory-review-of-pt010-in-copd-01102019",
      "id": "4d7bfbf203f611f1542e69c1134a3bbe5e2c033c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/us-fda-accepts-regulatory-submission-for-selumetinib-in-neurofibromatosis-type-1-and-grants-priority-review-14112019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/us-fda-accepts-regulatory-submission-for-selumetinib-in-neurofibromatosis-type-1-and-grants-priority-review-14112019",
      "id": "0e67ca83d2d6991849720e02131b1dd818e8366c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/us-fda-grants-breakthrough-therapy-designation-for-potential-next-generation-rsv-medicine-medi8897.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/us-fda-grants-breakthrough-therapy-designation-for-potential-next-generation-rsv-medicine-medi8897",
      "id": "a9cb493e07d83ac6b584c60a104ed43b6e0a226f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/us-fda-grants-fasenra-orphan-drug-designation-for-hypereosinophilic-syndrome.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/us-fda-grants-fasenra-orphan-drug-designation-for-hypereosinophilic-syndrome",
      "id": "4a28011b8e0bbf5b530a46815d78ba9d49e1fbd9"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/us-fda-grants-saracatinib-orphan-drug-designation-for-idiopathic-pulmonary-fibrosis-18032019.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/us-fda-grants-saracatinib-orphan-drug-designation-for-idiopathic-pulmonary-fibrosis-18032019",
      "id": "e708460fbab4e668099077dabd9b542186545ad7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2019/year-to-date-and-q3-2019-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2019/year-to-date-and-q3-2019-results",
      "id": "d14af53e34145141b21ffae4e6781bc9992d5f9e"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020",
      "id": "10a8863b93dc8ed050098c686ef37ff192421319"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-acquires-oral-pcsk9-inhibitor-programme-from-dogma-therapeutics.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-acquires-oral-pcsk9-inhibitor-programme-from-dogma-therapeutics",
      "id": "369157858de1405c40dd3b3d9fa34dbd5905c5af"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-advances-leadership-in-renal-disease-with-more-than-80-abstracts-at-asn-kidney-week-2020-reimagined.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-advances-leadership-in-renal-disease-with-more-than-80-abstracts-at-asn-kidney-week-2020-reimagined",
      "id": "1cf8e9d5c1be3e85d3dca6f6f99d2f9df30976e4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-advances-response-to-global-covid-19-challenge-as-it-receives-first-commitments-for-oxfords-potential-new-vaccine.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-advances-response-to-global-covid-19-challenge-as-it-receives-first-commitments-for-oxfords-potential-new-vaccine",
      "id": "62d15bbc6141994ee1d21928c6bb09454ae7031b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-advances-the-science-of-cancer-medicine-with-practice-changing-data-at-the-asco20-virtual-scientific-program.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-advances-the-science-of-cancer-medicine-with-practice-changing-data-at-the-asco20-virtual-scientific-program",
      "id": "02475e87ba83e5bd677bb5d562c6b78f4125a08b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-aims-to-transform-cancer-treatment-and-advance-clinical-practice-with-data-presented-at-esmo-2020.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-aims-to-transform-cancer-treatment-and-advance-clinical-practice-with-data-presented-at-esmo-2020",
      "id": "edebf38f32332d59e93cc1d23d0c708f376d1056"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-and-daiichi-sankyo-enter-collaboration-to-develop-and-commercialise-new-antibody-drug-conjugate.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-and-daiichi-sankyo-enter-collaboration-to-develop-and-commercialise-new-antibody-drug-conjugate",
      "id": "6dcdf28ad4255f3b7a73233751056a3e6a0dfac7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-and-oxford-university-announce-landmark-agreement-for-covid-19-vaccine.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-and-oxford-university-announce-landmark-agreement-for-covid-19-vaccine",
      "id": "a4dca6890f1338377e5842c09be0744cf33f0c0b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-and-saint-lukes-mid-america-heart-institute-initiate-phase-iii-dare-19-trial-with-farxiga-in-covid-19-patients.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-and-saint-lukes-mid-america-heart-institute-initiate-phase-iii-dare-19-trial-with-farxiga-in-covid-19-patients",
      "id": "5b1294ca9a53b08dbbf7e4ba3d010fafb5e5cdcf"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-collaborates-with-archerdx-to-use-personalised-cancer-assays-to-detect-minimal-residual-disease-in-lung-cancer-trials.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-collaborates-with-archerdx-to-use-personalised-cancer-assays-to-detect-minimal-residual-disease-in-lung-cancer-trials",
      "id": "92e4d58b799a37c0e8af3c3f5dab97be748e4763"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-completes-divestment-agreement-with-atnahs-pharma-for-established-hypertension-medicines.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-completes-divestment-agreement-with-atnahs-pharma-for-established-hypertension-medicines",
      "id": "28e54f748e86be9454b0f3e89e6d81bd6642986e"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-concludes-agreement-with-the-european-commission-for-the-supply-of-up-to-400-million-doses-of-azd1222-covid-19-vaccine.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-concludes-agreement-with-the-european-commission-for-the-supply-of-up-to-400-million-doses-of-azd1222-covid-19-vaccine",
      "id": "69a29b013212ca240a7e89d1d8ce4298c43606a7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-demonstrates-growing-leadership-in-breast-cancer-at-sabcs.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-demonstrates-growing-leadership-in-breast-cancer-at-sabcs",
      "id": "ad0fffa772f6f8ad46ca7e49acf119547eeb0dd0"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-demonstrates-strengths-in-haematology-with-robust-data-at-ash-2020.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-demonstrates-strengths-in-haematology-with-robust-data-at-ash-2020",
      "id": "9519c4a8844f272f880e8e2b0a9295295d05e077"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-divestment-of-movantik-to-redhill-biopharma-completed.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-divestment-of-movantik-to-redhill-biopharma-completed",
      "id": "87ef459d134f61d94402bdb31bf6baac07a357c4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-divests-global-rights-to-movantik-25022020.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-divests-global-rights-to-movantik-25022020",
      "id": "c88bf22b0eb624c56e6d264e7a548cf9852ecc45"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-divests-rights-to-established-hypertension-medicines-27012020.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-divests-rights-to-established-hypertension-medicines-27012020",
      "id": "5dd95f49298ee5ee99b658c1e418058504160995"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-initiates-calavi-clinical-trial-with-calquence-against-covid-19.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-initiates-calavi-clinical-trial-with-calquence-against-covid-19",
      "id": "3a20f373f77cb664ac069cd444c009d8c1568da5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-presents-new-data-across-continuum-of-care-from-its-broad-renal-portfolio-at-era-edta-2020-virtual-congress.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-presents-new-data-across-continuum-of-care-from-its-broad-renal-portfolio-at-era-edta-2020-virtual-congress",
      "id": "00f758282495d17e6474033ed1c1977c4e374556"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-recovery-of-global-rights-to-brazikumab-medi2070-from-allergan-completed.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-recovery-of-global-rights-to-brazikumab-medi2070-from-allergan-completed",
      "id": "fca264c51679918deace993f9eda902d9f7f4faf"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-takes-next-steps-towards-broad-and-equitable-access-to-oxford-universitys-covid-19-vaccine.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-takes-next-steps-towards-broad-and-equitable-access-to-oxford-universitys-covid-19-vaccine",
      "id": "7724730e3911d7f93b9ca2d57695a0e32f8940ff"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-acquire-alexion.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-to-acquire-alexion",
      "id": "f18ce038d98c86ede6acb2d64b0b317295e7f00c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-discover-and-develop-novel-therapies-targeting-rna-modifying-proteins-in-oncology-collaboration-with-accent-therapeutics.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-to-discover-and-develop-novel-therapies-targeting-rna-modifying-proteins-in-oncology-collaboration-with-accent-therapeutics",
      "id": "e2fc919babf858515d43d75abc21dc51e220b44f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-discover-and-develop-sirna-therapeutics-for-cardiovascular-renal-metabolic-and-respiratory-diseases-in-new-collaboration.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-to-discover-and-develop-sirna-therapeutics-for-cardiovascular-renal-metabolic-and-respiratory-diseases-in-new-collaboration",
      "id": "222127ccca3e925026ab15eb460dee43d8245630"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-donate-9-million-face-masks-to-support-healthcare-workers-around-the-world-in-the-fight-against-covid-19.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-to-donate-9-million-face-masks-to-support-healthcare-workers-around-the-world-in-the-fight-against-covid-19",
      "id": "78e34d5afb90d7af01b1d6f45a1f5b12806dbb83"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-list-us-adr-equity-and-all-us-debt-securities-on-nasdaq.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-to-list-us-adr-equity-and-all-us-debt-securities-on-nasdaq",
      "id": "3288db317ee1e9c90ba4dff1e2cdf4cba42549ef"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-recover-the-global-rights-to-brazikumab-medi2070-from-allergan-27012020.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-to-recover-the-global-rights-to-brazikumab-medi2070-from-allergan-27012020",
      "id": "84f964f865b385a425b48ad3073eab2fd9f5589a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-showcase-leadership-in-treating-type-2-diabetes-and-cardiorenal-complications-at-ada-2020.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-to-showcase-leadership-in-treating-type-2-diabetes-and-cardiorenal-complications-at-ada-2020",
      "id": "fc2327f76fbf69a8f8568b3801594f7676809094"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-supply-europe-with-up-to-400-million-doses-of-oxford-universitys-vaccine-at-no-profit.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-to-supply-europe-with-up-to-400-million-doses-of-oxford-universitys-vaccine-at-no-profit",
      "id": "1dabca297d85534c2a656c67a3a9e1e9fbc7e5cc"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-young-health-programme-to-partner-with-unicef-to-prevent-non-communicable-diseases-among-young-people.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazeneca-young-health-programme-to-partner-with-unicef-to-prevent-non-communicable-diseases-among-young-people",
      "id": "9cb9ebc9d83a074a98de4373d295bc9a57d98ebc"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazenecas-ambition-zero-carbon-strategy-to-eliminate-emissions-by-2025-and-be-carbon-negative-across-the-entire-value-chain-by-2030-22012020.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazenecas-ambition-zero-carbon-strategy-to-eliminate-emissions-by-2025-and-be-carbon-negative-across-the-entire-value-chain-by-2030-22012020",
      "id": "0f9ec2ad992abc824506a288bb0a7ae412380aa3"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazenecas-covid-19-vaccine-authorised-in-uk.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazenecas-covid-19-vaccine-authorised-in-uk",
      "id": "e69d9f8b7ffbd5013a200a1f4c25825c1e916110"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/astrazenecas-scientific-and-social-commitment-for-covid-19-vaccine.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/astrazenecas-scientific-and-social-commitment-for-covid-19-vaccine",
      "id": "304bca46a52da6984881549b58914bc30d6deb6e"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/atacand-to-be-divested-to-cheplapharm-in-more-than-70-countries.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/atacand-to-be-divested-to-cheplapharm-in-more-than-70-countries",
      "id": "811329c435686ac76e553f731ba354ed273e8c7b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222-oxford-phase-iii-trials-interim-analysis-results-published-in-the-lancet.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/azd1222-oxford-phase-iii-trials-interim-analysis-results-published-in-the-lancet",
      "id": "8e0722c17140fb5b445828e085897d44afd2fd6c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/azd1222hlr",
      "id": "7af5a3c741d973793256f5f9425edfc93b75a624"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/bevespi-aerosphere-approved-in-china-for-patients-with-copd.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/bevespi-aerosphere-approved-in-china-for-patients-with-copd",
      "id": "288faa0e53ae86db72ef8ad5d3478fcefea2c7ab"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/biopharma-leaders-unite-to-stand-with-science.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/biopharma-leaders-unite-to-stand-with-science",
      "id": "ae2aeb661ae20163df60a9c18577007443c951c4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/breztri-aerosphere-approved-in-the-us-for-copd.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/breztri-aerosphere-approved-in-the-us-for-copd",
      "id": "eb272dec14afe24953654780ad091034390d0367"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/breztri-aerosphere-significantly-reduced-rate-of-moderate-or-severe-copd-exacerbations-in-phase-iii-ethos-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/breztri-aerosphere-significantly-reduced-rate-of-moderate-or-severe-copd-exacerbations-in-phase-iii-ethos-trial",
      "id": "3f8a22e9af9d10ce8a7514eff8ace5a6f77e5426"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/brilinta-approved-in-the-us-in-stroke.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/brilinta-approved-in-the-us-in-stroke",
      "id": "7b623f53aef33ac5ac127df64dd09d9edecb7a19"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/brilinta-approved-in-the-us-to-reduce-the-risk-of-a-first-heart-attack-or-stroke-in-high-risk-patients-with-coronary-artery-disease.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/brilinta-approved-in-the-us-to-reduce-the-risk-of-a-first-heart-attack-or-stroke-in-high-risk-patients-with-coronary-artery-disease",
      "id": "6be448ffdeb3cca94eabd30cfdb7da44817e999b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/brilinta-granted-fda-priority-review-for-the-reduction-of-subsequent-stroke-in-patients-who-had-an-acute-ischemic-stroke-or-transient-ischemic-attack.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/brilinta-granted-fda-priority-review-for-the-reduction-of-subsequent-stroke-in-patients-who-had-an-acute-ischemic-stroke-or-transient-ischemic-attack",
      "id": "7bb7d740a7d71da58c59f3221cbe9d5d30004080"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/brilinta-met-primary-endpoint-in-phase-iii-thales-trial-in-stroke-27012020.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/brilinta-met-primary-endpoint-in-phase-iii-thales-trial-in-stroke-27012020",
      "id": "d01d4ce65dc0d7867d8f7a67c667db50045d2d32"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/brilinta-reduced-bleeding-vs-dual-therapy-in-high-risk-coronary-patients-in-sub-analyses-from-phase-iv-twilight-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/brilinta-reduced-bleeding-vs-dual-therapy-in-high-risk-coronary-patients-in-sub-analyses-from-phase-iv-twilight-trial",
      "id": "e2a7f8eea9e7ff31766f474d722b7545e74c0cf3"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/brilinta-significantly-reduced-the-rate-of-the-composite-of-stroke-and-death-in-patients.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/brilinta-significantly-reduced-the-rate-of-the-composite-of-stroke-and-death-in-patients",
      "id": "00ac0a1a768751d078e91123ae3e1ded3c0dd4b7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/calquence-approved-in-the-eu-for-cll.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/calquence-approved-in-the-eu-for-cll",
      "id": "8a97e982b9a17cf0db46f8fda32a84826cce3612"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/calquence-data-across-four-trials-reinforces-cardiovascular-safety-profile-in-patients-with-chronic-lymphocytic-leukaemia.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/calquence-data-across-four-trials-reinforces-cardiovascular-safety-profile-in-patients-with-chronic-lymphocytic-leukaemia",
      "id": "8a0f7cb5c1c01620257db4bb9d350cc1cf894888"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/calquence-recommended-for-approval-in-the-eu-by-chmp-for-chronic-lymphocytic-leukaemia.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/calquence-recommended-for-approval-in-the-eu-by-chmp-for-chronic-lymphocytic-leukaemia",
      "id": "c51d955fbf21cef848b27d384af5fdbf135d23b8"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/calquence-showed-long-term-efficacy-and-tolerability-for-patients-with-chronic-lymphocytic-leukaemia-in-two-trials.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/calquence-showed-long-term-efficacy-and-tolerability-for-patients-with-chronic-lymphocytic-leukaemia-in-two-trials",
      "id": "aef86ae0e7f67b99e0c8cd62ea1673c86fc7ec3a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/calquence-showed-promising-clinical-improvement-in-majority-of-19-hospitalised-covid-19-patients.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/calquence-showed-promising-clinical-improvement-in-majority-of-19-hospitalised-covid-19-patients",
      "id": "5db1df20f8639f0a6d168dce13f5897672daa13e"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/calquence-shows-long-term-efficacy-and-tolerability-at-three-years-for-patients-with-relapsed-or-refractory-mantle-cell-lymphoma.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/calquence-shows-long-term-efficacy-and-tolerability-at-three-years-for-patients-with-relapsed-or-refractory-mantle-cell-lymphoma",
      "id": "631db0387fd944a01c912a5a0cb4eabb6e11d7dd"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/covid-19-long-acting-antibody-laab-combination-azd7442-rapidly-advances-into-phase-iii-clinical-trials.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/covid-19-long-acting-antibody-laab-combination-azd7442-rapidly-advances-into-phase-iii-clinical-trials",
      "id": "bb058c32dfe63c8ed253a234726a5df5bcbc500b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/covid-19-vaccine-azd1222-clinical-trial-resumed-in-japan-follows-restart-of-trials-in-the-uk-brazil-south-africa-and-india.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/covid-19-vaccine-azd1222-clinical-trial-resumed-in-japan-follows-restart-of-trials-in-the-uk-brazil-south-africa-and-india",
      "id": "c4ddc6326f94c1db4d435151eee0f7ac5e4786b9"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/covid-19-vaccine-azd1222-clinical-trials-resumed-in-the-uk.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/covid-19-vaccine-azd1222-clinical-trials-resumed-in-the-uk",
      "id": "3f9545118fd20c3743a13dd99f18c65e577050f7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/covid-19-vaccine-azd1222-showed-robust-immune-responses-in-all-participants-in-phase-i-ii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/covid-19-vaccine-azd1222-showed-robust-immune-responses-in-all-participants-in-phase-i-ii-trial",
      "id": "cb9a4de27323363c677a7a37e8284bfaac5d23aa"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/crestor-to-be-divested-to-grunenthal-in-europe.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/crestor-to-be-divested-to-grunenthal-in-europe",
      "id": "221529a55f29d35cb46a5f850dca66e24214b45c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/development-of-covid-19-vaccine-azd1222-expands-into-us-phase-iii-clinical-trial-across-all-adult-age-groups.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/development-of-covid-19-vaccine-azd1222-expands-into-us-phase-iii-clinical-trial-across-all-adult-age-groups",
      "id": "5147b244289450e772fbd333733a742433e35c53"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-achieved-a-tumour-response-rate-of-45p-in-patients-with-her2-positive-metastatic-colorectal-cancer-in-phase-ii-destiny-crc01-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/enhertu-achieved-a-tumour-response-rate-of-45p-in-patients-with-her2-positive-metastatic-colorectal-cancer-in-phase-ii-destiny-crc01-trial",
      "id": "e87bc46dccd86e7926e6cbdbd671da610062e128"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-continues-to-demonstrate-durable-responses-with-new-data-from-destiny-breast01-in-her2-positive-metastatic-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/enhertu-continues-to-demonstrate-durable-responses-with-new-data-from-destiny-breast01-in-her2-positive-metastatic-breast-cancer",
      "id": "3d43c0a3cb61d6f1b0ef6bbdeae59a01d4a3605b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-demonstrated-meaningful-clinical-activity-in-patients-with-her2-mutant-non-small-cell-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/enhertu-demonstrated-meaningful-clinical-activity-in-patients-with-her2-mutant-non-small-cell-lung-cancer",
      "id": "6a7ca10df9fed46b1a029fff8fe448209c36f5f1"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-granted-breakthrough-therapy-designation-in-the-us-for-her2-mutant-metastatic-non-small-cell-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/enhertu-granted-breakthrough-therapy-designation-in-the-us-for-her2-mutant-metastatic-non-small-cell-lung-cancer",
      "id": "a1de3bfc91fb6e578eba0bd618a41cbd41ab634a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-granted-breakthrough-therapy-designation-in-the-us-for-her2-positive-metastatic-gastric-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/enhertu-granted-breakthrough-therapy-designation-in-the-us-for-her2-positive-metastatic-gastric-cancer",
      "id": "7c840f19f06b7bd69692a13d759cb6549e0164fe"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-granted-orphan-drug-designation-in-the-us-for-gastric-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/enhertu-granted-orphan-drug-designation-in-the-us-for-gastric-cancer",
      "id": "d7527bba53eed7214b6208c5d8625c0cf2a4786a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-significantly-improved-tumour-response-rate-and-overall-survival-in-her2-positive-metastatic-gastric-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/enhertu-significantly-improved-tumour-response-rate-and-overall-survival-in-her2-positive-metastatic-gastric-cancer",
      "id": "d2bea7d0099f783181bfa7de47e772655cda9ada"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/enhertu-us-priority-review-in-gastric-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/enhertu-us-priority-review-in-gastric-cancer",
      "id": "ad6059d0628ec4fa28439624ec02b8afc8ac69c1"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-approved-in-the-us-for-the-treatment-of-heart-failure-in-patients-with-heart-failure-with-reduced-ejection-fraction.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/farxiga-approved-in-the-us-for-the-treatment-of-heart-failure-in-patients-with-heart-failure-with-reduced-ejection-fraction",
      "id": "de34940b6d2bfa9324c40718cd0162117bc765c8"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-dapa-ckd-phase-iii-trial-reduced-worsening-of-kidney-function-risk-of-cardiovascular-or-renal-death-in-patients-with-chronic-kidney-disease.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/farxiga-dapa-ckd-phase-iii-trial-reduced-worsening-of-kidney-function-risk-of-cardiovascular-or-renal-death-in-patients-with-chronic-kidney-disease",
      "id": "6c8455d2021ef5280fbb313c28fc3af5f6750095"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-demonstrated-reduction-in-the-risk-of-kidney-failure-and-cardiovascular-or-renal-death-in-patients-with-ckd-in-the-phase-iii-dapa-ckd-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/farxiga-demonstrated-reduction-in-the-risk-of-kidney-failure-and-cardiovascular-or-renal-death-in-patients-with-ckd-in-the-phase-iii-dapa-ckd-trial",
      "id": "9fbfc1dac322d166727463d01452fea1c174a812"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-granted-breakthrough-therapy-designation-in-us-for-chronic-kidney-disease.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/farxiga-granted-breakthrough-therapy-designation-in-us-for-chronic-kidney-disease",
      "id": "e379283a46d92e25f37440e8bd37d99c8a0b661f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-granted-fast-track-designation-in-the-us-for-heart-failure-following-acute-myocardial-infarction-leveraging-an-innovative-registry-based-trial-design.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/farxiga-granted-fast-track-designation-in-the-us-for-heart-failure-following-acute-myocardial-infarction-leveraging-an-innovative-registry-based-trial-design",
      "id": "5c5886adbff7a60c57ef989ae84cf682c0ca2b39"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-granted-fda-priority-review-for-patients-with-heart-failure-with-reduced-ejection-fraction-06012020.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/farxiga-granted-fda-priority-review-for-patients-with-heart-failure-with-reduced-ejection-fraction-06012020",
      "id": "3ad5262f7ac7c3e892df0db0d9bd2781c5bc3b76"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-met-all-primary-and-secondary-endpoints-in-groundbreaking-phase-iii-dapa-ckd-trial-for-the-treatment-of-patients-with-chronic-kidney-disease.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/farxiga-met-all-primary-and-secondary-endpoints-in-groundbreaking-phase-iii-dapa-ckd-trial-for-the-treatment-of-patients-with-chronic-kidney-disease",
      "id": "909a83733ad7e6226a837a5946b197323aa48c26"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-phase-iii-dapa-ckd-trial-paradigm-shifting-data-to-be-presented-at-esc-2020.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/farxiga-phase-iii-dapa-ckd-trial-paradigm-shifting-data-to-be-presented-at-esc-2020",
      "id": "5b76db96f212d67571efba17c6ec5b21366b7d3f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-phase-iii-dapa-ckd-trial-will-be-stopped-early-after-overwhelming-efficacy-in-patients-with-chronic-kidney-disease.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/farxiga-phase-iii-dapa-ckd-trial-will-be-stopped-early-after-overwhelming-efficacy-in-patients-with-chronic-kidney-disease",
      "id": "d4a376299fd51fa4e4ba63fd131127024a24dd50"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-reduced-the-incidence-of-heart-failure-worsening-or-cardiovascular-death-in-a-sub-analysis-from-landmark-phase-iii-dapa-hf-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/farxiga-reduced-the-incidence-of-heart-failure-worsening-or-cardiovascular-death-in-a-sub-analysis-from-landmark-phase-iii-dapa-hf-trial",
      "id": "efe25715a19f3c8a750e1dcb8d5bad72c508a7b6"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/fasenra-eliminated-oral-corticosteroid-use-in-a-majority-of-ocs-dependent-patients-with-asthma-in-ponente-phase-iiib-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/fasenra-eliminated-oral-corticosteroid-use-in-a-majority-of-ocs-dependent-patients-with-asthma-in-ponente-phase-iiib-trial",
      "id": "600964c8638f3692388abaa933d0f108a9f8ea33"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/fasenra-met-both-co-primary-endpoints-of-reduced-nasal-polyp-size-and-blockage-in-the-ostro-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/fasenra-met-both-co-primary-endpoints-of-reduced-nasal-polyp-size-and-blockage-in-the-ostro-phase-iii-trial",
      "id": "22fa4e6e6be605b5f2316f5b4e516967a0b6fe59"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/fda-authorises-restart-of-the-covid-19-azd1222-vaccine-us-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/fda-authorises-restart-of-the-covid-19-azd1222-vaccine-us-phase-iii-trial",
      "id": "09e437747eb33afdc49e339aac8e09bb177a4231"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/forxiga-approved-in-japan-for-heart-failure.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/forxiga-approved-in-japan-for-heart-failure",
      "id": "58386cf3dd5a24caff0ce4988da26d63bd62f9ee"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/forxiga-approved-in-the-eu-for-heart-failure.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/forxiga-approved-in-the-eu-for-heart-failure",
      "id": "ef61682f92970a6340ea5182f2a9d862697108dd"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/forxiga-cv-outcomes-benefit-approved-in-china.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/forxiga-cv-outcomes-benefit-approved-in-china",
      "id": "747f815a9daa7cce311ca832245b60f193002457"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/forxiga-recommended-for-approval-in-the-eu-by-chmp-for-heart-failure.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/forxiga-recommended-for-approval-in-the-eu-by-chmp-for-heart-failure",
      "id": "6dce983ba7f8864e2481397d40b89ebd41fc27ad"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/full-year-and-q4-2019-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/full-year-and-q4-2019-results",
      "id": "e2c0350652c83c4a81600fb847616b15314aeb69"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/h1-2020-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/h1-2020-results",
      "id": "49b23d1b98de33ab20b6c73e194ecc23bf1d41db"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-and-tremelimumab-granted-orphan-drug-designation-in-the-us-for-liver-cancer-20012020.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/imfinzi-and-tremelimumab-granted-orphan-drug-designation-in-the-us-for-liver-cancer-20012020",
      "id": "6df478a303a4d52bcaeb138a7fda4080a154cee0"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-approved-in-EU-for-small-cell-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/imfinzi-approved-in-eu-for-small-cell-lung-cancer",
      "id": "7d1feed21c23eacd632ccf33c882cdfe8e54af29"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-approved-in-japan-for-sclc.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/imfinzi-approved-in-japan-for-sclc",
      "id": "40aa163ce864b79c823b5bc9b08bc6cbf05c9d53"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-approved-in-the-us-for-extensive-stage-small-cell-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/imfinzi-approved-in-the-us-for-extensive-stage-small-cell-lung-cancer",
      "id": "780003c0c99bdc5aa39c794b26a251010855351d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-confirmed-a-sustained-overall-survival-benefit-in-final-analysis-of-the-phase-iii-caspian-trial-in-1st-line-extensive-stage-small-cell-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/imfinzi-confirmed-a-sustained-overall-survival-benefit-in-final-analysis-of-the-phase-iii-caspian-trial-in-1st-line-extensive-stage-small-cell-lung-cancer",
      "id": "f30179adad55271daf6555a7c69f7579501070ba"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-demonstrated-unprecedented-survival-in-unresectable-stage-III-nsclc.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/imfinzi-demonstrated-unprecedented-survival-in-unresectable-stage-iii-nsclc",
      "id": "572f0d8a990eaf1c2c4b1f85a7283546c68d052d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-granted-fda-priority-review-for-less-frequent-fixed-dose-use.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/imfinzi-granted-fda-priority-review-for-less-frequent-fixed-dose-use",
      "id": "e5c414a16f4bb6b372cebad99fe961b0cf55e48d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-new-dose-receives-positive-eu-chmp-opinion.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/imfinzi-new-dose-receives-positive-eu-chmp-opinion",
      "id": "8d75910b97029c731ffb1de60dab93795288e5c8"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-new-dosing-approved-in-the-us.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/imfinzi-new-dosing-approved-in-the-us",
      "id": "5599ff49426ad1110275b2af1e81c536d97ca372"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-plus-tremelimumab-demonstrated-promising-clinical-activity-and-tolerability-in-patients-with-advanced-liver-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/imfinzi-plus-tremelimumab-demonstrated-promising-clinical-activity-and-tolerability-in-patients-with-advanced-liver-cancer",
      "id": "0714b4f0d5377e77974448fb91a7e4b8c087d9b4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-recommended-for-approval-in-the-eu-by-chmp-for-extensive-stage-small-cell-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/imfinzi-recommended-for-approval-in-the-eu-by-chmp-for-extensive-stage-small-cell-lung-cancer",
      "id": "cbf3be72e6755f6d358c43c4d0d9b4bf0316fcf2"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/imfinzi-showed-a-sustained-overall-survival-benefit-in-1st-line-extensive-stage-small-cell-lung-cancer-in-the-phase-iii-caspian-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/imfinzi-showed-a-sustained-overall-survival-benefit-in-1st-line-extensive-stage-small-cell-lung-cancer-in-the-phase-iii-caspian-trial",
      "id": "8e7a97a1229cee54a195c63ff2a0fd9b127396e4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas",
      "id": "0eb952bc0ad9bbfdfc5050b15256bd2574fb1710"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/lokelma-approved-in-china-for-the-treatment-of-adult-patients-with-hyperkalaemia-06012020.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/lokelma-approved-in-china-for-the-treatment-of-adult-patients-with-hyperkalaemia-06012020",
      "id": "ad746c35a4b97bd4b971cb5425e5dd717ce8a8af"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/lokelma-approved-in-japan-for-the-treatment-of-hyperkalaemia.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/lokelma-approved-in-japan-for-the-treatment-of-hyperkalaemia",
      "id": "da5a711767f1fffdeece871e15fb52ffe373e972"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/lokelma-recommended-for-approval-in-eu-for-patients-with-hyperkalaemia-on-stable-haemodialysis.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/lokelma-recommended-for-approval-in-eu-for-patients-with-hyperkalaemia-on-stable-haemodialysis",
      "id": "60d08e46a038f001a636ae08b742dbeb672af6bf"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-approved-in-japan-for-three-cancers.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/lynparza-approved-in-japan-for-three-cancers",
      "id": "528f47b2c2c515d240c7d706ee7d59b186e1b4d8"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-approved-in-the-eu-for-brca-mutated-metastatic-pancreatic-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/lynparza-approved-in-the-eu-for-brca-mutated-metastatic-pancreatic-cancer",
      "id": "875201777481d313a4fddf0d5d6b79e63fe41554"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-approved-in-the-eu-for-prostate-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/lynparza-approved-in-the-eu-for-prostate-cancer",
      "id": "986e8b5b311c4a4251aa3579555c6349a44a85ae"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-approved-in-the-eu-for-wider-ovarian-use.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/lynparza-approved-in-the-eu-for-wider-ovarian-use",
      "id": "31afef2c8de2909532b73f9ea65e17d8fc3ae90d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-approved-in-the-us-for-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/lynparza-approved-in-the-us-for-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer",
      "id": "2ca943dba48d130d24b84f67496b02f5ac35ffa7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-eu-recommendation-in-ovarian-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/lynparza-eu-recommendation-in-ovarian-cancer",
      "id": "ce7bf524dd71806bf9d2691ee2985d996e15034c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-eu-recommendation-in-prostate-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/lynparza-eu-recommendation-in-prostate-cancer",
      "id": "6af147b17270dd964de7b4cd56edfb86afac118a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-granted-orphan-drug-designation-in-japan-for-brca-mutated-metastatic-pancreatic-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/lynparza-granted-orphan-drug-designation-in-japan-for-brca-mutated-metastatic-pancreatic-cancer",
      "id": "af937b7a929dd8cbca5c7049547fe7d9d702bb02"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-improved-median-time-patients-lived-without-disease-progression-to-over-four-and-half-years-in-BRCA-mutated-advanced-ovarian-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/lynparza-improved-median-time-patients-lived-without-disease-progression-to-over-four-and-half-years-in-brca-mutated-advanced-ovarian-cancer",
      "id": "a26310580a1ed7284bc8a709d271240b092a4a34"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-recommended-for-approval-in-eu-by-chmp-for-brca-mutated-metastatic-pancreatic-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/lynparza-recommended-for-approval-in-eu-by-chmp-for-brca-mutated-metastatic-pancreatic-cancer",
      "id": "f4b1079798914a231b4c2759085910b5591be3e0"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-reduced-the-risk-of-death-by-31-percent-in-brca-or-atm-mcrpc-in-profound.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/lynparza-reduced-the-risk-of-death-by-31-percent-in-brca-or-atm-mcrpc-in-profound",
      "id": "83694b039883986f8a61d985fbe22a79a05dd52c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-regulatory-submission-granted-priority-review-in-the-us-for-1st-line-maintenance-treatment-with-bevacizumab-in-advanced-ovarian-cancer-13012020.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/lynparza-regulatory-submission-granted-priority-review-in-the-us-for-1st-line-maintenance-treatment-with-bevacizumab-in-advanced-ovarian-cancer-13012020",
      "id": "e5c1f542ac87daf808b7a5ecb6805777f1533127"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-regulatory-submission-granted-priority-review-in-the-us-for-hrr-mutated-metastatic-castration-resistant-prostate-cancer-20012020.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/lynparza-regulatory-submission-granted-priority-review-in-the-us-for-hrr-mutated-metastatic-castration-resistant-prostate-cancer-20012020",
      "id": "d32ce5b8a0b6d83637d63dd2f6d464a49a40863e"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-shows-overall-survival-in-prostate-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/lynparza-shows-overall-survival-in-prostate-cancer",
      "id": "04d910c51464d79463b9d6f7ef3cba9bcdf696ed"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/new-analyses-from-breztri-aerosphere-phase-iii-ethos-trial-to-be-presented-at-the-european-respiratory-society-international-congress-2020.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/new-analyses-from-breztri-aerosphere-phase-iii-ethos-trial-to-be-presented-at-the-european-respiratory-society-international-congress-2020",
      "id": "3bc4a8225ace4891ffefc39b94979aa104050c72"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/nirsevimab-reduced-respiratory-syncytial-virus-infections-and-hospitalisations-in-preterm-infants-in-phase-iib-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/nirsevimab-reduced-respiratory-syncytial-virus-infections-and-hospitalisations-in-preterm-infants-in-phase-iib-trial",
      "id": "65ddc4e0a9090af141ec04f52089e8cfd017530c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/phase-1-clinical-trial-initiated-for-monoclonal-antibody-combination-for-the-prevention-and-treatment-of-covid-19.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/phase-1-clinical-trial-initiated-for-monoclonal-antibody-combination-for-the-prevention-and-treatment-of-covid-19",
      "id": "f252f931807944cab12f4197640847f750f325f2"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/phase-ii-destiny-gastric01-trial-of-enhertu-versus-chemotherapy-met-primary-endpoint-27012020.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/phase-ii-destiny-gastric01-trial-of-enhertu-versus-chemotherapy-met-primary-endpoint-27012020",
      "id": "94870c1ff19981837a03646c318ae2ee2be9beaf"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/q1-2020-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/q1-2020-results",
      "id": "16f098e65d558fd7ed8edb920dcde45bd7ce5aec"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/selumetinib-granted-orphan-drug-designation-in-japan-for-neurofibromatosis-type-1.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/selumetinib-granted-orphan-drug-designation-in-japan-for-neurofibromatosis-type-1",
      "id": "bf0bb955fdc1f0409e404fb4304bd7eb0da1377a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/statement-on-astrazeneca-oxford-sars-cov-2-vaccine-azd1222-covid-19-vaccine-trials-temporary-pause.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/statement-on-astrazeneca-oxford-sars-cov-2-vaccine-azd1222-covid-19-vaccine-trials-temporary-pause",
      "id": "c0f14fbc07f1f5cccc0aec98929e6f65e0c24bc4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/tagrisso-adjuvant-lung-cancer-us-priority-review.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/tagrisso-adjuvant-lung-cancer-us-priority-review",
      "id": "db266aa0c9f3e75e7496e4a93616e5a33e78599b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/tagrisso-approved-in-the-us-for-early-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/tagrisso-approved-in-the-us-for-early-lung-cancer",
      "id": "9292983c806f995b1e4b38b540eb39f535b2a18a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/tagrisso-demonstrated-unprecedented-disease-free-survival-in-the-adjuvant-treatment-of-stage-ib-iiia-patients-with-egfr-mutated-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/tagrisso-demonstrated-unprecedented-disease-free-survival-in-the-adjuvant-treatment-of-stage-ib-iiia-patients-with-egfr-mutated-lung-cancer",
      "id": "709fe09cbc0b93cdd9d1416341f00ffc6371c04e"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/tagrisso-phase-iii-adaura-trial-will-be-unblinded-early-after-overwhelming-efficacy-in-the-adjuvant-treatment-of-patients-with-egfr-mutated-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/tagrisso-phase-iii-adaura-trial-will-be-unblinded-early-after-overwhelming-efficacy-in-the-adjuvant-treatment-of-patients-with-egfr-mutated-lung-cancer",
      "id": "6b61dc874737db4100f7c684cda680b4475c8eef"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/tagrisso-reduces-brain-recurrence-in-early-lung.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/tagrisso-reduces-brain-recurrence-in-early-lung",
      "id": "f803027c1a27b12010356a65580aa9ece8828e72"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/tagrisso-us-btd-for-egfrm-adjuvant-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/tagrisso-us-btd-for-egfrm-adjuvant-lung-cancer",
      "id": "93604b8efda82d888f6d1c398e6e5e9b2d6dc1f4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/tezepelumab-navigator-phase-iii-trial-met-primary-endpoint.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/tezepelumab-navigator-phase-iii-trial-met-primary-endpoint",
      "id": "f50ff8eac2ca5d2a84e28ae72945685306da50f0"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/tlynparza-approved-in-the-us-as-1st-line-maintenance-treatment-with-bevacizumab-for-hrd-positive-advanced-ovarian-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/tlynparza-approved-in-the-us-as-1st-line-maintenance-treatment-with-bevacizumab-for-hrd-positive-advanced-ovarian-cancer",
      "id": "ed190490fc30f25b9ef60540a3579c574c0c68e6"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/trastuzumab-deruxtecan-positive-chmp.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/trastuzumab-deruxtecan-positive-chmp",
      "id": "f625af1cab303b2529e71f2d192e17e6518302f2"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/trixeo-aerosphere-approved-in-the-eu-for-copd.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/trixeo-aerosphere-approved-in-the-eu-for-copd",
      "id": "bf2aaf878ca40464d415c64578c33a1f6fb00954"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/trixeo-aerosphere-recommended-for-approval-in-the-eu-by-chmp-for-the-maintenance-treatment-of-copd.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/trixeo-aerosphere-recommended-for-approval-in-the-eu-by-chmp-for-the-maintenance-treatment-of-copd",
      "id": "96a02a93196bf8821061a4ac580280b203ce2b81"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-calavi-phase-ii-trials-for-calquence-in-patients-hospitalised-with-respiratory-symptoms-of-covid-19.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/update-on-calavi-phase-ii-trials-for-calquence-in-patients-hospitalised-with-respiratory-symptoms-of-covid-19",
      "id": "bfb5ef6aaca02232455e5b9101c0cc753ad62876"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-phase-iii-danube-trial-for-imfinzi-and-tremelimumab-in-unresectable-stage-iv-bladder-cancer-06032020.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/update-on-phase-iii-danube-trial-for-imfinzi-and-tremelimumab-in-unresectable-stage-iv-bladder-cancer-06032020",
      "id": "3e0f048e2e01a38bcbdbef043f1e769fa7e0913b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-phase-iii-gy004-trial-for-cediranib-added-to-lynparza-in-platinum-sensitive-relapsed-ovarian-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/update-on-phase-iii-gy004-trial-for-cediranib-added-to-lynparza-in-platinum-sensitive-relapsed-ovarian-cancer",
      "id": "a2c8e7b454a6761dfbdcfd06808fb1599b6f33a7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-phase-iii-strength-trial-for-epanova-in-mixed-dyslipidaemia-13012020.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/update-on-phase-iii-strength-trial-for-epanova-in-mixed-dyslipidaemia-13012020",
      "id": "12b9786d451760041342b333c13d51e720122bcf"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-source-phase-iii-trial-for-tezepelumab-in-patients-with-severe-oral-corticosteroid-dependent-asthma.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/update-on-source-phase-iii-trial-for-tezepelumab-in-patients-with-severe-oral-corticosteroid-dependent-asthma",
      "id": "1240c88784614c0c7083c1d340fc2276789b413c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-us-regulatory-review-of-roxadustat-in-anaemia-of-chronic-kidney-disease.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/update-on-us-regulatory-review-of-roxadustat-in-anaemia-of-chronic-kidney-disease",
      "id": "3b6e0c929bb30f682a8a5a3b6cd0146db92687b0"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/year-to-date-and-q3-2020-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2020/year-to-date-and-q3-2020-results",
      "id": "fd821ce9e2f4ec8fe6875b1302695b24f89b9224"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021",
      "id": "c388b941526400471c20bfdae893541e2ea25524"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/acquisition-of-alexion-completed.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/acquisition-of-alexion-completed",
      "id": "6b5765d69490a139b5eb4fd5a963f0ff2c3ceee5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/alxn1840-wilson-phase-iii-met-primary-endpoint.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/alxn1840-wilson-phase-iii-met-primary-endpoint",
      "id": "1494adaa0d9ad0914fb495136302ff16cfc327f2"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/anifrolumab-showed-benefit-across-different-measures-of-skin-and-joint-disease-activity-in-patients-with-systemic-lupus-erythematosus.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/anifrolumab-showed-benefit-across-different-measures-of-skin-and-joint-disease-activity-in-patients-with-systemic-lupus-erythematosus",
      "id": "6ade356a46b67f4210f8e6046a88d3954bdb2a84"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/approval-recognises-acquisitions-advancement-of-the-companys-strategic-and-financial-development.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/approval-recognises-acquisitions-advancement-of-the-companys-strategic-and-financial-development",
      "id": "caaf0d699341c36aaa125b28f39859e9b683c263"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-360m-irish-manufacturing-investment.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-360m-irish-manufacturing-investment",
      "id": "fd2ca3ce7123d7ab70fb00fc696d5004514e81e5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-accelerates-early-oncology-pipeline-across-key-strategic-scientific-platforms-at-aacr.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-accelerates-early-oncology-pipeline-across-key-strategic-scientific-platforms-at-aacr",
      "id": "67dac46e978ff48d5a70adbb90ac870a62361c3b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-advances-ambition-to-redefine-care-for-blood-cancer-at-ash-2021.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-advances-ambition-to-redefine-care-for-blood-cancer-at-ash-2021",
      "id": "39f4330c744e90265c16180be6c8fb8d8d47f773"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-advances-mass-global-rollout-of-covid-19-vaccine-through-covax.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-advances-mass-global-rollout-of-covid-19-vaccine-through-covax",
      "id": "5984159c331fa7e7a7821d58f9894340dc81f093"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-agrees-to-divest-viela-shareholding.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-agrees-to-divest-viela-shareholding",
      "id": "51725e48e1f43519c332d5dbccf69aaef681d7ad"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-alexion-transaction-cleared-in-the-eu.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-alexion-transaction-cleared-in-the-eu",
      "id": "4d6c252d6049b8656879a0dd886d1395f4cd416c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-alexion-transaction-cleared-in-the-uk.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-alexion-transaction-cleared-in-the-uk",
      "id": "fdd83158cbe1846b93694fd633afe0fb736eeb11"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-and-european-commission-reach-settlement-agreement-over-vaccine-supply-ending-litigation.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-and-european-commission-reach-settlement-agreement-over-vaccine-supply-ending-litigation",
      "id": "e45b4a31965ff1417df4417ba02d3c12d2a75bd3"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-and-idt-biologika-sign-letter-of-intent-to-increase-covid-19-vaccine-manufacturing-in-europe-and-secure-long-term-supply-capacity.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-and-idt-biologika-sign-letter-of-intent-to-increase-covid-19-vaccine-manufacturing-in-europe-and-secure-long-term-supply-capacity",
      "id": "9371ffdb02d6b091df723c368b7cc608efb5ab14"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-and-ionis-close-eplontersen-deal.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-and-ionis-close-eplontersen-deal",
      "id": "78a6d824880407bcdd075bc40a80753993ac1055"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-and-regeneron-to-research-develop-and-commercialise-new-small-molecule-medicines-for-obesity.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-and-regeneron-to-research-develop-and-commercialise-new-small-molecule-medicines-for-obesity",
      "id": "4ccf1369ded724f9584882fbda8fbfa7396e3e5b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-appoints-aradhana-sarin-as-new-chief-financial-officer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-appoints-aradhana-sarin-as-new-chief-financial-officer",
      "id": "117fc7571e133f3ace483eff2d1c713102e1f87c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-appoints-dr-susan-galbraith-as-executive-vice-president-oncology-research-and-development.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-appoints-dr-susan-galbraith-as-executive-vice-president-oncology-research-and-development",
      "id": "e94e8af27b1230553ab1dcc2e76432bc82b5ff5a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-asco-2021-data-support-ambition-to-revolutionise-cancer-outcomes-by-treating-earlier-and-transforming-the-patient-experience.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-asco-2021-data-support-ambition-to-revolutionise-cancer-outcomes-by-treating-earlier-and-transforming-the-patient-experience",
      "id": "611dfdb83ca5e4fed6477eee333d829fbdaca731"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-covid-19-and-rsv-presentations-at-idweek-2021-will-showcase-scientific-progress-in-infectious-diseases.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-covid-19-and-rsv-presentations-at-idweek-2021-will-showcase-scientific-progress-in-infectious-diseases",
      "id": "f4e28d3072f01c423c59a19ac22a4689314e4ea5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-covid-19-vaccine-authorised-for-emergency-use-by-the-world-health-organization.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-covid-19-vaccine-authorised-for-emergency-use-by-the-world-health-organization",
      "id": "66641b30819c29cba10a9be6bd7b0c2a548be4c0"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-covid-19-vaccine-vaxzevria-authorised-for-emergency-use-in-japan.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-covid-19-vaccine-vaxzevria-authorised-for-emergency-use-in-japan",
      "id": "a570b6dce6a1f30eb88c00d0592014687155c484"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-ionis-to-collaborate-on-eplontersen.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-ionis-to-collaborate-on-eplontersen",
      "id": "32c916c13e3e088b31a127413cf9218f42af0cc2"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-lung-and-breast-cancer-data-at-wclc-and-esmo-2021-underscore-ambition-to-revolutionise-outcomes-for-patients.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-lung-and-breast-cancer-data-at-wclc-and-esmo-2021-underscore-ambition-to-revolutionise-outcomes-for-patients",
      "id": "bc1be88de4d1771c89d6efbff7d73e416ae0ce36"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-reinforces-leadership-in-breast-cancer-at-sabcs-2021-with-new-data-underscoring-ambition-to-redefine-cancer-care.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-reinforces-leadership-in-breast-cancer-at-sabcs-2021-with-new-data-underscoring-ambition-to-redefine-cancer-care",
      "id": "2ec86ddca79aa603c44c18a7aabb53959ef9e629"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-to-discover-and-develop-self-amplifying-rna-therapeutics-in-new-collaboration-with-vaxequity.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-to-discover-and-develop-self-amplifying-rna-therapeutics-in-new-collaboration-with-vaxequity",
      "id": "e8f23e27baeead4ceed08b4a5a75260fd5643f99"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-to-fully-acquire-caelum-biosciences.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-to-fully-acquire-caelum-biosciences",
      "id": "0e86f9617393a0c0eb71eb696f5abc1e518f67b7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-to-showcase-transformative-data-across-diverse-pipeline-at-world-conference-on-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-to-showcase-transformative-data-across-diverse-pipeline-at-world-conference-on-lung-cancer",
      "id": "005325a004d4a05788489d71ee95d145dfcff83c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-to-transfer-rights-to-eklira-duaklir.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-to-transfer-rights-to-eklira-duaklir",
      "id": "007cdc16249ac4cb87faf6368f81ac3355c9db8c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-unveils-the-discovery-centre-disc-in-cambridge.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-unveils-the-discovery-centre-disc-in-cambridge",
      "id": "7035c793fd708e943d6d8e31d0caa11d96e32691"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-us-vaccine-trial-met-primary-endpoint.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-us-vaccine-trial-met-primary-endpoint",
      "id": "026778a7ce0dda9181bf8ba97bc5571148ce5002"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-welcomes-court-ruling-on-supply-of-its-covid-19-vaccine-to-europe.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/astrazeneca-welcomes-court-ruling-on-supply-of-its-covid-19-vaccine-to-europe",
      "id": "6906996d5d922180db8178b86ea966deb9c3a02f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/atacand-divestment-in-over-70-countries-completed.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/atacand-divestment-in-over-70-countries-completed",
      "id": "dfb5acaa9dc768e107c3c6e1720d0961b366ede5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy",
      "id": "ad4150b1ed314f975a6cabb75ab0d5a379b09426"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/azd7442-phiii-trial-positive-in-covid-outpatients.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/azd7442-phiii-trial-positive-in-covid-outpatients",
      "id": "95e2a8aaac1fc24e2462da7fa11e48a3946697c5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/azd7442-prophylaxis-trial-met-primary-endpoint.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/azd7442-prophylaxis-trial-met-primary-endpoint",
      "id": "a3d73c8b35ed6aa916faffbf9d273b8933ba0ccd"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/azd7442-request-for-emergency-use-authorization-for-covid-19-prophylaxis-filed-in-us.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/azd7442-request-for-emergency-use-authorization-for-covid-19-prophylaxis-filed-in-us",
      "id": "a423d5fc26621f09f0917c39c64cb38e3534c2a9"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/azd8601-epiccure-phase-ii-trial-demonstrated-safety-and-tolerability-in-patients-with-heart-failure.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/azd8601-epiccure-phase-ii-trial-demonstrated-safety-and-tolerability-in-patients-with-heart-failure",
      "id": "5bbd740994ad2dd2407e2bc3b26fd5c67d9bdc4e"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/calquence-approved-in-japan-for-cll.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/calquence-approved-in-japan-for-cll",
      "id": "3f6fc1cd58974ee9f8c0709a13f7d11e4e43a7c5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/calquence-head-to-head-results-versus-ibrutinib.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/calquence-head-to-head-results-versus-ibrutinib",
      "id": "b674bafaaf8c95d9c954455cdd78dc260540ffa3"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/calquence-met-primary-endpoint-against-ibrutinib.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/calquence-met-primary-endpoint-against-ibrutinib",
      "id": "0415b8f63b4ffd1ef3d86ea6deba7d21dd293e30"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/calquence-reduced-the-risk-of-disease-progression-or-death-vs-standard-of-care-combinations-at-three-years-in-the-ascend-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/calquence-reduced-the-risk-of-disease-progression-or-death-vs-standard-of-care-combinations-at-three-years-in-the-ascend-phase-iii-trial",
      "id": "8ca528163f159517ae99a4ac4707b808179c8f8d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-confirms-protection-against-severe-disease-hospitalisation-and-death-in-the-primary-analysis-of-phase-iii-trials.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-confirms-protection-against-severe-disease-hospitalisation-and-death-in-the-primary-analysis-of-phase-iii-trials",
      "id": "37385e14b2c59574c7b9adb42db221c2ef577a29"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-effective-against-delta-indian-variant.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-effective-against-delta-indian-variant",
      "id": "d7b09d6f812974aa7843b7659204da2b218a8403"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-recommended-for-use-in-the-eu.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-recommended-for-use-in-the-eu",
      "id": "284340afea6c119629352744879ed41820e2d273"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-authorised-for-use-in-the-eu.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/covid-19-vaccine-authorised-for-use-in-the-eu",
      "id": "c5d64c1daccff6d4fcda55f58b0af37bcd3ecc15"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/datopotamab-deruxtecan-and-enhertu-show-promising-early-clinical-activity-in-patients-with-advanced-non-small-cell-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/datopotamab-deruxtecan-and-enhertu-show-promising-early-clinical-activity-in-patients-with-advanced-non-small-cell-lung-cancer",
      "id": "56015da900f088d95bd1958c1c9606b3b16b336c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/divestment-of-crestor-in-europe-completed.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/divestment-of-crestor-in-europe-completed",
      "id": "7ed0e9c8c58e905ba65aa7697e2e828abe1cb822"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/divestment-of-viela-shareholding-completed.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/divestment-of-viela-shareholding-completed",
      "id": "8f87fdc4c20c1c3e6bc1e10f6f3489f3f23d9717"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-additional-analyses-further-reinforce-ground-breaking-efficacy-in-patients-with-her2-positive-metastatic-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/enhertu-additional-analyses-further-reinforce-ground-breaking-efficacy-in-patients-with-her2-positive-metastatic-breast-cancer",
      "id": "6443536966e8eaae7c562baad7c8c0cb7e0f1b2a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-approved-in-the-eu-for-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/enhertu-approved-in-the-eu-for-breast-cancer",
      "id": "0aaecc2b72cc7ba2b28caaf70147ccc5e8ca2a5b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-approved-in-the-us-for-gastric-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/enhertu-approved-in-the-us-for-gastric-cancer",
      "id": "fe70e1ad7573aeee8411af9985baf036e37e61ee"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-demonstrated-clinically-meaningful-and-durable-response-in-patients-with-her2-positive-advanced-gastric-cancer-in-destiny-gastric02-phase-ii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/enhertu-demonstrated-clinically-meaningful-and-durable-response-in-patients-with-her2-positive-advanced-gastric-cancer-in-destiny-gastric02-phase-ii-trial",
      "id": "c80024620cf3987b8eb145f1040adbe8bbec0e6f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-demonstrated-robust-and-durable-tumour-response-of-549-in-patients-with-her2-mutant-metastatic-non-small-cell-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/enhertu-demonstrated-robust-and-durable-tumour-response-of-549-in-patients-with-her2-mutant-metastatic-non-small-cell-lung-cancer",
      "id": "8c413989a1a514bc65d2d85b751e8fce18c199d9"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-granted-btd-for-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/enhertu-granted-btd-for-breast-cancer",
      "id": "136bcc5e190c3945437cd948445e3d16a4fc6fca"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-head-to-head-trial-meets-primary-endpoint.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/enhertu-head-to-head-trial-meets-primary-endpoint",
      "id": "e17da5880749b085993dba6f978716649c4bc014"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-reduced-the-risk-of-disease-progression-or-death-by-72-vs-trastuzumab-emtansine-t-dm1-in-patients-with-her2-positive-metastatic-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/enhertu-reduced-the-risk-of-disease-progression-or-death-by-72-vs-trastuzumab-emtansine-t-dm1-in-patients-with-her2-positive-metastatic-breast-cancer",
      "id": "c768d4b9d14fa5c52d4cd68214a659c919b6db63"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-authorised-for-emergency-use-in-the-us-for-pre-exposure-prophylaxis-prevention-of-covid-19.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-authorised-for-emergency-use-in-the-us-for-pre-exposure-prophylaxis-prevention-of-covid-19",
      "id": "888aba648c38be08b3b4deb08aeba2962a368a43"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-variant-in-independent-fda-study.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-variant-in-independent-fda-study",
      "id": "8565dfe43f972cf13a7372174d379b40014fbb24"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-variant-in-studies-from-oxford-and-washington-universities.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-variant-in-studies-from-oxford-and-washington-universities",
      "id": "d089e2c949e6716b74ccdff52d79d2af6b8183c2"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/farxiga-approved-in-the-us-for-ckd.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/farxiga-approved-in-the-us-for-ckd",
      "id": "03aa4e88da5aeab46a610a992d1a90152dcb09b0"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/farxiga-granted-us-priority-review-for-ckd.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/farxiga-granted-us-priority-review-for-ckd",
      "id": "864689266f3d6ccc290e6c71f00316a3012ea972"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/first-covid-19-variant-vaccine-azd2816-phase-ii-iii-trial-participants-vaccinated.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/first-covid-19-variant-vaccine-azd2816-phase-ii-iii-trial-participants-vaccinated",
      "id": "562b180b4e55a7e032bb7bc83d6292c77afb1a1f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/forxiga-approved-in-china-for-heart-failure.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/forxiga-approved-in-china-for-heart-failure",
      "id": "d6bac723846e0a2ef3b68ef68dce1829b327a1c6"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/forxiga-approved-in-japan-for-ckd.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/forxiga-approved-in-japan-for-ckd",
      "id": "e5204d4d28ac56f4216b9bdda2c20d0ce8d7bd03"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/forxiga-approved-in-the-eu-for-ckd.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/forxiga-approved-in-the-eu-for-ckd",
      "id": "56ae98ec640f646895986aab568063bca24b6426"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/forxiga-recommended-in-eu-for-patients-with-ckd.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/forxiga-recommended-in-eu-for-patients-with-ckd",
      "id": "53cc546661eca2c3ce645d3a69a33372af773de6"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/full-year-2020-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/full-year-2020-results",
      "id": "456df477ae39c797c947c05621f88cd2f6642d44"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/further-update-on-us-regulatory-review-of-roxadustat-in-anaemia-of-chronic-kidney-disease.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/further-update-on-us-regulatory-review-of-roxadustat-in-anaemia-of-chronic-kidney-disease",
      "id": "2e490c031458f3169fa54b461aa46a6ce6e7d7b7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/h1-2021-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/h1-2021-results",
      "id": "ebb146087ed9cfd59b400c16814ff754ce217c16"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-and-tremelimumab-improved-os-in-liver-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/imfinzi-and-tremelimumab-improved-os-in-liver-cancer",
      "id": "3f426532a5afba8844627d0e713e048d3c73fe5a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-and-tremelimumab-showed-survival-in-poseidon.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/imfinzi-and-tremelimumab-showed-survival-in-poseidon",
      "id": "764ac664bff44772764b0d69b176fb99db715916"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-approved-in-china-for-extensive-stage-sclc.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/imfinzi-approved-in-china-for-extensive-stage-sclc",
      "id": "b66a148490ef4d29360198d4009b99fc501771f1"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-combined-with-novel-immunotherapies-improved-clinical-outcomes-for-patients-with-unresectable-stage-iii-non-small-cell-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/imfinzi-combined-with-novel-immunotherapies-improved-clinical-outcomes-for-patients-with-unresectable-stage-iii-non-small-cell-lung-cancer",
      "id": "9afbb43897ef5cfab570afb593f67282ddfdacb0"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-demonstrated-unprecedented-survival-in-unresectable-stage-iii-lung-cancer-with-43-percent-of-patients-surviving-five-years.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/imfinzi-demonstrated-unprecedented-survival-in-unresectable-stage-iii-lung-cancer-with-43-percent-of-patients-surviving-five-years",
      "id": "57a76311791160c46c569f80bb9c79670c267aca"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-improved-survival-in-biliary-tract-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/imfinzi-improved-survival-in-biliary-tract-cancer",
      "id": "1cecb879dedb715608acf6a360493d930f491f4f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-improves-survival-in-nsclc-in-poseidon.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/imfinzi-improves-survival-in-nsclc-in-poseidon",
      "id": "2a38326290dfd2658b70b49406c7df3a2d98af74"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-new-dosing-approved-in-eu.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/imfinzi-new-dosing-approved-in-eu",
      "id": "1b7f247c893dd579674ba177c92a6b053be3f803"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-plus-chemotherapy-tripled-patient-survival-at-three-years-in-the-caspian-phase-iii-trial-in-extensive-stage-small-cell-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/imfinzi-plus-chemotherapy-tripled-patient-survival-at-three-years-in-the-caspian-phase-iii-trial-in-extensive-stage-small-cell-lung-cancer",
      "id": "f0fefb110e39f1eef6cc36731d4bc3209fd66b3b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/international-respiratory-coalition-launches-to-transform-post-pandemic-respiratory-healthcare.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/international-respiratory-coalition-launches-to-transform-post-pandemic-respiratory-healthcare",
      "id": "18e54052c9b225958851de10c6c8758abc780755"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/koselugo-approved-in-the-eu-for-children-with-neurofibromatosis-type-1-and-plexiform-neurofibromas.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/koselugo-approved-in-the-eu-for-children-with-neurofibromatosis-type-1-and-plexiform-neurofibromas",
      "id": "e9c01460263a2b16e591ea3bb0b6e910483e05b3"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/lynparza-approved-in-china-for-prostate-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/lynparza-approved-in-china-for-prostate-cancer",
      "id": "e391d33f48e56d9704417d03d7e8731fbf24f422"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/lynparza-granted-fda-priority-review-for-olympia.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/lynparza-granted-fda-priority-review-for-olympia",
      "id": "2bc32f101f6a79bf9f84775bd47fa0799b42c801"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/lynparza-propel-trial-meets-primary-endpoint.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/lynparza-propel-trial-meets-primary-endpoint",
      "id": "cc38e3b9846df4e360931acee6e451c5846b74bd"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/lynparza-reduced-the-risk-of-cancer-recurrence-by-42-in-the-adjuvant-treatment-of-patients-with-germline-brca-mutated-high-risk-early-breast-cancer-in-olympia-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/lynparza-reduced-the-risk-of-cancer-recurrence-by-42-in-the-adjuvant-treatment-of-patients-with-germline-brca-mutated-high-risk-early-breast-cancer-in-olympia-phase-iii-trial",
      "id": "0a04a705ed3b2be93a3ce200b8f3d7a46a9f5617"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/new-analyses-of-two-azd7442-covid-19-phase-iii-trials-in-high-risk-populations-confirm-robust-efficacy-and-long-term-prevention.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/new-analyses-of-two-azd7442-covid-19-phase-iii-trials-in-high-risk-populations-confirm-robust-efficacy-and-long-term-prevention",
      "id": "bd073d05682e5afa560385131b7278a771d11c90"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/nirsevimab-phase-iii-trial-met-primary-endpoint.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/nirsevimab-phase-iii-trial-met-primary-endpoint",
      "id": "57cf4dd9ebfb699e2ea452b6dfdb45dd2203d09e"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/nirsevimab-phii-iii-trial-confirms-safety-profile.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/nirsevimab-phii-iii-trial-confirms-safety-profile",
      "id": "ee554c984e180016d32413b866f4fe7b8f5036a3"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/olympia-trial-of-lynparza-idmc-recommend-early-analysis.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/olympia-trial-of-lynparza-idmc-recommend-early-analysis",
      "id": "6acb9945f5e43e4a87e97b745af0de45afba46e5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/orpathys-approved-in-china-for-patients-with-lung-cancer-and-met-gene-alterations.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/orpathys-approved-in-china-for-patients-with-lung-cancer-and-met-gene-alterations",
      "id": "e7f37a1c07f3f93bb3b63f97b6bfab79cde6a4e7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/pt027-phiii-asthma-trials-met-primary-endpoints.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/pt027-phiii-asthma-trials-met-primary-endpoints",
      "id": "795a4a6fa8c22b944f09ed10713a186794b67868"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/q1-2021-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/q1-2021-results",
      "id": "da0cdca6bc60c53f88492db57171ea19e1124e6c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/results-of-annual-general-meeting-held-on-11-may-2021.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/results-of-annual-general-meeting-held-on-11-may-2021",
      "id": "e4dde8e91199725fdda8775cc112681f979f74f4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/saphnelo-approved-in-japan-for-sle.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/saphnelo-approved-in-japan-for-sle",
      "id": "ab5c31308346a3eeb9123d6ac9216a14ed1be910"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/saphnelo-approved-in-the-us-for-sle.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/saphnelo-approved-in-the-us-for-sle",
      "id": "f911561d25ae6b1163d45b75a84d958e3a2abf49"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/saphnelo-recommended-for-eu-approval-for-sle.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/saphnelo-recommended-for-eu-approval-for-sle",
      "id": "421bf5885527d8ab9f09ebc8f8a92170a8b66462"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/selumetinib-recommended-for-eu-approval-in-nf1.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/selumetinib-recommended-for-eu-approval-in-nf1",
      "id": "c239b7665b6576c51cdd73502b0f1d39494dc3ef"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/serum-institute-of-india-obtains-emergency-use-authorisation-in-india-for-astrazenecas-covid-19-vaccine.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/serum-institute-of-india-obtains-emergency-use-authorisation-in-india-for-astrazenecas-covid-19-vaccine",
      "id": "22ef0bf27a0e74f9d7840f22a789eff822289405"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/statement-on-covid-19-vaccine-supply-at-anagni-plant-in-italy.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/statement-on-covid-19-vaccine-supply-at-anagni-plant-in-italy",
      "id": "5bdacedcfc14c89040885081ae2dc6f326523544"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/statement-on-the-passing-of-jose-baselga.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/statement-on-the-passing-of-jose-baselga",
      "id": "48aaef1afb698643b2b058abcd00680f3eed17be"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/status-on-us-fda-advisory-committee-for-roxadustat.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/status-on-us-fda-advisory-committee-for-roxadustat",
      "id": "35360a5b183b6c5f27c8f88ccde70ad9848def2a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/symbicort-approved-in-china-for-mild-asthma.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/symbicort-approved-in-china-for-mild-asthma",
      "id": "be5ca56c7d9fed76868c1095d8ab2be300d67923"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/tagrisso-adjuvant-receives-positive-chmp-opinion.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/tagrisso-adjuvant-receives-positive-chmp-opinion",
      "id": "768324b1e6bf6837f66d04313b5564efdc22b713"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/tagrisso-approved-in-china-in-early-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/tagrisso-approved-in-china-in-early-lung-cancer",
      "id": "73842c51765c8c0b6bda2f1e3361b7d03b38c1bb"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/tagrisso-approved-in-eu-in-early-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/tagrisso-approved-in-eu-in-early-lung-cancer",
      "id": "152ea9fdf5d8807082c5cc45465466c0c9a7b40c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/tagrisso-extended-disease-free-survival-regardless-of-prior-adjuvant-chemotherapy-in-early-stage-egfr-mutated-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/tagrisso-extended-disease-free-survival-regardless-of-prior-adjuvant-chemotherapy-in-early-stage-egfr-mutated-lung-cancer",
      "id": "cad9614047963a555b50e31cd78b4f4d13e71e1b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/tezepelumab-granted-fda-priority-review-for-asthma.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/tezepelumab-granted-fda-priority-review-for-asthma",
      "id": "a933ce81d81ae12d8e31c5e926bd2d1aa7e14102"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/tezepelumab-granted-orphan-drug-designation-in-the-us-for-eosinophilic-esophagitis.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/tezepelumab-granted-orphan-drug-designation-in-the-us-for-eosinophilic-esophagitis",
      "id": "22cd25aa3268efc3ea446bc0bd5b5d1015c40d6d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/tezepelumab-is-the-first-biologic-to-consistently-and-significantly-reduce-exacerbations-in-broad-population-of-severe-asthma-patients.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/tezepelumab-is-the-first-biologic-to-consistently-and-significantly-reduce-exacerbations-in-broad-population-of-severe-asthma-patients",
      "id": "b18bde4184a3c02e3845e4dcf21c8bf3b8b18d39"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/tezspire-tezepelumab-approved-in-the-us-for-severe-asthma.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/tezspire-tezepelumab-approved-in-the-us-for-severe-asthma",
      "id": "d505feeea04bac03212e4ac3cff388085b688b29"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/two-billion-doses-of-astrazenecas-covid-19-vaccine-supplied-to-countries-across-the-world-less-than-12-months-after-first-approval.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/two-billion-doses-of-astrazenecas-covid-19-vaccine-supplied-to-countries-across-the-world-less-than-12-months-after-first-approval",
      "id": "86db45f105c89128f310925567e55e0936b857bc"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/uk-and-eu-regulatory-agencies-confirm-covid-19-vaccine-astrazeneca-is-effective-and-generally-well-tolerated.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/uk-and-eu-regulatory-agencies-confirm-covid-19-vaccine-astrazeneca-is-effective-and-generally-well-tolerated",
      "id": "1e0cafce20dd7b5e12a69f1e0661ef2506e772e0"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/ultomiris-accepted-for-fda-priority-review-for-gmg.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/ultomiris-accepted-for-fda-priority-review-for-gmg",
      "id": "704d27e96f018c8869550f5ae7c7e5f0d72c8523"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/ultomiris-approved-in-eu-for-children-with-pnh.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/ultomiris-approved-in-eu-for-children-with-pnh",
      "id": "8dfb5da429742573ae6a678a265eed22fd2a732d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/ultomiris-recommended-in-eu-for-children-with-pnh.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/ultomiris-recommended-in-eu-for-children-with-pnh",
      "id": "62e6f50bdbc0fa02c93cf8731c13ba4f79c4de8c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/update-following-statement-by-niaid-on-azd1222-us-phase-iii-trial-data.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/update-following-statement-by-niaid-on-azd1222-us-phase-iii-trial-data",
      "id": "48c994011882a07043ef4d762a8709b5672818e4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-azd7442-storm-chaser-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/update-on-azd7442-storm-chaser-trial",
      "id": "9b936ea7eef9e9e298d3fa0e0d460f7a007e9408"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-farxiga-covid-19-dare-19-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/update-on-farxiga-covid-19-dare-19-phase-iii-trial",
      "id": "0ec34624aa49c8c2986aa8c37dc9ca8a0e72d932"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-kestrel-phase-iii-trial-for-imfinzi.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/update-on-kestrel-phase-iii-trial-for-imfinzi",
      "id": "39c9369fc26570a3bd1b2d1ead95d7093dd1d69f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-the-safety-of-covid-19-vaccine-astrazeneca.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/update-on-the-safety-of-covid-19-vaccine-astrazeneca",
      "id": "411c95d723c1af4f08830f53e8980a43c9ed2dac"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-ultomiris-phase-iii-als-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/update-on-ultomiris-phase-iii-als-trial",
      "id": "a47f76d3fa4edce2ff8db53f82a606a0b0dd4935"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-us-review-of-roxadustat.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/update-on-us-review-of-roxadustat",
      "id": "5d947d6fde5eda428f8ea22eeef267c14cac9f23"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/us-clearance-of-proposed-acquisition-of-alexion.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/us-clearance-of-proposed-acquisition-of-alexion",
      "id": "1944deb0dba92332bbb5e63f2b2994c5fc8ee96f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/us-court-decision-favours-symbicort-patents.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/us-court-decision-favours-symbicort-patents",
      "id": "33d9d45d9f2836de3e85e140419e172cc8daf7f7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/us-supply-agreement-for-additional-azd7442-doses.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/us-supply-agreement-for-additional-azd7442-doses",
      "id": "206352f56b6f210396b1495552212e65c3ff70b7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/vaxzevria-and-mrna-covid-19-vaccines-showed-similar-and-favourable-safety-profiles-in-a-population-based-cohort-study-of-over-a-million-people.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/vaxzevria-and-mrna-covid-19-vaccines-showed-similar-and-favourable-safety-profiles-in-a-population-based-cohort-study-of-over-a-million-people",
      "id": "cf3d0d8a40dcdd90a1fe5eae0b50f2d9d770bccb"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/vaxzevria-induced-immunity-for-at-least-1-year-following-a-single-dose-and-strong-immune-responses-following-either-a-late-second-dose-or-a-third-dose.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/vaxzevria-induced-immunity-for-at-least-1-year-following-a-single-dose-and-strong-immune-responses-following-either-a-late-second-dose-or-a-third-dose",
      "id": "e8f2fbb614a9e500a9f8176722dfe55da4198706"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/vaxzevria-is-highly-effective-after-one-dose-against-severe-disease-or-hospitalisation-caused-by-beta-and-delta-variants-of-concern.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/vaxzevria-is-highly-effective-after-one-dose-against-severe-disease-or-hospitalisation-caused-by-beta-and-delta-variants-of-concern",
      "id": "3c11296c18908b8c5c7b47e54b0b16e2b7744423"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/vaxzevria-showed-no-increased-incidence-of-thrombosis-with-thrombocytopenia-after-second-dose.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/vaxzevria-showed-no-increased-incidence-of-thrombosis-with-thrombocytopenia-after-second-dose",
      "id": "8f53a4e625559453019dc44a65c3ffbd097184a1"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/vaxzevria-significantly-boosted-antibody-levels-against-omicron.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/vaxzevria-significantly-boosted-antibody-levels-against-omicron",
      "id": "64a67db6ad0b5a377c46b3e4c589985d7822cd9f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/voluntary-withdrawal-imfinzi-us-bladder-indication.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/voluntary-withdrawal-imfinzi-us-bladder-indication",
      "id": "16966f52f2f0864e4b841046170e60b28da8300a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2021/year-to-date-and-q3-2021-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2021/year-to-date-and-q3-2021-results",
      "id": "ec8fff984535790bffdc1830fec3ad1ec94f8d86"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022",
      "id": "8fe7586da8f0aeadae8e81df648384c7eab052d1"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/acquisition-of-teneotwo-for-its-clinical-stage-t-cell-engager-completed.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/acquisition-of-teneotwo-for-its-clinical-stage-t-cell-engager-completed",
      "id": "594ad0436270eee386d01eef2a72376d019fa603"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/alexion-aims-to-advance-nmosd-treatment-landscape-with-exceptional-ultomiris-efficacy-data-at-ectrims-2022.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/alexion-aims-to-advance-nmosd-treatment-landscape-with-exceptional-ultomiris-efficacy-data-at-ectrims-2022",
      "id": "9194423098872c4c50c7e30f223db16c5401fae0"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/alxn1840-shows-rapid-and-sustained-improvement-in-copper-mobilisation-from-tissues.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/alxn1840-shows-rapid-and-sustained-improvement-in-copper-mobilisation-from-tissues",
      "id": "1f94f39b6f8b8d2ea7bb254a51eafdd1d8058b40"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-advances-scientific-leadership-in-cardiovascular-and-renal-diseases-with-over-60-abstracts.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazeneca-advances-scientific-leadership-in-cardiovascular-and-renal-diseases-with-over-60-abstracts",
      "id": "39c6cfaeb6ffa45ebc9b4fbb4757583d9e114970"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-aims-to-redefine-breast-cancer-care-with-new-data-across-the-treatment-spectrum-at-sabcs-2022.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazeneca-aims-to-redefine-breast-cancer-care-with-new-data-across-the-treatment-spectrum-at-sabcs-2022",
      "id": "b4b16cdd67845c839a6eb8357326671e6cbffb9c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-aims-to-redefine-liver-biliary-tract-and-prostate-cancer-treatment-with-practice-changing-imfinzi-and-lynparza-data-at-asco-gi-and-gu.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazeneca-aims-to-redefine-liver-biliary-tract-and-prostate-cancer-treatment-with-practice-changing-imfinzi-and-lynparza-data-at-asco-gi-and-gu",
      "id": "dc0e13387c926e896dfa97681d700ec14418cfe9"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-aims-to-transform-cancer-outcomes-with-new-data-across-industry-leading-portfolio-at-esmo-2022.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazeneca-aims-to-transform-cancer-outcomes-with-new-data-across-industry-leading-portfolio-at-esmo-2022",
      "id": "776c4688264e84c55a7a5b8cde89663278ec2420"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-aims-to-transform-the-oncology-treatment-landscape-with-diverse-early-pipeline-and-novel-combinations-at-aacr.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazeneca-aims-to-transform-the-oncology-treatment-landscape-with-diverse-early-pipeline-and-novel-combinations-at-aacr",
      "id": "22505e4101db46030914f26f713b8dfcceac68a0"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-aims-transform-cancer-care-practice-changing-data-asco-2022.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazeneca-aims-transform-cancer-care-practice-changing-data-asco-2022",
      "id": "45d5a0d1001e26ddf58e8e36eaa4afc5b9bb1688"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-and-neurimmune-close-deal-for-ni006.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazeneca-and-neurimmune-close-deal-for-ni006",
      "id": "9f658b9fece186283b260be8590fe0e96ae73ab3"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-and-neurimmune-sign-deal-for-ni006.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazeneca-and-neurimmune-sign-deal-for-ni006",
      "id": "d4d061f67c6aa04995fbd411658defb70ace0d0c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-and-scorpion-therapeutics-enter-agreement-to-discover-develop-and-commercialise-novel-cancer-treatments-against-undruggable-targets.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazeneca-and-scorpion-therapeutics-enter-agreement-to-discover-develop-and-commercialise-novel-cancer-treatments-against-undruggable-targets",
      "id": "b82824639df5b3d12362feae5fae19129329b358"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-announces-plans-for-new-strategic-rd-centre-and-alexion-headquarters-in-cambridge-massachusetts.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazeneca-announces-plans-for-new-strategic-rd-centre-and-alexion-headquarters-in-cambridge-massachusetts",
      "id": "a74e10ff0ff6bed14565ce01dc59ad1f70b6f839"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-announces-sale-of-west-chester-site.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazeneca-announces-sale-of-west-chester-site",
      "id": "99e53277c1af0cc83752b1bfeaf0ae00d7132a26"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-demonstrates-pipeline-and-portfolio-strength-across-malignant-and-rare-haematological-diseases-at-eha-2022.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazeneca-demonstrates-pipeline-and-portfolio-strength-across-malignant-and-rare-haematological-diseases-at-eha-2022",
      "id": "6622077b9a8c4084dc55faac25906d9c757c90f5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-expands-global-footprint-in-rare-disease-with-availability-of-first-alexion-rare-disease-therapy-for-patients-in-china.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazeneca-expands-global-footprint-in-rare-disease-with-availability-of-first-alexion-rare-disease-therapy-for-patients-in-china",
      "id": "c5bcc9468d362a22ce93d1b29f43c713e85b5351"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-funds-rd-postdoctoral-challenge-finalists.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazeneca-funds-rd-postdoctoral-challenge-finalists",
      "id": "bcb3a4bd1ac1b58e4cedf1b2e678bfd48aa19ab9"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-launches-global-rd-postdoctoral-challenge-to-accelerate-scientific-discovery-and-diversity.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazeneca-launches-global-rd-postdoctoral-challenge-to-accelerate-scientific-discovery-and-diversity",
      "id": "3a90d3066b0f056f154d6dc78f3cacdc71c5c8d5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-progresses-ambition-zero-carbon-programme-with-honeywell-partnership-to-develop-next-generation-respiratory-inhalers.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazeneca-progresses-ambition-zero-carbon-programme-with-honeywell-partnership-to-develop-next-generation-respiratory-inhalers",
      "id": "fb16fdc63b8bc4f377c24321e89579b6ffc5129e"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-ranked-in-top-three-in-the-access-to-medicine-index.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazeneca-ranked-in-top-three-in-the-access-to-medicine-index",
      "id": "e73b9dd1bb78d6f892e36a6906ff6173dba72599"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-reaches-settlement-agreement-resolving-patent-litigation-related-to-ultomiris.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazeneca-reaches-settlement-agreement-resolving-patent-litigation-related-to-ultomiris",
      "id": "36b84d2a536b5f48b298c455be798b775a771ecb"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-showcases-strength-of-haematology-portfolio-and-pipeline-across-multiple-hard-to-treat-conditions-at-ash-2022.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazeneca-showcases-strength-of-haematology-portfolio-and-pipeline-across-multiple-hard-to-treat-conditions-at-ash-2022",
      "id": "fd715b56fbe76b2faaa3921990d9b8ca90ac49b1"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-signs-licence-agreement-with-rq-biotechnology-for-monoclonal-antibodies-against-covid-19.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazeneca-signs-licence-agreement-with-rq-biotechnology-for-monoclonal-antibodies-against-covid-19",
      "id": "2a3d3c38c65252d840258a22736af4174f1e16f5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-to-acquire-neogene-therapeutics-accelerating-ambition-in-oncology-cell-therapy.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazeneca-to-acquire-neogene-therapeutics-accelerating-ambition-in-oncology-cell-therapy",
      "id": "263f2f3380ca7c5480f6f0548d14ec86816afc34"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-to-acquire-teneotwo-and-t-cell-engager.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazeneca-to-acquire-teneotwo-and-t-cell-engager",
      "id": "f42832f2dbe07170b6d1f3b02008ef2c6799ed3a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazenecas-antibody-combination-evusheld-authorised-for-use-in-great-britain-for-pre-exposure-prophylaxis-prevention-of-covid-19.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazenecas-antibody-combination-evusheld-authorised-for-use-in-great-britain-for-pre-exposure-prophylaxis-prevention-of-covid-19",
      "id": "45e27a93f8b6d4279acbd2beb467b0d9934fa083"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/astrazenecas-pascal-soriot-awarded-british-knighthood-services-uk-life-sciences-leadership-global-response-covid-pandemic.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/astrazenecas-pascal-soriot-awarded-british-knighthood-services-uk-life-sciences-leadership-global-response-covid-pandemic",
      "id": "1dc2c1471a13e9e8bd5599f58ad3eb85bb973a49"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/az-data-at-asn-kidney-week-reinforces-urgent-need-for-early-screening-of-ckd-and-benefits-of-earlier-treatment-for-patients-and-healthcare-systems.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/az-data-at-asn-kidney-week-reinforces-urgent-need-for-early-screening-of-ckd-and-benefits-of-earlier-treatment-for-patients-and-healthcare-systems",
      "id": "ee323dc4fa5620a12a3056afe860d09611d17fe0"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/azd8233-reduced-low-density-lipoprotein-cholesterol-levels-73-patients-high-risk-hypercholesterolemia-etesian-phase-iib-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/azd8233-reduced-low-density-lipoprotein-cholesterol-levels-73-patients-high-risk-hypercholesterolemia-etesian-phase-iib-trial",
      "id": "f41491f6f76c518e052d1404c1b078b700c68d88"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/beyfortus-approved-in-the-eu-for-the-prevention-of-rsv-lower-respiratory-tract-disease-in-infants.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/beyfortus-approved-in-the-eu-for-the-prevention-of-rsv-lower-respiratory-tract-disease-in-infants",
      "id": "4d5508c7d1380c8ca14f1cbd800ca9073a50cb54"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/calquence-japan-approval-for-treatment-naive-cll.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/calquence-japan-approval-for-treatment-naive-cll",
      "id": "6e0f54e5e7e4c8ba868403ab8b740a841c6ea369"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/calquence-plus-obinutuzumab-demonstrated-sustained-survival-benefit-in-1st-line-chronic-lymphocytic-leukaemia.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/calquence-plus-obinutuzumab-demonstrated-sustained-survival-benefit-in-1st-line-chronic-lymphocytic-leukaemia",
      "id": "874c660085c5b907ccd865fb65656f46564d03dc"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/calquence-tablet-formulation-approved-in-the-us-across-current-indications.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/calquence-tablet-formulation-approved-in-the-us-across-current-indications",
      "id": "0ec51d5cf1c58807fa57a3a9c2e21e5b8807902b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/camizestrant-significantly-delayed-disease-progression-in-advanced-er-positive-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/camizestrant-significantly-delayed-disease-progression-in-advanced-er-positive-breast-cancer",
      "id": "3f048bcee6a6c725b70af4e7a47feb20a16335fb"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/camizestrant-significantly-improved-progression-free-survival.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/camizestrant-significantly-improved-progression-free-survival",
      "id": "902d10fe0aafea749964c9628f53a39034fef353"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/capivasertib-pfs-in-hr-positive-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/capivasertib-pfs-in-hr-positive-breast-cancer",
      "id": "371fa752da43c52a5537df07bc7dbbe2f516f248"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/capivasertib-phase-iii-trial-met-primary-endpoints.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/capivasertib-phase-iii-trial-met-primary-endpoints",
      "id": "75af5978fb5cf0c8e97bf755638c314ba8b1f15d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/danicopan-phase-iii-trial-met-primary-endpoint.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/danicopan-phase-iii-trial-met-primary-endpoint",
      "id": "84f2a3d31c0871b7e67ec92b342fb4e1f2af0c27"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/datopotamab-deruxtecan-based-combinations-show-promising-clinical-activity-in-patients.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/datopotamab-deruxtecan-based-combinations-show-promising-clinical-activity-in-patients",
      "id": "774d66fbabc717bd9a9b8327a021b0a01a040e4f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/datopotamab-deruxtecan-showed-encouraging-and-durable-efficacy-in-patients-with-metastatic-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/datopotamab-deruxtecan-showed-encouraging-and-durable-efficacy-in-patients-with-metastatic-breast-cancer",
      "id": "5c14d74c7688dd1a473d9bd951e869b820b0c1e9"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/datopotamab-deruxtecan-showed-promising-responses-as-monotherapy-and-in-combination-with-imfinzi-in-patients.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/datopotamab-deruxtecan-showed-promising-responses-as-monotherapy-and-in-combination-with-imfinzi-in-patients",
      "id": "ffaec554eff342f0cd3b3cd89d0067ee2e5d1e0a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-achieved-statistically-significant-overall-survival.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/enhertu-achieved-statistically-significant-overall-survival",
      "id": "7f2d3c17c0d6670288c2636ba6ae8cb46cab5302"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-approved-in-eu-for-gastric-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/enhertu-approved-in-eu-for-gastric-cancer",
      "id": "631d2d2d9e0c86d34bc15c5913a6a36e8cb6ab77"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-approved-in-eu-for-her2-positive-mbc.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/enhertu-approved-in-eu-for-her2-positive-mbc",
      "id": "fa3ee3033067c533e51d0e02c69eda4ef5574118"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-approved-in-the-us-for-her2-low-mbc.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/enhertu-approved-in-the-us-for-her2-low-mbc",
      "id": "87bb524c984f658c92c3c3686a782da911302911"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-approved-in-us-for-2l-her2-positive-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/enhertu-approved-in-us-for-2l-her2-positive-breast-cancer",
      "id": "db16204a7afd9cd607b24bdc5bb771ce195d2e00"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-approved-in-us-for-her2-mutant-nsclc.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/enhertu-approved-in-us-for-her2-mutant-nsclc",
      "id": "cdd847af27b71c3f92a785f42439891383a6faaa"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-continues-to-demonstrate-clinically-meaningful-tumour-response-in-patients-with-her2-mutant-metastatic-non-small-cell-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/enhertu-continues-to-demonstrate-clinically-meaningful-tumour-response-in-patients-with-her2-mutant-metastatic-non-small-cell-lung-cancer",
      "id": "a57f4e4089b89e540e8b34975d48dc76723042e1"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-efficacy-results-in-her2-low-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/enhertu-efficacy-results-in-her2-low-breast-cancer",
      "id": "f653418e763cfdfe8d7d90b39e977eb7c8dee8b5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-granted-btd-her2-low-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/enhertu-granted-btd-her2-low-breast-cancer",
      "id": "f9d8c1c81fdbcf30e8d8a9cd9263775c3d229b44"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-granted-priority-review-for-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/enhertu-granted-priority-review-for-breast-cancer",
      "id": "06f3d0bd80bfd714f5796b06e08ecef1cc85f568"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-granted-priority-review-for-her2-low-mbc.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/enhertu-granted-priority-review-for-her2-low-mbc",
      "id": "46fe675f0c990c91633ba837f35a77a45811c852"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-granted-priority-review-for-her2m-nsclc.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/enhertu-granted-priority-review-for-her2m-nsclc",
      "id": "ea2fd55e6048b9782ba6e99e18b80edb18b5faa2"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-improved-pfs-in-mbc-in-destiny-breast02.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/enhertu-improved-pfs-in-mbc-in-destiny-breast02",
      "id": "5f1c293ccb43edab9747f89c95606c2924b2baaf"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-improves-pfs-and-os-in-her2-low-bc.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/enhertu-improves-pfs-and-os-in-her2-low-bc",
      "id": "a00100fe22df6b0d3003d98506d9e4c74a591574"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-previously-treated-her2-positive-advanced-gastric-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/enhertu-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-previously-treated-her2-positive-advanced-gastric-cancer",
      "id": "ce33d2047ff1d815caa7f6b1c55331950cbd1beb"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-recommended-for-breast-cancer-eu-approval.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/enhertu-recommended-for-breast-cancer-eu-approval",
      "id": "8589071058c2dc72dc33c13eae82a978c743dd1e"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-recommended-for-eu-approval-in-her2-low-bc.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/enhertu-recommended-for-eu-approval-in-her2-low-bc",
      "id": "3cab8d2a4674277803dfa4cb8676d22a77d5e0c6"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/eplontersen-phase-iii-trial-met-co-primary-endpoints.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/eplontersen-phase-iii-trial-met-co-primary-endpoints",
      "id": "e202a08449c00d383429e29369d0d1b82c701377"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-approved-for-covid-19-in-japan.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/evusheld-approved-for-covid-19-in-japan",
      "id": "05c3d8e5be8dac202fb78fac24ba6826594d8674"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-approved-in-eu-for-covid-19-treatment.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/evusheld-approved-in-eu-for-covid-19-treatment",
      "id": "5710d46bb1489453269f4fba1dcc3545dac211d0"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-approved-in-the-eu-for-covid-19.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/evusheld-approved-in-the-eu-for-covid-19",
      "id": "341d0a62d7183a66958c0da7e2fde8c33fee7855"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-long-acting-antibody-combination-recommended-for-approval-in-the-eu-for-the-pre-exposure-prophylaxis-prevention-of-covid-19.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/evusheld-long-acting-antibody-combination-recommended-for-approval-in-the-eu-for-the-pre-exposure-prophylaxis-prevention-of-covid-19",
      "id": "673208d64b5889931d1004d2c2676a188c63682b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-positive-chmp-opinion-in-eu.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/evusheld-positive-chmp-opinion-in-eu",
      "id": "ef82f7cdc2268847c89d305dae99afb556ca4c8a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-significantly-prevented-covid-19-disease-progression-or-death-in-tackle-phase-iii-treatment-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/evusheld-significantly-prevented-covid-19-disease-progression-or-death-in-tackle-phase-iii-treatment-trial",
      "id": "496019f056e4c588d17840b7a4b260b35bbf4737"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-significantly-protected-against-symptomatic-covid-19-for-at-least-six-months-in-provent-phase-iii-trial-in-high-risk-populations1.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/evusheld-significantly-protected-against-symptomatic-covid-19-for-at-least-six-months-in-provent-phase-iii-trial-in-high-risk-populations1",
      "id": "32a72f5959f98d1f7446e603cd953ef3b1bf05f4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/farxiga-deliver-phase-III-trial-reduced-cv-death.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/farxiga-deliver-phase-iii-trial-reduced-cv-death",
      "id": "ee8e9a28e53d44ca37142a3d28b1d7f8f2132e0d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/farxiga-hfpef-phase-iii-trial-met-primary-endpoint.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/farxiga-hfpef-phase-iii-trial-met-primary-endpoint",
      "id": "c04df29991651097f26c3b12b74a901caa3a930f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/farxiga-improved-symptom-burden-in-deliver-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/farxiga-improved-symptom-burden-in-deliver-phase-iii-trial",
      "id": "cc1f560f5f414df567767787ba8309f02b713a62"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/farxiga-lowers-risk-cv-death-heart-failure.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/farxiga-lowers-risk-cv-death-heart-failure",
      "id": "332df5e6d277120f3c6aca583a5a6aa498f3ad91"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/fda-advisory-committee-recommends-pt027-in-asthma.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/fda-advisory-committee-recommends-pt027-in-asthma",
      "id": "2b50c6674a93411f6838d6c9e118b2f54aa1bbd3"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/forxiga-approved-in-china-for-ckd.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/forxiga-approved-in-china-for-ckd",
      "id": "cbbe552ecab2bd218e381b66498e3bf5a3787a86"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/forxiga-chmp-opinion-for-symptomatic-chronic-hf.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/forxiga-chmp-opinion-for-symptomatic-chronic-hf",
      "id": "ef17738b7c71f344e18faf60daeb7c46315a4eaf"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/full-year-2021-and-q4-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/full-year-2021-and-q4-results",
      "id": "b5a72d9d2c8fecb373b8ec9fda16c4c2a660c8b9"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/h1-2022-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/h1-2022-results",
      "id": "c967137d5f0e87efc9b8d30a2d98748b94dad820"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/human-ventricular-progenitor-cells-promote-formation-new-heart-tissue-following-heart-attack.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/human-ventricular-progenitor-cells-promote-formation-new-heart-tissue-following-heart-attack",
      "id": "ca87c024cf577cb023abac873b132be909ee9700"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/idweek-data-reinforces-astrazenecas-commitment-to-advance-science-in-vaccines-and-immune-therapies.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/idweek-data-reinforces-astrazenecas-commitment-to-advance-science-in-vaccines-and-immune-therapies",
      "id": "7feaafb78e0b6010eaa8156343863bc7c03cdccd"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-and-imjudo-approved-in-advanced-liver-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/imfinzi-and-imjudo-approved-in-advanced-liver-cancer",
      "id": "9909456fe28fd19dee7703dc11769a83d18a86b3"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-and-imjudo-approved-in-us-for-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/imfinzi-and-imjudo-approved-in-us-for-lung-cancer",
      "id": "085797700b2de091083bd165581b81f794da1c48"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-and-tremelimumab-with-chemotherapy-demonstrated-sustained-survival-benefit-in-metastatic-non-small-cell-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/imfinzi-and-tremelimumab-with-chemotherapy-demonstrated-sustained-survival-benefit-in-metastatic-non-small-cell-lung-cancer",
      "id": "90e4057264f591aa92121f93adbc303216e0c49d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-approved-in-eu-for-biliary-tract-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/imfinzi-approved-in-eu-for-biliary-tract-cancer",
      "id": "c3f1b4f98861dc8c92f217ed9ce8086d133ed280"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-approved-in-us-for-biliary-tract-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/imfinzi-approved-in-us-for-biliary-tract-cancer",
      "id": "1302ac5d01dbe918dbd5834d4a3abf9f4e1f878c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-combo-granted-priority-review-for-btc.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/imfinzi-combo-granted-priority-review-for-btc",
      "id": "b9fadc0f5fd08ea8661f96c6ba9d43266bb69ca8"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-imjudo-approved-in-japan-for-3-cancers.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/imfinzi-imjudo-approved-in-japan-for-3-cancers",
      "id": "988f2988a2219eeff53f52ec7cd6240ce4f5f3b3"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-imjudo-recommended-for-approvals-in-eu.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/imfinzi-imjudo-recommended-for-approvals-in-eu",
      "id": "bfc2beb6621c589be836007c2a95654cae33b65e"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-improved-pcr-in-resectable-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/imfinzi-improved-pcr-in-resectable-lung-cancer",
      "id": "1bd2b0ed980c6daecd4ebecf7b1bec76656270ca"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-plus-chemotherapy-further-improved-overall-survival-benefit-in-advanced-biliary-tract-cancer-in-the-topaz-1-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/imfinzi-plus-chemotherapy-further-improved-overall-survival-benefit-in-advanced-biliary-tract-cancer-in-the-topaz-1-phase-iii-trial",
      "id": "fc66356b7556931ecc488357eb3f98c60f052c1a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-plus-chemotherapy-recommended-for-approval-in-the-eu-by-chmp-as-first-immunotherapy-regimen-for-advanced-biliary-tract-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/imfinzi-plus-chemotherapy-recommended-for-approval-in-the-eu-by-chmp-as-first-immunotherapy-regimen-for-advanced-biliary-tract-cancer",
      "id": "c590919d3a80629da1ff341b8b50d2fb271532c7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-plus-chemotherapy-reduced-risk-of-death-by-20-in-1st-line-advanced-biliary-tract-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/imfinzi-plus-chemotherapy-reduced-risk-of-death-by-20-in-1st-line-advanced-biliary-tract-cancer",
      "id": "aeb010b6ef4ee639f95951726edd1d10f7cb122c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-plus-tremelimumab-unprecedented-survival-1st-line-unresectable-liver-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/imfinzi-plus-tremelimumab-unprecedented-survival-1st-line-unresectable-liver-cancer",
      "id": "03f6bdbc3b4c74d6373fe638ae375c7689f822db"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/koselugo-approved-in-japan-for-paediatric-patients-with-plexiform-neurofibromas.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/koselugo-approved-in-japan-for-paediatric-patients-with-plexiform-neurofibromas",
      "id": "f2f36da9690968b293588994a29dbc21a5e828e2"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-approved-in-china-for-ovarian-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/lynparza-approved-in-china-for-ovarian-cancer",
      "id": "fb83bc4a2491c9f2febfb9c55701c79607248dd8"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-approved-in-eu-for-early-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/lynparza-approved-in-eu-for-early-breast-cancer",
      "id": "e2ea7a42d0f69fc7727053544fce13c204472463"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-approved-in-eu-for-prostate-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/lynparza-approved-in-eu-for-prostate-cancer",
      "id": "9c3a47c18f7db9afade9355aa806074b3315c85a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-approved-in-japan-for-early-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/lynparza-approved-in-japan-for-early-breast-cancer",
      "id": "c9b1ac7d713f56b0beee68ad1dff43a42d0d2b07"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-approved-in-the-us-as-adjuvant-treatment-for-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/lynparza-approved-in-the-us-as-adjuvant-treatment-for-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer",
      "id": "16993c7628723d675d070bafca74761766e76150"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-combo-delays-progression-risk-in-prostate-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/lynparza-combo-delays-progression-risk-in-prostate-cancer",
      "id": "acc206949a49f4d91e8cfb3dcf2a4b46185d8a01"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-granted-fda-priority-review-for-propel.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/lynparza-granted-fda-priority-review-for-propel",
      "id": "dcf01d744685969f7003703c9319efb52481e312"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-in-combination-with-abiraterone-recommended-for-approval-in-the-eu-by-chmp-as-1st-line-treatment-for-patients-with-metastatic-castration-resistant-prostate-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/lynparza-in-combination-with-abiraterone-recommended-for-approval-in-the-eu-by-chmp-as-1st-line-treatment-for-patients-with-metastatic-castration-resistant-prostate-cancer",
      "id": "611de54134ef5eb5448918bf03c94fd9eabeaf85"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-in-combination-with-bevacizumab-demonstrates-clinically-meaningful-survival-benefit-in-advanced-ovarian-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/lynparza-in-combination-with-bevacizumab-demonstrates-clinically-meaningful-survival-benefit-in-advanced-ovarian-cancer",
      "id": "8dde6912852b57a1af693897869a21e1959a0c50"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-recommended-in-eu-for-early-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/lynparza-recommended-in-eu-for-early-breast-cancer",
      "id": "06da3a172992711bb0684b2d25c23c18c251a981"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-reduced-risk-of-death-by-32-percent-in-the-adjuvant-treatment-of-patients-with-germline-brca-mutated-high-risk-early-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/lynparza-reduced-risk-of-death-by-32-percent-in-the-adjuvant-treatment-of-patients-with-germline-brca-mutated-high-risk-early-breast-cancer",
      "id": "ce1df7a0a56bbab0d01530d2bcf494686d93cfbe"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/michel-demare-to-succeed-leif-johansson-as-non-executive-chair-of-the-board.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/michel-demare-to-succeed-leif-johansson-as-non-executive-chair-of-the-board",
      "id": "5c2e6173a0daa77a798a3ee2f4f244d53c2ab128"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/new-chronic-kidney-disease-ckd-study-indicates-that-ckd-is-present-in-one-out-of-ten-adults.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/new-chronic-kidney-disease-ckd-study-indicates-that-ckd-is-present-in-one-out-of-ten-adults",
      "id": "a071d05faf7b5e0b4852d360742ff468f6d91397"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/new-vaxzevria-data-further-support-its-use-as-third-dose-booster.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/new-vaxzevria-data-further-support-its-use-as-third-dose-booster",
      "id": "2cbcc670b3817259c51c9a316ca40889bb39a565"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/nirsevimab-ema-regulatory-submission-accepted-under-accelerated-assessment-for-rsv-protection-in-all-infants.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/nirsevimab-ema-regulatory-submission-accepted-under-accelerated-assessment-for-rsv-protection-in-all-infants",
      "id": "5e0eb2e4fa79f67ea659dee84c12400a193791bb"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/nirsevimab-recommended-for-approval-in-eu-by-chmp.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/nirsevimab-recommended-for-approval-in-eu-by-chmp",
      "id": "a7d650a347df7a92f3c200c97f7cc09b9f097226"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/nirsevimab-significantly-protected-infants-against-rsv-disease-in-phase-iii-melody-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/nirsevimab-significantly-protected-infants-against-rsv-disease-in-phase-iii-melody-trial",
      "id": "ec672ddcfd1c762310209483dc8d06f2e8550c0a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/ondexxya-approved-in-japan-for-fxai-reversal.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/ondexxya-approved-in-japan-for-fxai-reversal",
      "id": "d3047ba5c0f2f699043fd1e243b70687cc2b9d78"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/pt027-significantly-reduced-the-risk-of-a-severe-exacerbation-compared-to-albuterol-in-patients-with-asthma.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/pt027-significantly-reduced-the-risk-of-a-severe-exacerbation-compared-to-albuterol-in-patients-with-asthma",
      "id": "b7941b6b64cffb9b1e13a6ce161a17901ae181d7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/q1-2022-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/q1-2022-results",
      "id": "34daa1351948efd65f26a2eb20b9c023231e2735"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/saphnelo-approved-in-eu-for-sle.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/saphnelo-approved-in-eu-for-sle",
      "id": "45910e607d2975301f5a8a241a9fc4a7a4818ce3"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/tagrisso-approved-in-japan-for-early-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/tagrisso-approved-in-japan-for-early-lung-cancer",
      "id": "b4d9a7555f1f01d885a1c3a5a2e33212a1a4ef61"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/tagrisso-demonstrated-5-year-median-disease-free-survival-in-the-adjuvant-treatment-of-patients-with-egfr-mutated-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/tagrisso-demonstrated-5-year-median-disease-free-survival-in-the-adjuvant-treatment-of-patients-with-egfr-mutated-lung-cancer",
      "id": "e0668138c1942b1512d66cb7345db2036fb2f303"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/tagrisso-plus-savolitinib-demonstrated-49-objective-response-rate-in-lung-cancer-patients-in-savannah-phase-ii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/tagrisso-plus-savolitinib-demonstrated-49-objective-response-rate-in-lung-cancer-patients-in-savannah-phase-ii-trial",
      "id": "2cc6a5730ae99b0837ec6eebaaea73a50f06a378"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/tezspire-approved-in-japan-for-severe-asthma.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/tezspire-approved-in-japan-for-severe-asthma",
      "id": "f583e4364d09ff6593b2f8424f346b1b815b4aab"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/tezspire-approved-in-the-eu-for-the-treatment-of-severe-asthma.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/tezspire-approved-in-the-eu-for-the-treatment-of-severe-asthma",
      "id": "7942b32ab94e3a256823d9f96fb4db1f966fac70"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/tezspire-recommended-for-approval-in-the-eu-by-chmp.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/tezspire-recommended-for-approval-in-the-eu-by-chmp",
      "id": "d21a65e963ed829ccaeb7a256534a61ccf609275"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/transfer-of-global-rights-for-eklira-and-duaklir-to-covis-pharma-completed.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/transfer-of-global-rights-for-eklira-and-duaklir-to-covis-pharma-completed",
      "id": "df6db663fb57704d9ff1cbb432bc561b35293f4d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/tremelimumab-us-priority-review-imfinzi-combo.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/tremelimumab-us-priority-review-imfinzi-combo",
      "id": "972ac5ef257fe32b9d542082f95df17186e3f78c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/ultomiris-approved-in-eu-for-gmg.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/ultomiris-approved-in-eu-for-gmg",
      "id": "c79cd23396ecff439bbc22a882cc97c8c2c08d73"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/ultomiris-approved-in-japan-for-the-treatment-of-adults-with-generalised-myasthenia-gravis.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/ultomiris-approved-in-japan-for-the-treatment-of-adults-with-generalised-myasthenia-gravis",
      "id": "e664de3e9e984533a23a4f64cfb70045ec67b4d6"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/ultomiris-approved-in-the-us-for-adults-with-generalised-myasthenia-gravis.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/ultomiris-approved-in-the-us-for-adults-with-generalised-myasthenia-gravis",
      "id": "db6bfa198583bac2f5a03bf778a4d80d5e4a94bd"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/ultomiris-demonstrated-sustained-improvements-functional-activities-quality-life-adults-generalised-myasthenia-gravis-60-weeks.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/ultomiris-demonstrated-sustained-improvements-functional-activities-quality-life-adults-generalised-myasthenia-gravis-60-weeks",
      "id": "60b6270ea6777acdad3ca6d18772b7d993f4fad5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/ultomiris-nmosd-ph-iii-trial-met-primary-endpoint.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/ultomiris-nmosd-ph-iii-trial-met-primary-endpoint",
      "id": "4c2e9d984e40f1fb274a0363e094440a24bf7311"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/ultomiris-recommended-for-approval-in-the-eu-by-chmp.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/ultomiris-recommended-for-approval-in-the-eu-by-chmp",
      "id": "e0ae18e58b79af40580e5c2627adb4923d22e93d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/ultomiris-showed-zero-relapses-in-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd-with-median-treatment-duration-of-73-weeks.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/ultomiris-showed-zero-relapses-in-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd-with-median-treatment-duration-of-73-weeks",
      "id": "f981753595a72af27497b25f6b03f13bc5858cd5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-calla-phase-iii-trial-for-imfinzi.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/update-on-calla-phase-iii-trial-for-imfinzi",
      "id": "2752307cd840090838baf5b50a9364bbaa25fee3"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-imfinzi-pearl-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/update-on-imfinzi-pearl-trial",
      "id": "a1ddaed7571a17d127a5123505eceee3612b8706"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-messina-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/update-on-messina-phase-iii-trial",
      "id": "b2368636f565e7867a03702059bd11432a14b58f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-us-review-of-fasenra-in-nasal-polyps.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/update-on-us-review-of-fasenra-in-nasal-polyps",
      "id": "72ad29a98fab08acf1d32e97d15bd99710085652"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-us-review-of-lynparza-propel-snda.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/update-on-us-review-of-lynparza-propel-snda",
      "id": "d88d09f82e0e7e2f0f0d0d5a162bac6f51099a56"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/vaxzevria-approved-eu-third-dose-booster-covid-19.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/vaxzevria-approved-eu-third-dose-booster-covid-19",
      "id": "c4f70a52b72d8c3404e8b09f986020785e1a4e0a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/vaxzevria-receives-full-marketing-authorisation-in-the-eu-for-the-prevention-of-covid-19.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/vaxzevria-receives-full-marketing-authorisation-in-the-eu-for-the-prevention-of-covid-19",
      "id": "8b8226e52228e28db8c9cf4a2d6fa65e8cd46fc4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2022/year-to-date-and-q3-2022-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2022/year-to-date-and-q3-2022-results",
      "id": "efbe486ed3d449e6cb2413622bbd4b3378da4206"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023",
      "id": "3d6b33f0de4242472fcd5ab7e0cf67d5f8a7a5ed"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/9m-and-q3-2023-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/9m-and-q3-2023-results",
      "id": "f21d0aec08ff6a4b5cdb11f5e78177a0b76698b8"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/acquisition-of-neogene-therapeutics-completed.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/acquisition-of-neogene-therapeutics-completed",
      "id": "331f6177dfb5f38e778a7e3ded84bc1ec02377db"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/agreement-with-eccogene-for-clinical-stage-glp-1ra.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/agreement-with-eccogene-for-clinical-stage-glp-1ra",
      "id": "6e00b42f733e17a72d896d3230701fa9885a3894"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/airsupra-pt027-approved-in-the-us-for-asthma.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/airsupra-pt027-approved-in-the-us-for-asthma",
      "id": "407d45e5f07b7e494a23922f69b63b67dd6144f6"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/alexion-completes-purchase-licence-agreement-early-stage-rare-disease-gene-therapy-portfolio-pfizer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/alexion-completes-purchase-licence-agreement-early-stage-rare-disease-gene-therapy-portfolio-pfizer",
      "id": "ac0d33aa8c75cb2f9ed4494a6db2e1c6eb1cdb10"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/alexion-data-at-9th-joint-ectrims-actrims-meeting-msmilan2023-showcase-impact-of-c5-inhibition-in-nmosd.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/alexion-data-at-9th-joint-ectrims-actrims-meeting-msmilan2023-showcase-impact-of-c5-inhibition-in-nmosd",
      "id": "9db15a853a6011b7324f878bbaa119eca018dfba"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/alexion-enters-gene-therapy-agreement-with-pfizer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/alexion-enters-gene-therapy-agreement-with-pfizer",
      "id": "af7247aa8b2eb9ff6cea7546ec865c8f4d2f8e15"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/andexxa-phase-iv-trial-stopped-early-after-achieving-pre-specified-criteria-on-haemostatic-efficacy-versus-usual-care.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/andexxa-phase-iv-trial-stopped-early-after-achieving-pre-specified-criteria-on-haemostatic-efficacy-versus-usual-care",
      "id": "aa792f6d987a7187cc4783f21267af61c3094655"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-acquire-cincor-for-cardiorenal-asset.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/astrazeneca-acquire-cincor-for-cardiorenal-asset",
      "id": "c1bcdcc0574493eb14998132972747d36defcd52"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-acquires-cincor-for-cardiorenal-asset.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/astrazeneca-acquires-cincor-for-cardiorenal-asset",
      "id": "4390e0f1b3eb1effc80f4d0735b8d8e1335fc3e5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-advances-its-pipeline-and-highlights-progress-in-immuno-oncology-adcs-cell-therapy-and-epigenetics-at-aacr.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/astrazeneca-advances-its-pipeline-and-highlights-progress-in-immuno-oncology-adcs-cell-therapy-and-epigenetics-at-aacr",
      "id": "5f681a57b407f85415f886435bf50ffa94706105"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-advances-scientific-leadership-across-multiple-cancers-with-first-data-from-four-pivotal-phase-iii-trials-at-esmo.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/astrazeneca-advances-scientific-leadership-across-multiple-cancers-with-first-data-from-four-pivotal-phase-iii-trials-at-esmo",
      "id": "c36c111e19112d1cb7182639485842d479305563"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-advances-scientific-leadership-in-haematology-at-ash-2023.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/astrazeneca-advances-scientific-leadership-in-haematology-at-ash-2023",
      "id": "8cfac9214476935b27e9cd03b43440067552be86"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-agreement-with-quell-therapeutics.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/astrazeneca-agreement-with-quell-therapeutics",
      "id": "8980c4311e96a0ed905ec7f214f5fe57837ac7c6"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-announces-400-million-investment-in-reforestation-and-biodiversity-in-support-of-climate-action-and-human-health.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/astrazeneca-announces-400-million-investment-in-reforestation-and-biodiversity-in-support-of-climate-action-and-human-health",
      "id": "9f1770a5ade10036d6bcba891ff2e50a71fa759f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-appoints-sharon-barr-as-executive-vice-president-biopharmaceuticals-rd.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/astrazeneca-appoints-sharon-barr-as-executive-vice-president-biopharmaceuticals-rd",
      "id": "6461c7cc30197a0fb636a1938bf493da0116e80a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-awards-funding-to-eight-innovative-research-projects.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/astrazeneca-awards-funding-to-eight-innovative-research-projects",
      "id": "04e2481f9443d966fd1d59bd37bff5050d618fc2"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-cell-and-gene-therapy-deal-w-cellectis.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/astrazeneca-cell-and-gene-therapy-deal-w-cellectis",
      "id": "8eb8bb3a59eafddb4bfecbd81639e4add3bfa002"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-completes-agreement-with-kym-for-cmg901.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/astrazeneca-completes-agreement-with-kym-for-cmg901",
      "id": "adf9ed3b0a58c970a3aec0dd764553fdf81cc344"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-data-ers-2023-demonstrate-leadership-transforming-care-across-broad-respiratory-portfolio-inhaled-biologic-medicines.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/astrazeneca-data-ers-2023-demonstrate-leadership-transforming-care-across-broad-respiratory-portfolio-inhaled-biologic-medicines",
      "id": "8a1eae632c65f8b7e0fd49b38d42e031cc7cfb9d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-demonstrates-scientific-leadership-with-compelling-new-data-at-esc-congress-2023-on-the-interconnections-across-chronic-diseases.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/astrazeneca-demonstrates-scientific-leadership-with-compelling-new-data-at-esc-congress-2023-on-the-interconnections-across-chronic-diseases",
      "id": "6ab7add25470679af2499442edd449f909224732"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-enters-license-agreement-with-kym-biosciences-for-cmg901-a-claudin-182-antibody-drug-conjugate.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/astrazeneca-enters-license-agreement-with-kym-biosciences-for-cmg901-a-claudin-182-antibody-drug-conjugate",
      "id": "1678330a0bb0f23f1f2f0c11dcc19480bc0a32f6"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-launches-call-for-entries-to-the-2023-global-rd-postdoctoral-challenge.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/astrazeneca-launches-call-for-entries-to-the-2023-global-rd-postdoctoral-challenge",
      "id": "75924ad4f00c8bc3432b816a42cd40957c8384d4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-launches-evinova-health-tech-business-to-accelerate-innovation-across-the-life-sciences-sector.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/astrazeneca-launches-evinova-health-tech-business-to-accelerate-innovation-across-the-life-sciences-sector",
      "id": "2d71b44e9cc59fb736834bdba7326eedcc5eb6af"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-reinforces-commitment-to-protecting-the-most-vulnerable-from-serious-infectious-diseases-at-idweek-2023.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/astrazeneca-reinforces-commitment-to-protecting-the-most-vulnerable-from-serious-infectious-diseases-at-idweek-2023",
      "id": "c143c1ae2c0e30e6612632a1bf514095f132c59e"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-research-reveals-unique-associations-between-rare-changes-in-genes-and-plasma-proteins-that-could-improve-drug-discovery.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/astrazeneca-research-reveals-unique-associations-between-rare-changes-in-genes-and-plasma-proteins-that-could-improve-drug-discovery",
      "id": "175b2ee7975a6f6882e3a7a291f5319c1544e05c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-settles-nexium-and-prilosec-product-liability-litigations.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/astrazeneca-settles-nexium-and-prilosec-product-liability-litigations",
      "id": "bc1c488eee359fad768d0e989fe7af674e348ba4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-showcases-scientific-advances-across-rare-and-malignant-haematological-conditions-at-eha-2023.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/astrazeneca-showcases-scientific-advances-across-rare-and-malignant-haematological-conditions-at-eha-2023",
      "id": "5144532be4200968ccf5424af0e03aa93b3cd355"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-gracell-furthering-cell-therapy-ambition-across-oncology-and-autoimmune-diseases.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/astrazeneca-to-acquire-gracell-furthering-cell-therapy-ambition-across-oncology-and-autoimmune-diseases",
      "id": "5af565bdedb11bf07785a2d3047514079ccecad5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-icosavax-including-potential-first-in-class-rsv-and-hmpv-combination-vaccine-with-positive-phase-ii-data.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/astrazeneca-to-acquire-icosavax-including-potential-first-in-class-rsv-and-hmpv-combination-vaccine-with-positive-phase-ii-data",
      "id": "ad4ae76b009aff44fa99d552bf56080aec45cb8e"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-will-highlight-momentum-of-practice-changing-cancer-medicines-across-its-robust-pipeline-at-asco-2023.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/astrazeneca-will-highlight-momentum-of-practice-changing-cancer-medicines-across-its-robust-pipeline-at-asco-2023",
      "id": "6efbe5adfb100177acd34bea90d58321bb87fca8"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/beyfortus-approved-in-the-us-for-the-prevention-of-rsv-lower-respiratory-tract-disease-in-infants.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/beyfortus-approved-in-the-us-for-the-prevention-of-rsv-lower-respiratory-tract-disease-in-infants",
      "id": "d759fbe2dada4221db786c2442d27fbc9ab76db4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/calquence-approved-china-chronic-lymphocytic-leukaemia.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/calquence-approved-china-chronic-lymphocytic-leukaemia",
      "id": "c4ac6d65aca65b872e7dcb7b038d0430a005d4c8"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/calquence-granted-first-regulatory-approval-in-china-for-adults-with-previously-treated-mantle-cell-lymphoma.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/calquence-granted-first-regulatory-approval-in-china-for-adults-with-previously-treated-mantle-cell-lymphoma",
      "id": "8444d89aa1210bd52cf2065c4bda34dede1cd439"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/calquence-tablet-formulation-approved-in-the-eu-for-patients-with-chronic-lymphocytic-leukaemia.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/calquence-tablet-formulation-approved-in-the-eu-for-patients-with-chronic-lymphocytic-leukaemia",
      "id": "5dc37b3331fe3c26a8d0cdba05bcc13d173fc00f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/capivasertib-in-combination-with-faslodex-granted-priority-review-in-the-us.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/capivasertib-in-combination-with-faslodex-granted-priority-review-in-the-us",
      "id": "95e600d0cafbb994e0b8f1a4ebf6871e7dca4eca"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/danicopan-as-add-on-to-ultomiris-or-soliris-improved-haemoglobin-levels-and-maintained-disease-control-in-patients.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/danicopan-as-add-on-to-ultomiris-or-soliris-improved-haemoglobin-levels-and-maintained-disease-control-in-patients",
      "id": "478e48048a0cd096a1d4d12697facb8a3198d869"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/dato-dxd-improved-pfs-in-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/dato-dxd-improved-pfs-in-breast-cancer",
      "id": "6a1060920c3a3c17fd33f4b20baf398233b2e468"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/dato-dxd-plus-imfinzi-robust-durable-tumour-responses-1st-line-treatment-patients-metastatic-triple-negative-breast-cancer-begonia-phase-ibii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/dato-dxd-plus-imfinzi-robust-durable-tumour-responses-1st-line-treatment-patients-metastatic-triple-negative-breast-cancer-begonia-phase-ibii-trial",
      "id": "b361dedcd8d42daf52533b7faf7b54f307f9ab7d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/datopotamab-deruxtecan-combinations-showed-encouraging-tumour-responses-in-patients.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/datopotamab-deruxtecan-combinations-showed-encouraging-tumour-responses-in-patients",
      "id": "5d75221d1b18a71ef971262a92bf82dcccb5f124"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/datopotamab-deruxtecan-improved-progression-free-survival-vs-chemotherapy-in-tropion-lung01-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/datopotamab-deruxtecan-improved-progression-free-survival-vs-chemotherapy-in-tropion-lung01-phase-iii-trial",
      "id": "f73d303a9b433c04286027d8c6f63b12bc1e7484"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/datopotamab-deruxtecan-met-dual-primary-endpoint-of-progression-free-survival-in-patients-with-advanced-non-small-cell-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/datopotamab-deruxtecan-met-dual-primary-endpoint-of-progression-free-survival-in-patients-with-advanced-non-small-cell-lung-cancer",
      "id": "ecc46f139b5df8a5cfbfd4f1a167b247f693adff"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/datopotamab-deruxtecan-plus-imfinzi-showed-promising-clinical-activity-in-the-first-line-advanced-non-small-cell-lung-cancer-setting.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/datopotamab-deruxtecan-plus-imfinzi-showed-promising-clinical-activity-in-the-first-line-advanced-non-small-cell-lung-cancer-setting",
      "id": "7021e6d19bac055f723aaf1efef72b56f22bfe47"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/datopotamab-deruxtecan-significantly-extended-progression-free-survival-vs-chemotherapy-in-tropion-breast01-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/datopotamab-deruxtecan-significantly-extended-progression-free-survival-vs-chemotherapy-in-tropion-breast01-phase-iii-trial",
      "id": "ab32003de9ba9a21e94735de56776c66bc9ec522"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/eccmid-data-reinforces-astrazenecas-commitment-to-transform-protection-for-the-most-vulnerable-by-advancing-science-in-vaccines-and-immune-therapies.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/eccmid-data-reinforces-astrazenecas-commitment-to-transform-protection-for-the-most-vulnerable-by-advancing-science-in-vaccines-and-immune-therapies",
      "id": "31742a9bdc4ab2cb19ab001ba44d00992afb35fa"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-approved-in-china-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/enhertu-approved-in-china-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer",
      "id": "281f6a2cc2c2eb932fb7886fe92c999238244973"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-approved-in-china-for-patients-with-her2-positive-metastatic-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/enhertu-approved-in-china-for-patients-with-her2-positive-metastatic-breast-cancer",
      "id": "78b369ee7dcea5d99a364a8c2c1a9e5152dee95d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-approved-in-the-eu-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/enhertu-approved-in-the-eu-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer",
      "id": "d3a3d3cd584e1329334cb078eab1f99fc974a48a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-approved-in-the-eu-as-the-first-her2-directed-therapy-for-patients-with-her2-mutant-advanced-non-small-cell-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/enhertu-approved-in-the-eu-as-the-first-her2-directed-therapy-for-patients-with-her2-mutant-advanced-non-small-cell-lung-cancer",
      "id": "4ab42d78694ff9f227be487937311a413cf8bc90"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-demonstrated-clinically-meaningful-and-durable-responses-in-patients-across-multiple-her2-expressing.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/enhertu-demonstrated-clinically-meaningful-and-durable-responses-in-patients-across-multiple-her2-expressing",
      "id": "d6fd89a319e1cac6f3a86c845730b151e9a9f2d7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-demonstrated-clinically-meaningful-progression-free-survival-and-overall-survival-in-destiny-pantumor02-phase-ii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/enhertu-demonstrated-clinically-meaningful-progression-free-survival-and-overall-survival-in-destiny-pantumor02-phase-ii-trial",
      "id": "712d330e010b9927cf1ddf7bfd9afd36626fc37b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-demonstrated-clinically-meaningful-survival-across-multiple-her2-expressing-advanced-solid-tumours-in-destiny-pantumor02-phase-ii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/enhertu-demonstrated-clinically-meaningful-survival-across-multiple-her2-expressing-advanced-solid-tumours-in-destiny-pantumor02-phase-ii-trial",
      "id": "02857dcda0d7c79c442ae61233377fe97f10dc59"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-demonstrated-strong-and-durable-tumour-responses-in-previously-treated-her2-mutant-advanced-lung-cancer-in-the-destiny-lung02-phase-ii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/enhertu-demonstrated-strong-and-durable-tumour-responses-in-previously-treated-her2-mutant-advanced-lung-cancer-in-the-destiny-lung02-phase-ii-trial",
      "id": "0930248eabd1502eaeb4a75c860f592ed648662f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-destiny-pantumor02-shows-positive-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/enhertu-destiny-pantumor02-shows-positive-results",
      "id": "d9356cdcc2f4d7a48b7bf28504c670a7b359db9f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-her2-mutant-advanced-non-small-cell-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/enhertu-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-her2-mutant-advanced-non-small-cell-lung-cancer",
      "id": "6fd8b2657ca29e16dd60478b764debf79f376e2d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/eplontersen-demonstrated-sustained-benefit-in-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/eplontersen-demonstrated-sustained-benefit-in-phase-iii-trial",
      "id": "0ef470ae91e19cc1c6e57065f3bfc9359156b0d5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/farxiga-extended-in-the-us-for-heart-failure.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/farxiga-extended-in-the-us-for-heart-failure",
      "id": "236788beae98a2aa1f27921fa7a2c0911d71dd25"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/fasenra-phase-iii-egpa-trial-met-primary-endpoint.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/fasenra-phase-iii-egpa-trial-met-primary-endpoint",
      "id": "907bf3aadb9e32a9561a357059581c5341aef2d9"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/forxiga-approved-china-reduce-risk-cardiovascular-death-hospitalisation-patients-with-symptomatic-chronic-heart-failure.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/forxiga-approved-china-reduce-risk-cardiovascular-death-hospitalisation-patients-with-symptomatic-chronic-heart-failure",
      "id": "22fc4f9a46bbe6efb25b04ea081e4229a54d435f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/forxiga-approved-in-the-eu-for-the-treatment-of-symptomatic-chronic-heart-failure.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/forxiga-approved-in-the-eu-for-the-treatment-of-symptomatic-chronic-heart-failure",
      "id": "827d0c530915f2a5396d29174b42b0d443c4a671"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/forxiga-met-primary-endpoint-in-t2now-phase-iii-trial-one-of-the-largest-paediatric-type-2-diabetes-studies-performed-to-date.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/forxiga-met-primary-endpoint-in-t2now-phase-iii-trial-one-of-the-largest-paediatric-type-2-diabetes-studies-performed-to-date",
      "id": "be9e5689e9bc2b9d6b3d114fa73e07f92f11255b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/full-year-and-q4-2022-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/full-year-and-q4-2022-results",
      "id": "abdd58a7ec9ae63223b39cd1f3c83cc59ee97d95"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/h1-and-q2-2023-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/h1-and-q2-2023-results",
      "id": "4bffb477a085c9fb80ff295c5ce0b17dc4a7234f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-based-treatment-before-and-after-surgery-reduced-the-risk-of-disease-recurrence-progression-events-or-death-in-resectable-non-small-cell-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/imfinzi-based-treatment-before-and-after-surgery-reduced-the-risk-of-disease-recurrence-progression-events-or-death-in-resectable-non-small-cell-lung-cancer",
      "id": "9260bacc502acf61ab30155abe4aad24144ccd5d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-combination-improves-pfs-in-liver-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/imfinzi-combination-improves-pfs-in-liver-cancer",
      "id": "6e5e80d30515b0269a4b86f80a2936ed07cab995"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-improved-efs-in-resectable-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/imfinzi-improved-efs-in-resectable-lung-cancer",
      "id": "340549ace9300ef04a34e25e8f13088e6939889d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-lynparza-prolonged-pfs-in-endometrial-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/imfinzi-lynparza-prolonged-pfs-in-endometrial-cancer",
      "id": "277e4159801286109233e8bc35346729135b1ec5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-chemotherapy-approved-in-china-as-first-immunotherapy-regimen-for-patients-with-locally-advanced-or-metastatic-biliary-tract-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/imfinzi-plus-chemotherapy-approved-in-china-as-first-immunotherapy-regimen-for-patients-with-locally-advanced-or-metastatic-biliary-tract-cancer",
      "id": "183852daccf68cb401accfbe3bff41e4f0102214"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-chemotherapy-doubled-pathologic-complete-response-rate-resectable-early-stage-gastric-gastroesophageal-junction-cancers-vs-chemotherapy.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/imfinzi-plus-chemotherapy-doubled-pathologic-complete-response-rate-resectable-early-stage-gastric-gastroesophageal-junction-cancers-vs-chemotherapy",
      "id": "7063b8b6c5e0b620cfb4e8987f8f74e26c2126a5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-chemotherapy-significantly-improved-pathologic-complete-response-in-gastric-and-gastroesophageal-junction-cancers-in-matterhorn-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/imfinzi-plus-chemotherapy-significantly-improved-pathologic-complete-response-in-gastric-and-gastroesophageal-junction-cancers-in-matterhorn-phase-iii-trial",
      "id": "5b4473e45d5aef7c34d02913a5e029b25f655abd"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-imjudo-approved-in-the-eu-for-patients-with-advanced-liver-and-non-small-cell-lung-cancers.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/imfinzi-plus-imjudo-approved-in-the-eu-for-patients-with-advanced-liver-and-non-small-cell-lung-cancers",
      "id": "2d737e4b29ed7bc85316736165b26fae159f644c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-imjudo-demonstrated-sustained-overall-survival-benefit-in-the-himalaya-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/imfinzi-plus-imjudo-demonstrated-sustained-overall-survival-benefit-in-the-himalaya-phase-iii-trial",
      "id": "ee5c9d993ccc4e314594856cc09a740f5049caf5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-lynparza-reduced-risk-disease-progression-death-45-percent-vs-chemotherapy-advanced-recurrent-endometrial-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/imfinzi-plus-lynparza-reduced-risk-disease-progression-death-45-percent-vs-chemotherapy-advanced-recurrent-endometrial-cancer",
      "id": "dddbd4133c9abb3ad77daeae9d67f6304a282549"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/koselugo-approved-in-china-for-paediatric-patients-with-neurofibromatosis-type-1-and-plexiform-neurofibromas.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/koselugo-approved-in-china-for-paediatric-patients-with-neurofibromatosis-type-1-and-plexiform-neurofibromas",
      "id": "63e6f08eded6bc904bedc7588a2f1de37c57449c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/long-term-alpha-phase-iii-trial-data-danicopan-ultomiris-soliris-improvement-patients-pnh-experiencing-clinically-significant-extravascular-haemolysis.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/long-term-alpha-phase-iii-trial-data-danicopan-ultomiris-soliris-improvement-patients-pnh-experiencing-clinically-significant-extravascular-haemolysis",
      "id": "975e5159d5a8d49de3fb68c77f7c4f391df1f3f5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/lynparza-and-imfinzi-combination-reduced-risk-of-disease-progression-or-death-vs-chemotherapy-and-bevacizumab-in-patients-with-advanced-ovarian-cancer-without-tumour-brca-mutations-in-the-duo-o-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/lynparza-and-imfinzi-combination-reduced-risk-of-disease-progression-or-death-vs-chemotherapy-and-bevacizumab-in-patients-with-advanced-ovarian-cancer-without-tumour-brca-mutations-in-the-duo-o-phase-iii-trial",
      "id": "d05573170aa94e2e859665fc95b67cc0689a127c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/lynparza-approved-in-us-for-brcam-prostate-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/lynparza-approved-in-us-for-brcam-prostate-cancer",
      "id": "1521ddbf3485266444b622bf9ac3564a5206616f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/lynparza-imfinzi-met-endpoint-in-ovarian-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/lynparza-imfinzi-met-endpoint-in-ovarian-cancer",
      "id": "227f1632c0cc078e393c9f4390102c662d6086fc"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/lynparza-plus-abiraterone-approved-japan-treatment-brca-mutated-metastatic-castration-resistant-prostate-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/lynparza-plus-abiraterone-approved-japan-treatment-brca-mutated-metastatic-castration-resistant-prostate-cancer",
      "id": "b2dc71c784b8118a0855a0e92cb99b26ca6dc71c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/neuro-ttransform-phase-iii-results-presented-at-aan-showed-eplontersen-demonstrated-consistent-and-sustained-improvement.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/neuro-ttransform-phase-iii-results-presented-at-aan-showed-eplontersen-demonstrated-consistent-and-sustained-improvement",
      "id": "37c6a272154751f8d173681977cd283840422804"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/nirsevimab-recommended-for-infant-rsv-protection.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/nirsevimab-recommended-for-infant-rsv-protection",
      "id": "0bfce6dc8d1f20e90cdbbca9245fdd1592c21e78"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/nirsevimab-us-regulatory-submission-accepted-for-the-prevention-of-rsv-lower-respiratory-tract-disease-in-infants-and-children.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/nirsevimab-us-regulatory-submission-accepted-for-the-prevention-of-rsv-lower-respiratory-tract-disease-in-infants-and-children",
      "id": "de7d1f06292e95330015eaa4e99034ab88a0ddbe"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/odac-vote-on-lynparza-combo-in-prostate-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/odac-vote-on-lynparza-combo-in-prostate-cancer",
      "id": "030d06814d7d454e0b504fb5407d2c0afb27ce9a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/overall-survival-analysis-of-the-lynparza-propel-phase-iii-trial-in-metastatic-castration-resistant-prostate-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/overall-survival-analysis-of-the-lynparza-propel-phase-iii-trial-in-metastatic-castration-resistant-prostate-cancer",
      "id": "2b2e165ab818eb041f8e5fe84fdcb129fce7f465"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/q1-2023-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/q1-2023-results",
      "id": "51868de4481f05df193109c0949cd0efdc5c63b8"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/resvinet-2023-data-reinforce-astrazenecas-commitment-to-help-prevent-respiratory-syncytial-virus-in-infants.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/resvinet-2023-data-reinforce-astrazenecas-commitment-to-help-prevent-respiratory-syncytial-virus-in-infants",
      "id": "1d3339d6c434a49364c4ebfd73ac8daf15dfcbc0"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/soliris-approved-china-treatment-adults-neuromyelitis-optica-spectrum-disorder-nmosd.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/soliris-approved-china-treatment-adults-neuromyelitis-optica-spectrum-disorder-nmosd",
      "id": "7a368e80ff4f61401969df92dfc785e03529d409"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/soliris-approved-in-china-for-the-treatment-of-adults-with-refractory-generalised-myasthenia-gravis.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/soliris-approved-in-china-for-the-treatment-of-adults-with-refractory-generalised-myasthenia-gravis",
      "id": "d87e54583f0d758c3a443674181dfc292f0a298d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/soliris-approved-in-the-eu-for-children-and-adolescents-with-refractory-generalised-myasthenia-gravis-gmg.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/soliris-approved-in-the-eu-for-children-and-adolescents-with-refractory-generalised-myasthenia-gravis-gmg",
      "id": "4677bc6bcf1e179c0fdfbefb259c3b4b40c1a289"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/soliris-approved-japan-paediatric-patients-generalised-myasthenia-gravis-gmg.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/soliris-approved-japan-paediatric-patients-generalised-myasthenia-gravis-gmg",
      "id": "90343f9afc4645ee80486a48607a4a2734e16b72"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/soliris-recommended-for-approval-in-the-eu-by-chmp-for-children-and-adolescents.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/soliris-recommended-for-approval-in-the-eu-by-chmp-for-children-and-adolescents",
      "id": "7997107acd42c36fb6eda252b07e8b77cef579bc"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/tagrisso-achieved-unprecedented-survival-in-early-stage-egfr-mutated-lung-cancer-with-88-of-patients-alive-at-five-years-in-adaura-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/tagrisso-achieved-unprecedented-survival-in-early-stage-egfr-mutated-lung-cancer-with-88-of-patients-alive-at-five-years-in-adaura-phase-iii-trial",
      "id": "7224ea9cf35bc883530a1f839d16e085a5d2aea8"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/tagrisso-demonstrated-strong-overall-survival-benefit-in-the-adaura-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/tagrisso-demonstrated-strong-overall-survival-benefit-in-the-adaura-phase-iii-trial",
      "id": "dc162a70ae32f69ea22dfbdf7f0fff4d267d3937"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/tagrisso-plus-chemo-improved-pfs-in-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/tagrisso-plus-chemo-improved-pfs-in-lung-cancer",
      "id": "343d45e4149f575656c03b0ff5761117eb0b9eab"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/tagrisso-plus-chemotherapy-extended-median-progression-free-survival-by-nearly-9-months-in-egfr-mutated-advanced-lung-cancer-in-flaura2-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/tagrisso-plus-chemotherapy-extended-median-progression-free-survival-by-nearly-9-months-in-egfr-mutated-advanced-lung-cancer-in-flaura2-phase-iii-trial",
      "id": "1c9d20d2636af5284d7205b50c1a98b1dacfff2d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/tagrisso-plus-chemotherapy-granted-priority-review-us-patients-egfr-mutated-advanced-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/tagrisso-plus-chemotherapy-granted-priority-review-us-patients-egfr-mutated-advanced-lung-cancer",
      "id": "961ab3ddc7a4412f5301cfff5faf0b70d9613659"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/tagrisso-plus-chemotherapy-reduced-risk-disease-progression-brain-42-percent-patients-egfr-mutated-advanced-lung-cancer-brain-metastases-baseline.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/tagrisso-plus-chemotherapy-reduced-risk-disease-progression-brain-42-percent-patients-egfr-mutated-advanced-lung-cancer-brain-metastases-baseline",
      "id": "4d567e3a38368210ac8a6f7ae114f94fb9c4ca57"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/tezspire-approved-for-self-administration-in-the-eu-in-a-new-pre-filled-pen.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/tezspire-approved-for-self-administration-in-the-eu-in-a-new-pre-filled-pen",
      "id": "2902b2364e7b587d95063e07a37fa64ad4cb630c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/tezspire-approved-for-self-administration-in-the-us-with-a-new-pre-filled-pen.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/tezspire-approved-for-self-administration-in-the-us-with-a-new-pre-filled-pen",
      "id": "ba36518ca463c09d452d93f8c55529248cad79b4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/truqap-approved-in-us-for-hr-plus-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/truqap-approved-in-us-for-hr-plus-breast-cancer",
      "id": "0f4072589c4b929bc5beaad9c5a88a2c60efd005"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/ultomiris-approved-in-japan-for-the-prevention-of-relapses-in-patients-with-nmosd.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/ultomiris-approved-in-japan-for-the-prevention-of-relapses-in-patients-with-nmosd",
      "id": "93dad83f5aa968ce2e2002f1aa0756d10ebc2d60"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/ultomiris-approved-in-the-eu-for-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/ultomiris-approved-in-the-eu-for-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd",
      "id": "e659d67acc38f9c53dae77951db201205131c1d2"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/ultomiris-recommended-for-nmosd-eu-approval.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/ultomiris-recommended-for-nmosd-eu-approval",
      "id": "6b600216a7e7ac98ed6e1d1daaed50c4abebb642"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/update-on-brazikumab-development-programme.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/update-on-brazikumab-development-programme",
      "id": "a312b4d1ce11f3f5b265f1f26821bfc438fbfea6"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/update-on-crystalize-evidence-trials.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/update-on-crystalize-evidence-trials",
      "id": "ade3b9afb6834995960542e87442ddc0eb36b7cf"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/update-on-evusheld-us-eua.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/update-on-evusheld-us-eua",
      "id": "e41b361d5eee506cb2740bc4e1153759b7436821"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/update-on-pacific-2-phase-iii-trial-for-imfinzi.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/update-on-pacific-2-phase-iii-trial-for-imfinzi",
      "id": "8b29ba1ec59c01a2ee58a4db489b9d7b5c880659"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/update-on-us-regulatory-review-of-lynparza-in-combination-with-abiraterone-for-mcrpc.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/update-on-us-regulatory-review-of-lynparza-in-combination-with-abiraterone-for-mcrpc",
      "id": "4d169fdb79028bc58767ff9add8df6caf49eeb57"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/update-on-us-review-of-ultomiris-for-nmosd.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/update-on-us-review-of-ultomiris-for-nmosd",
      "id": "c0e725f31837d83d5e10eac1280f408386b237fa"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/update-to-arrangements-with-sobi-and-sanofi.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/update-to-arrangements-with-sobi-and-sanofi",
      "id": "10913350b82e335e16fb1a534103c64333751bf6"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/us-food-drug-administration-accepts-review-astrazeneca-supplemental-biologics-license-application-self-administration-flumist-quadrivalent.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/us-food-drug-administration-accepts-review-astrazeneca-supplemental-biologics-license-application-self-administration-flumist-quadrivalent",
      "id": "3ea8aaf387cf41de9b6a3113a244eba638ba0c9a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/wainua-eplontersen-granted-first-ever-regulatory-approval-us-treatment-of-adults-with-polyneuropathy-hereditary-transthyretin-mediated-amyloidosis.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/wainua-eplontersen-granted-first-ever-regulatory-approval-us-treatment-of-adults-with-polyneuropathy-hereditary-transthyretin-mediated-amyloidosis",
      "id": "d4f3265c9090446e89d7a74f4896e83ab4c319ba"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/wclc-advance-ambition-astrazeneca-medicine-for-more-than-half-of-all-patients-treated-for-lung-cancer-2030.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/wclc-advance-ambition-astrazeneca-medicine-for-more-than-half-of-all-patients-treated-for-lung-cancer-2030",
      "id": "fd43dfbe60d69ee92506c7b1769b22a070e34a15"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/xigduo-xr-approved-in-china-for-adults-with-type-2-diabetes.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/xigduo-xr-approved-in-china-for-adults-with-type-2-diabetes",
      "id": "dc71635d1bce45ed0e17d9ec2274dd74c02dd56d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/zibotentan-dapagliflozin-combination-demonstrated-significant-albuminuria-reduction-in-patients-with-chronic-kidney-disease-and-proteinuria-in-zenith-ckd-phase-IIb-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/zibotentan-dapagliflozin-combination-demonstrated-significant-albuminuria-reduction-in-patients-with-chronic-kidney-disease-and-proteinuria-in-zenith-ckd-phase-iib-trial",
      "id": "016918fa6e368f52b76c9a93e4c744958690f62c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/zora-real-world-evidence-demonstrates-that-lokelma-substantially-increases-cardiorenal-patients-chances-of-maintaining-lifesaving-raasi-therapy.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2023/zora-real-world-evidence-demonstrates-that-lokelma-substantially-increases-cardiorenal-patients-chances-of-maintaining-lifesaving-raasi-therapy",
      "id": "9ec13e7460bb203f5294876eaa64cbb507905c09"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024",
      "id": "5e0961622101f589bffe30f0d0bdb4a103d5b2ef"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/9m-and-q3-2024-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/9m-and-q3-2024-results",
      "id": "4d3a5afd17c4e01f7a838b517d0a5b99a79f4fbd"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/acquisition-of-amolyt-pharma-completed.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/acquisition-of-amolyt-pharma-completed",
      "id": "66fbba5ee6b2cd8762e6d8745119e603e49be3d2"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/acquisition-of-fusion-completed.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/acquisition-of-fusion-completed",
      "id": "7df544f4763139262afcf8ae971acbd4de708d01"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/acquisition-of-gracell-completed.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/acquisition-of-gracell-completed",
      "id": "2c0ac234fbceaa1a6d2c6e77963701d008de0c70"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/airsupra-positive-results-phase-iii-batura-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/airsupra-positive-results-phase-iii-batura-trial",
      "id": "d29b59db3bca53bf3570b23c60cebf9950779f16"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/alexion-astrazeneca-rare-disease-data-at-the-2024-aanem-annual-meeting-and-mgfa-scientific-session-further-demonstrate-advancement-in-gmg-care.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/alexion-astrazeneca-rare-disease-data-at-the-2024-aanem-annual-meeting-and-mgfa-scientific-session-further-demonstrate-advancement-in-gmg-care",
      "id": "ecc7d37d722188d769419b7a9cfbdf66949a6831"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/alexion-data-at-aan-2024-demonstrate-how-ultomiris-and-soliris-can-transform-outcomes-for-rare-neurological-diseases.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/alexion-data-at-aan-2024-demonstrate-how-ultomiris-and-soliris-can-transform-outcomes-for-rare-neurological-diseases",
      "id": "2c67fa7583fd7d6afa4b1eeddcd451a5ed664107"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-advances-ambition-to-improve-standards-of-care-in-multiple-cancer-types-at-wclc-and-esmo-2024.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/astrazeneca-advances-ambition-to-improve-standards-of-care-in-multiple-cancer-types-at-wclc-and-esmo-2024",
      "id": "6372caab4a6c79be4a9d591e8be1344b71a17686"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-advances-science-of-infectious-disease-protection-at-idweek-2024.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/astrazeneca-advances-science-of-infectious-disease-protection-at-idweek-2024",
      "id": "ed6764f068cbca977aec523c0b9d63d65c03c414"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-advances-the-science-of-infectious-disease-protection-at-eccmid-2024.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/astrazeneca-advances-the-science-of-infectious-disease-protection-at-eccmid-2024",
      "id": "3d81575179ce43fb7cca3dc6e06191f34c495fcc"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-announces-the-completion-of-the-clinical-programme-to-support-the-transition-of-breztri-to-next-generation-propellant-with-near-zero-global-warming-potential.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/astrazeneca-announces-the-completion-of-the-clinical-programme-to-support-the-transition-of-breztri-to-next-generation-propellant-with-near-zero-global-warming-potential",
      "id": "682dab3e0494e8e83795d309992261b3a5f84260"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-appoints-iskra-reic-as-executive-vice-president-international.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/astrazeneca-appoints-iskra-reic-as-executive-vice-president-international",
      "id": "f4fdd6591aab954434a7be3a2bdedf1b76966d36"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-china-president-currently-under-investigation.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/astrazeneca-china-president-currently-under-investigation",
      "id": "f465de78dc152fe78439135e676f5b0de1da3808"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-completes-acquisition-of-icosavax.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/astrazeneca-completes-acquisition-of-icosavax",
      "id": "0962353503c171fa0bb46f57260c7f923cc51854"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-completes-cellectis-equity-investment.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/astrazeneca-completes-cellectis-equity-investment",
      "id": "be608af97c4446995135771678b7e3667236d9c5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-furthers-ambition-to-transform-outcomes-in-early-lung-cancer-and-redefine-metastatic-breast-cancer-treatment-at-asco-2024.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/astrazeneca-furthers-ambition-to-transform-outcomes-in-early-lung-cancer-and-redefine-metastatic-breast-cancer-treatment-at-asco-2024",
      "id": "dd2fddc341a3950884da861bbfe2302f0ea12c15"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-increases-2024-dividend-by-7.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/astrazeneca-increases-2024-dividend-by-7",
      "id": "f86e061fa79945c671c2276732670a4a5fa841d5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-invests-3bn-500mn-in-us.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/astrazeneca-invests-3bn-500mn-in-us",
      "id": "e829703ffc32fdc323e9a7cf93a0fab3c03e47a0"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-licenses-lipid-lowering-lpa-asset.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/astrazeneca-licenses-lipid-lowering-lpa-asset",
      "id": "98094a3cbf21b28fec7a313e758a6edbe883e575"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-showcases-strength-of-haematology-portfolio-and-pipeline-at-ash-2024.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/astrazeneca-showcases-strength-of-haematology-portfolio-and-pipeline-at-ash-2024",
      "id": "7f57bed3fab62d3992c6cca769ad53a11dd50191"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-acquire-amolyt.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/astrazeneca-to-acquire-amolyt",
      "id": "ed265ac5a8937b11f72f1fcf174a721da67b4fd8"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-acquire-fusion.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/astrazeneca-to-acquire-fusion",
      "id": "e721ed722e75c425d209239d0d755ade2064179a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-deliver-80bn-revenue-by-2030.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/astrazeneca-to-deliver-80bn-revenue-by-2030",
      "id": "3cd053a165fb22a4df7c09afd436db8055683070"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-manufacture-adcs-in-singapore.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/astrazeneca-to-manufacture-adcs-in-singapore",
      "id": "c74532da87443c1d6d074f91dea5d7f375f32668"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/az-unveils-latest-research-across-key-respiratory-and-immune-mediated-diseases-at-ats-2024-showcasing-strength-of-its-broad-pipeline-and-portfolio.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/az-unveils-latest-research-across-key-respiratory-and-immune-mediated-diseases-at-ats-2024-showcasing-strength-of-its-broad-pipeline-and-portfolio",
      "id": "d1780b97cdbd59025c593f489d753a3ca9a01cc7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/azn-share-price-movement.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/azn-share-price-movement",
      "id": "df021ad981a2c3864ba48baff685769aef6b460b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/beyfortus-approved-in-china-for-the-prevention-of-rsv-disease-in-infants-bkp.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/beyfortus-approved-in-china-for-the-prevention-of-rsv-disease-in-infants-bkp",
      "id": "8457f7ac2051b8c4aa9fb2b43dc59105162e8165"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/beyfortus-approved-in-japan-for-the-prevention-of-rsv-disease-in-infants.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/beyfortus-approved-in-japan-for-the-prevention-of-rsv-disease-in-infants",
      "id": "e023172f65098c65a5e1681a1f855780421dfa62"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/calquence-combination-improved-pfs-in-1l-mcl.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/calquence-combination-improved-pfs-in-1l-mcl",
      "id": "5ce181c29f54300b85e822f0968a4e956199e7e5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/calquence-fixed-duration-combo-improved-1l-cll-pfs.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/calquence-fixed-duration-combo-improved-1l-cll-pfs",
      "id": "863d6c291385201e4db074fc443e5796c6d0a306"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/calquence-granted-priority-review-in-the-us-for-patients-with-untreated-mantle-cell-lymphoma.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/calquence-granted-priority-review-in-the-us-for-patients-with-untreated-mantle-cell-lymphoma",
      "id": "693d6ae6ba70b3093088e5a937038ac72317b2c6"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/calquence-plus-chemoimmunotherapy-reduced-the-risk-of-disease-progression-or-death-by-27-percent.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/calquence-plus-chemoimmunotherapy-reduced-the-risk-of-disease-progression-or-death-by-27-percent",
      "id": "e5f3360baea7275893a845afb66628ce32158602"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/dato-dxd-improved-os-in-nonsquamous-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/dato-dxd-improved-os-in-nonsquamous-lung-cancer",
      "id": "8e9837f99c049bdca3165ad041c4611c5eee7926"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/dato-dxd-new-bla-submitted-nsq-bla-withdrawn.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/dato-dxd-new-bla-submitted-nsq-bla-withdrawn",
      "id": "b08345de89b5ae05c1421fbc1ffab0f8829328ef"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/dato-dxd-nsq-nsclc-application-withdrawn-in-eu.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/dato-dxd-nsq-nsclc-application-withdrawn-in-eu",
      "id": "63fa5bde434ff7093f988f5b03941593f049c84f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/dato-dxd-showed-median-overall-survival-of-146-months-in-patients-with-advanced-nsclc-in-tropion-lung01-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/dato-dxd-showed-median-overall-survival-of-146-months-in-patients-with-advanced-nsclc-in-tropion-lung01-phase-iii-trial",
      "id": "cac955c12985a12ebb2356abd25c73f86d614f39"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/datopotamab-deruxtecan-final-overall-survival-results-reported-in-patients-with-metastatic-hr-positive-her2-low-or-negative-breast-cancer-in-tropion-breast01-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/datopotamab-deruxtecan-final-overall-survival-results-reported-in-patients-with-metastatic-hr-positive-her2-low-or-negative-breast-cancer-in-tropion-breast01-phase-iii-trial",
      "id": "87ab5d2fed8782288eff7e079e21a96af7f30cf4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/datopotamab-deruxtecan-granted-breakthrough-therapy-designation-us-patients-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/datopotamab-deruxtecan-granted-breakthrough-therapy-designation-us-patients-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer",
      "id": "f0cdf013e68f1ea9b33d7722c9e10393d18e1326"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/early-chronic-kidney-disease-intervention-could-save-four-european-health-systems-up-to-15-billion-euro-over-10-years.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/early-chronic-kidney-disease-intervention-could-save-four-european-health-systems-up-to-15-billion-euro-over-10-years",
      "id": "5cef9b0a17d192aacb8ccc3758f2425ac1a9a514"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/ema-validates-dato-dxd-maas-for-nsq-nsclc-and-bc.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/ema-validates-dato-dxd-maas-for-nsq-nsclc-and-bc",
      "id": "8ca110d4a9fbf8b36d6d0646e51c8b3e48839a0e"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-approved-in-china-as-first-her2-directe-therapy-for-patients-with-her2-mutant-metastatic-non-small-cell-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/enhertu-approved-in-china-as-first-her2-directe-therapy-for-patients-with-her2-mutant-metastatic-non-small-cell-lung-cancer",
      "id": "18161eea45ea74ccab1f40d57a2d0341c81d4de0"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-approved-in-china-for-patients-with-previously-treated-her2-positive-advanced-or-metastatic-gastric-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/enhertu-approved-in-china-for-patients-with-previously-treated-her2-positive-advanced-or-metastatic-gastric-cancer",
      "id": "4492f539c1746a4b63218b1405d3f7e0581fa505"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-approved-in-the-us-as-first-tumour-agnostic-her2-directed-therapy-for-previously-treated-patients-with-metastatic-her2-positive-solid-tumours.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/enhertu-approved-in-the-us-as-first-tumour-agnostic-her2-directed-therapy-for-previously-treated-patients-with-metastatic-her2-positive-solid-tumours",
      "id": "535fd5bf44d5e7289ecd44d34f2f92e8d47e135f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/Enhertu-demonstrated-median-progression-free-survival-thirteen-months.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/enhertu-demonstrated-median-progression-free-survival-thirteen-months",
      "id": "ff6f3cb41b63948664d8dadc984d5a833c2f173d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-granted-priority-review-in-the-us-for-patients-with-metastatic-her2-positive-solid-tumours.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/enhertu-granted-priority-review-in-the-us-for-patients-with-metastatic-her2-positive-solid-tumours",
      "id": "e5a6fc1c1063a08b66f7290a84773263c931ca50"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-granted-priority-review-us-for-patients-her2-low-or-her2-ultralow-metastatic-breast-cancer-who-have-received-at-least-1-line-endocrine-therapy.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/enhertu-granted-priority-review-us-for-patients-her2-low-or-her2-ultralow-metastatic-breast-cancer-who-have-received-at-least-1-line-endocrine-therapy",
      "id": "f8425052039b8cdd9578f6f65200fc9b518108ed"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-improved-pfs-in-her2-low-and-ultralow.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/enhertu-improved-pfs-in-her2-low-and-ultralow",
      "id": "53e188e7a730b16ed1fc7a35753dfe53550326fd"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-showed-substantial-clinical-activity-in-patients-with-her2-positive-metastatic-breast-cancer-and-brain-metastases.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/enhertu-showed-substantial-clinical-activity-in-patients-with-her2-positive-metastatic-breast-cancer-and-brain-metastases",
      "id": "7119b684b68acaf81a8fef7e11c5a88cf1147a5a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/farxiga-approved-in-the-us-for-the-treatment-of-paediatric-type-2-diabetes.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/farxiga-approved-in-the-us-for-the-treatment-of-paediatric-type-2-diabetes",
      "id": "b240938db697f9b4f285ee100dd67883f82366c7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/fasenra-approved-in-china-for-the-treatment-of-severe-eosinophilic-asthma.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/fasenra-approved-in-china-for-the-treatment-of-severe-eosinophilic-asthma",
      "id": "c0ce739828d5296fec5df1d3627b51b005894fbe"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/fasenra-approved-in-the-eu-for-eosinophilic-granulomatosis-with-polyangiitis.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/fasenra-approved-in-the-eu-for-eosinophilic-granulomatosis-with-polyangiitis",
      "id": "f944d837bf9a393ddcfc5c7b5ad0416624c784a4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/fasenra-approved-in-the-us-for-eosinophilic-granulomatosis-with-polyangiitis.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/fasenra-approved-in-the-us-for-eosinophilic-granulomatosis-with-polyangiitis",
      "id": "861cf968184b96d8059a89d9e5f6d1c44ea26e9b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/fasenra-recommended-for-eu-approval-in-egpa.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/fasenra-recommended-for-eu-approval-in-egpa",
      "id": "a5eb2139db7a9b73314d74b4f74ae9ac302619cc"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/fda-accepts-dato-dxd-bla-for-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/fda-accepts-dato-dxd-bla-for-breast-cancer",
      "id": "740ee559381c0948b47599481ee1d145ddb2dff7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/fda-accepts-dato-dxd-bla-for-nonsquamous-nsclc.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/fda-accepts-dato-dxd-bla-for-nonsquamous-nsclc",
      "id": "1023241cda011bbed9bcfe903946f156e77bbc09"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/fixed-duration-calquence-plus-venetoclax-demonstrated-superior-pfs-vs-standard-care-previously-untreated-cll-with-77-of-patients-progression-free-3-years-amplify-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/fixed-duration-calquence-plus-venetoclax-demonstrated-superior-pfs-vs-standard-care-previously-untreated-cll-with-77-of-patients-progression-free-3-years-amplify-phase-iii-trial",
      "id": "de5e177f4347c0f8576a5dfd9fe82e01b4042859"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/flumist-approved-for-self-administration-in-the-us.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/flumist-approved-for-self-administration-in-the-us",
      "id": "9450fa66a446e050609bc65c7a9555a1eedab093"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/full-year-and-q4-2023-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/full-year-and-q4-2023-results",
      "id": "5ad1be5a0b62625408b0308e9ecc8a428c8dc84e"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/h1-and-q2-2024-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/h1-and-q2-2024-results",
      "id": "a6d68024c44e279c8882e9e2187c243e19ad859c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-approved-in-the-us-for-endometrial-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/imfinzi-approved-in-the-us-for-endometrial-cancer",
      "id": "ceb807542c76366d567905684ec04ffdfdf69504"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-approved-in-us-for-limited-stage-sclc.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/imfinzi-approved-in-us-for-limited-stage-sclc",
      "id": "2438463120f0f5ddcd3707a0e0deb6e501170a3b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-approved-in-us-for-resectable-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/imfinzi-approved-in-us-for-resectable-lung-cancer",
      "id": "0dd99ff99df651b14637bee2af6aca465b6a96bf"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-granted-priority-review-and-breakthrough-therapy-designation-for-patients-with-limited-stage-small-cell-lung-cancer-in-the-us.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/imfinzi-granted-priority-review-and-breakthrough-therapy-designation-for-patients-with-limited-stage-small-cell-lung-cancer-in-the-us",
      "id": "864895fcc3f3a1e3edbe6aa25ab1211b37cf5fd7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-granted-priority-review-in-the-us-for-patients-with-muscle-invasive-bladder-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/imfinzi-granted-priority-review-in-the-us-for-patients-with-muscle-invasive-bladder-cancer",
      "id": "3412b6e26ff1e8da97606d2a25e00ffb0ce27559"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-improved-efs-and-os-in-bladder-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/imfinzi-improved-efs-and-os-in-bladder-cancer",
      "id": "866d470152dc69cce84db12611c852fe531fa60e"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-improved-os-and-pfs-in-limited-stage-sclc.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/imfinzi-improved-os-and-pfs-in-limited-stage-sclc",
      "id": "33fc1c05931a611c80705c55ccccd6eb89420bda"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-is-first-and-only-immunotherapy-to-show-survival-benefit-in-limited-stage-small-cell-lung-cancer-in-global-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/imfinzi-is-first-and-only-immunotherapy-to-show-survival-benefit-in-limited-stage-small-cell-lung-cancer-in-global-phase-iii-trial",
      "id": "c13bac5336fe63a20247a67758ac3b422936ad6b"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-perioperative-regimen-reduced-risk-recurrence-by-32-risk-death-by-25-vs-neoadjuvant-chemotherapy-alone-in-mibc-niagara-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/imfinzi-perioperative-regimen-reduced-risk-recurrence-by-32-risk-death-by-25-vs-neoadjuvant-chemotherapy-alone-in-mibc-niagara-phase-iii-trial",
      "id": "374a9ecfa04354b41c090f62d6f566d0a2d9c3b3"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-plus-chemotherapy-doubled-overall-survival-rate-at-three-years-for-patients-with-advanced-biliary-tract-cancer-in-topaz-1-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/imfinzi-plus-chemotherapy-doubled-overall-survival-rate-at-three-years-for-patients-with-advanced-biliary-tract-cancer-in-topaz-1-phase-iii-trial",
      "id": "c44cf1c2b3b70f84dabb9c8f4e22f960b55617b6"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-plus-imjudo-demonstrated-unprecedented-overall-survival-alc-with-one-in-five-patients-surviving-five-years-himalaya-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/imfinzi-plus-imjudo-demonstrated-unprecedented-overall-survival-alc-with-one-in-five-patients-surviving-five-years-himalaya-phase-iii-trial",
      "id": "7f7bd40e09ac54fb436ac83f096e19a25d926e65"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-with-tace-and-bevacizumab-in-patients-with-hepatocellular-carcinoma-eligible-for-embolisation.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/imfinzi-with-tace-and-bevacizumab-in-patients-with-hepatocellular-carcinoma-eligible-for-embolisation",
      "id": "cbeb224d69e0c747c0a89dbaeccaca888a9c4a89"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/komet-phase-iii-trial-met-primary-endpoint.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/komet-phase-iii-trial-met-primary-endpoint",
      "id": "3d615cab36da65b16a4c9a13100d91c8bf18a0b8"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/lynparza-and-imfinzi-combination-approved-in-the-eu-for-patients-with-mismatch-repair-proficient-advanced-or-recurrent-endometrial-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/lynparza-and-imfinzi-combination-approved-in-the-eu-for-patients-with-mismatch-repair-proficient-advanced-or-recurrent-endometrial-cancer",
      "id": "7f3e92ec11029eab9ef46e1d977a3346533f5cd7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/lynparza-and-imfinzi-demonstrated-strong-clinical-benefit-and-more-than-doubled-median-duration-of-response-vs-chemotherapy.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/lynparza-and-imfinzi-demonstrated-strong-clinical-benefit-and-more-than-doubled-median-duration-of-response-vs-chemotherapy",
      "id": "e4572dfad7864c8720553a9682a44a9fff711737"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/lynparza-and-imfinzi-positive-chmp-in-endometrial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/lynparza-and-imfinzi-positive-chmp-in-endometrial",
      "id": "ed21bc7abaf31ab5f743247ffab536abe18c33b1"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/lynparza-demonstrated-clinically-meaningful-prolonged-survival-benefit-in-early-breast-cancer-in-olympia-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/lynparza-demonstrated-clinically-meaningful-prolonged-survival-benefit-in-early-breast-cancer-in-olympia-phase-iii-trial",
      "id": "622b5545c23d7984aea47e7fab4b7d2d7b83517a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/new-modelling-reveals-the-escalating-toll-of-chronic-kidney-disease-on-patients-planet-and-economies.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/new-modelling-reveals-the-escalating-toll-of-chronic-kidney-disease-on-patients-planet-and-economies",
      "id": "0332f645555ddd7835e6d7c73f9c78ab24585257"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/novel-computational-pathology-based-trop2-biomarker-for-dato-dxd-was-predictive-of-clinical-outcomes-in-patients-with-nsclc-in-tropion-lung01-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/novel-computational-pathology-based-trop2-biomarker-for-dato-dxd-was-predictive-of-clinical-outcomes-in-patients-with-nsclc-in-tropion-lung01-phase-iii-trial",
      "id": "10a81da6c5df7734cda4587f8e31d685050b71cd"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/odac-reviewed-imfinzi-in-resectable-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/odac-reviewed-imfinzi-in-resectable-lung-cancer",
      "id": "d5c2927ea0e316862be3990ac349cd080e11a2be"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/positive-results-japan-phase-iii-trial-acoramidis-transthyretin-mediated-amyloid-cardiomyopathy-attr-cm-consistency-global-attribute-cm-phase-iii.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/positive-results-japan-phase-iii-trial-acoramidis-transthyretin-mediated-amyloid-cardiomyopathy-attr-cm-consistency-global-attribute-cm-phase-iii",
      "id": "8fa3e247d152345c0898ef653154743758d425f1"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/q1-2024-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/q1-2024-results",
      "id": "c57bfb81a32c8d65f02b36304895d34baf54e4d5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/sipavibart-ema-regulatory-submission-accepted-under-accelerated-assessment-for-covid-19-prevention.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/sipavibart-ema-regulatory-submission-accepted-under-accelerated-assessment-for-covid-19-prevention",
      "id": "5b0e75eef07a2ca18bcc938ce7866ef90a452b36"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/supernova-trial-met-covid-19-prevention-endpoint.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/supernova-trial-met-covid-19-prevention-endpoint",
      "id": "6bc9d041924728cab70a1b94de6ad45aaeef282c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-addition-chemotherapy-approved-japan-new-first-line-treatment-patients-egfr-mutated-advanced-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/tagrisso-addition-chemotherapy-approved-japan-new-first-line-treatment-patients-egfr-mutated-advanced-lung-cancer",
      "id": "d7e11cd9ee990a2b13453136411543d59dc8bdb9"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-approved-in-eu-based-on-laura-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/tagrisso-approved-in-eu-based-on-laura-trial",
      "id": "1df0725ff84792def052dec16f33eb6995346737"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-granted-priority-review-in-the-us-for-patients-with-unresectable-stage-iii-egfr-mutated-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/tagrisso-granted-priority-review-in-the-us-for-patients-with-unresectable-stage-iii-egfr-mutated-lung-cancer",
      "id": "3bc22dfca0ab747f5376cd55db9e248b4ef97d66"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-improved-pfs-in-stage-iii-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/tagrisso-improved-pfs-in-stage-iii-lung-cancer",
      "id": "98359ccd4fd88448816c082b32e14d4dce72a842"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-plus-chemo-approved-in-us-for-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/tagrisso-plus-chemo-approved-in-us-for-lung-cancer",
      "id": "fa43e9e31b383abfa3d30fe39e498c51197576b2"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-plus-chemo-recommended-for-approval-in-eu.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/tagrisso-plus-chemo-recommended-for-approval-in-eu",
      "id": "e842e44fe007d44f45d29a5d9edadcd0b9f5f89d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-recommended-for-eu-approval-laura.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/tagrisso-recommended-for-eu-approval-laura",
      "id": "52f81cdc2b82bf9bf6959fc21cd1416943e1a300"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-reduced-the-risk-of-disease-progression-or-death-by-84-percent-in-patients-with-unresectable-stage-iii-egfr-mutated-lung-cancer-vs-placebo.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/tagrisso-reduced-the-risk-of-disease-progression-or-death-by-84-percent-in-patients-with-unresectable-stage-iii-egfr-mutated-lung-cancer-vs-placebo",
      "id": "d6a8c60c96484c178445235972dd3f12f2849231"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-the-addition-chemotherapy-showed-favourable-trend-overall-survival-egfr-mutated-advanced-lung-cancer-further-follow-flaura2-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/tagrisso-the-addition-chemotherapy-showed-favourable-trend-overall-survival-egfr-mutated-advanced-lung-cancer-further-follow-flaura2-phase-iii-trial",
      "id": "f6d6658eccdff084fdc7023eb391b352a2ad2201"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-us-approval-in-unresectable-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/tagrisso-us-approval-in-unresectable-lung-cancer",
      "id": "79cc0b612452a3247e0c2987b4ee607d0f1434c8"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-with-the-addition-of-chemotherapy-approved-in-china-as-1st-line-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/tagrisso-with-the-addition-of-chemotherapy-approved-in-china-as-1st-line-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer",
      "id": "e3fc77e03c96a20b474bbbdb20de6689da04ab98"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-with-the-addition-of-chemotherapy-approved-in-the-eu-as-new-1st-line-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/tagrisso-with-the-addition-of-chemotherapy-approved-in-the-eu-as-new-1st-line-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer",
      "id": "bd72499111821f004e06e29564f7e4d78fe1779d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/tezspire-nasal-polyps-trial-met-primary-endpoints.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/tezspire-nasal-polyps-trial-met-primary-endpoints",
      "id": "815f4066898507282d898ac180785aaa2f9028a7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/truqap-improved-rpfs-in-advanced-prostate-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/truqap-improved-rpfs-in-advanced-prostate-cancer",
      "id": "001364e1ad96007600f9d56d2fa47397c9dac55a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/truqap-plus-faslodex-approved-in-japan-for-patients-with-advanced-hr-positive-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/truqap-plus-faslodex-approved-in-japan-for-patients-with-advanced-hr-positive-breast-cancer",
      "id": "00fa020e2d83ec54f10460f75ebad67b6bd73610"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/truqap-plus-faslodex-approved-in-the-eu-for-patients-with-advanced-er-positive-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/truqap-plus-faslodex-approved-in-the-eu-for-patients-with-advanced-er-positive-breast-cancer",
      "id": "737fc33470e19a4ddb6a15836382633c08c6a619"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/truqap-recommended-for-eu-breast-cancer-approval.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/truqap-recommended-for-eu-breast-cancer-approval",
      "id": "560870416fb40a35223e2542e374b1f53b1f34ab"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/ultomiris-approved-in-the-us-for-nmosd.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/ultomiris-approved-in-the-us-for-nmosd",
      "id": "af9c53b9a4ee17c44a1316311e7adf38e5501e89"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/update-on-capitello-290-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/update-on-capitello-290-phase-iii-trial",
      "id": "39dd721f2852a61efe4eb87c46226c14a029541a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/update-on-imfinzi-adjuvant-br31-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/update-on-imfinzi-adjuvant-br31-trial",
      "id": "7933edefabbe30c2768edda8bc02d27180dd72bf"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-approved-in-the-eu-as-add-on-treatment-to-ravulizumab-or-eculizumab-for-adults-with-rare-disease-pnh-who-have-residual-haemolytic-anaemia.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/voydeya-approved-in-the-eu-as-add-on-treatment-to-ravulizumab-or-eculizumab-for-adults-with-rare-disease-pnh-who-have-residual-haemolytic-anaemia",
      "id": "165e531dfe3c194efccb066a99a8633f0513b715"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-approved-in-us.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/voydeya-approved-in-us",
      "id": "76feba674a06a2893befec5097b131dbb5787b30"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-danicopan-granted-first-ever-regulatory-approval-in-japan-for-adults-with-pnh-to-be-used-in-combination-with-c5-inhibitor-therapy.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/voydeya-danicopan-granted-first-ever-regulatory-approval-in-japan-for-adults-with-pnh-to-be-used-in-combination-with-c5-inhibitor-therapy",
      "id": "04a9f849393bef8f3b0902bba1b1d443732672b8"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/voydeya-recommended-for-eu-approval.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/voydeya-recommended-for-eu-approval",
      "id": "cad0cad83e682004d8add66583667f1840a5ad11"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/wainzua-recommended-for-approval-in-the-eu.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2024/wainzua-recommended-for-approval-in-the-eu",
      "id": "566cbb6642c70e8cc7e7326cc732700fcfaaf63d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/acquisition-of-esobiotec-completed.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/acquisition-of-esobiotec-completed",
      "id": "dad45158b690e98454f5a43385d488f64ffa5952"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/alexion-data-presented-at-ean-2025-highlights-its-leadership-and-commitment-to-improving-patient-outcomes-in-rare-neurological-diseases.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/alexion-data-presented-at-ean-2025-highlights-its-leadership-and-commitment-to-improving-patient-outcomes-in-rare-neurological-diseases",
      "id": "3e4c5e560348147885a2312903ad194a2ce282ac"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/alexion-data-presented-at-the-2025-aan-annual-meeting-highlight-advancements-in-improving-care-for-rare-neurological-diseases.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/alexion-data-presented-at-the-2025-aan-annual-meeting-highlight-advancements-in-improving-care-for-rare-neurological-diseases",
      "id": "21f1f099d497f89b71410479eafce811664d08c7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-enters-into-collaboration-with-cspc.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/astrazeneca-enters-into-collaboration-with-cspc",
      "id": "ef90e32a9d97c096376076db7c0451a604775b16"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-enters-license-agreement-with-alteogen-for-subcutaneous-formulations-of-multiple-oncology-assets.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/astrazeneca-enters-license-agreement-with-alteogen-for-subcutaneous-formulations-of-multiple-oncology-assets",
      "id": "c1b7ab915a8732127465e3d3143bf4c75180e78a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-invests-2-and-half-bn-in-beijing-r-and-d-and-manufacturing.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/astrazeneca-invests-2-and-half-bn-in-beijing-r-and-d-and-manufacturing",
      "id": "a739447eec4c48dee1a462e9f701d45ea1ad624c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-c820-million-us570m-investment-in-canada-to-advance-growing-global-hub-and-clinical-delivery.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/astrazeneca-plans-c820-million-us570m-investment-in-canada-to-advance-growing-global-hub-and-clinical-delivery",
      "id": "0626dfa4c59beb51d0ce352a83d7f850e51fa77d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-to-invest-50bn-dollars-in-the-us.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/astrazeneca-plans-to-invest-50bn-dollars-in-the-us",
      "id": "00722f232ca7f677c6a08e7f40c25912867e842e"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-showcases-innovation-in-infectious-disease-protection-at-escmid-global-2025.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/astrazeneca-showcases-innovation-in-infectious-disease-protection-at-escmid-global-2025",
      "id": "7666bace9ee69ba0d78055b7f49d3f4a1a5a1155"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-acquire-esobiotec.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/astrazeneca-to-acquire-esobiotec",
      "id": "3517945cc56187bd9ffe6f222c57ae2bc87239d3"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-showcase-latest-research-on-comprehensive-portfolio-and-pipeline-aimed-at-transforming-respiratory-diseases-at-ats-2025.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/astrazeneca-to-showcase-latest-research-on-comprehensive-portfolio-and-pipeline-aimed-at-transforming-respiratory-diseases-at-ats-2025",
      "id": "a18c7ee6b01f836abb39f7de0ed079762598c612"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/astrazenecas-record-seventh-year-of-plenary-data-at-asco-furthers-ambition-to-redefine-breast-cancer-care-and-transform-outcomes-in-gastric-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/astrazenecas-record-seventh-year-of-plenary-data-at-asco-furthers-ambition-to-redefine-breast-cancer-care-and-transform-outcomes-in-gastric-cancer",
      "id": "68e318d156bc7e26bd2ce9f524c36dfa29d52299"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/azd0780-a-novel-oral-pcsk9-inhibitor-demonstrated-significant-ldl-cholesterol-ldl-c-reduction-in-pursuit-phase-iib-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/azd0780-a-novel-oral-pcsk9-inhibitor-demonstrated-significant-ldl-cholesterol-ldl-c-reduction-in-pursuit-phase-iib-trial",
      "id": "4131e8c8dd143c9bef66d0e368e0419fc3474d77"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/baxdrostat-demonstrated-statistically-significant-clinically-meaningful-reduction-sbp-patients-hard-control-hypertension-baxhtn-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/baxdrostat-demonstrated-statistically-significant-clinically-meaningful-reduction-sbp-patients-hard-control-hypertension-baxhtn-phase-iii-trial",
      "id": "b7c687a699836a6a983f45888bd4cea13ad35d92"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/baxdrostat-met-primary-and-all-secondary-endpts-in-baxhtn-phiii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/baxdrostat-met-primary-and-all-secondary-endpts-in-baxhtn-phiii-trial",
      "id": "b5d465f2f4e463f3723507c740677094d1f4eed7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/breztri-met-primary-endpoints-in-ph3-asthma-trials.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/breztri-met-primary-endpoints-in-ph3-asthma-trials",
      "id": "4d11b8c70b9b527cfa8aeaa3b44d3503442aefe3"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/calquence-combination-approved-in-eu-for-1l-mcl.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/calquence-combination-approved-in-eu-for-1l-mcl",
      "id": "94c67c57c6a217bbb0b86baaeaeabac0cc30898e"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/calquence-combination-approved-in-us-for-1l-mcl.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/calquence-combination-approved-in-us-for-1l-mcl",
      "id": "0b6ee9126647b614f22381c4254f489a2f7a32de"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/calquence-recommended-for-eu-approval-in-1l-mcl.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/calquence-recommended-for-eu-approval-in-1l-mcl",
      "id": "ac87f06803a387d9e1032a6c36c8e2cdf3e34ef8"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/camizestrant-improved-pfs-in-1l-hr-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/camizestrant-improved-pfs-in-1l-hr-breast-cancer",
      "id": "6774af1d586977f4cfd09ee6925eaa752abbaa7d"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/camizestrant-reduced-the-risk-of-disease-progression-or-death-by-56-in-patients-with-advanced-hr-positive-breast-cancer-with-an-emergent-esr1-tumour-mutation-in-serena-6-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/camizestrant-reduced-the-risk-of-disease-progression-or-death-by-56-in-patients-with-advanced-hr-positive-breast-cancer-with-an-emergent-esr1-tumour-mutation-in-serena-6-phase-iii-trial",
      "id": "bf97d56c7e163c56db2579a55b4c6e7cab93ee6a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/dato-dxd-approved-in-us-for-hr-p-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/dato-dxd-approved-in-us-for-hr-p-breast-cancer",
      "id": "3427ea4b4d2126e4f5ca7e5593f55882c112bb86"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/datopotamab-deruxtecan-granted-priority-review-in-the-us-for-patients-with-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/datopotamab-deruxtecan-granted-priority-review-in-the-us-for-patients-with-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer",
      "id": "2a4e244827ce5b2feacca7dfaadfa15f66622683"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/datroway-approved-in-us-for-egfrm-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/datroway-approved-in-us-for-egfrm-lung-cancer",
      "id": "6b0e64d14b5f94fdae6b0ff67aaf377c1260e987"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/eneboparatide-phase-iii-trial-met-primary-endpoint.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/eneboparatide-phase-iii-trial-met-primary-endpoint",
      "id": "10c0f1ac33bb9f3dba2304d99b2a479f5c48b7b8"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-approved-in-eu-in-post-et-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/enhertu-approved-in-eu-in-post-et-breast-cancer",
      "id": "c231e3231d5abe31d0d9a994282656b4f845abb7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-approved-in-us-for-breast-cancer-post-et.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/enhertu-approved-in-us-for-breast-cancer-post-et",
      "id": "1e808dda78251b483f612950a5f1106ab92a2ed2"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-combination-improved-pfs-in-1l-her-positive-mbc.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/enhertu-combination-improved-pfs-in-1l-her-positive-mbc",
      "id": "69f63c7861e48dd17e3eb95887a621d11858a0b2"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-improved-pcr-in-early-stage-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/enhertu-improved-pcr-in-early-stage-breast-cancer",
      "id": "dc241c09eb4129b9e81ce9d8aeaf7579b3ba9d41"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-plus-pertuzumab-reduced-the-risk-of-disease-progression-or-death-vs-thp-as-1st-line-therapy-in-patients-with-her2-positive-metastatic-breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/enhertu-plus-pertuzumab-reduced-the-risk-of-disease-progression-or-death-vs-thp-as-1st-line-therapy-in-patients-with-her2-positive-metastatic-breast-cancer",
      "id": "5bbd5abf497c3ad10008aaad63e7431fcb3efdc4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/enhertu-recommended-approval-eu-chmp-patients-low-ultralow-metastatic-breast-cancer-following-least-one-endocrine-therapy.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/enhertu-recommended-approval-eu-chmp-patients-low-ultralow-metastatic-breast-cancer-following-least-one-endocrine-therapy",
      "id": "0b41a1de0bf3ef08df15fcc4f311b8ca67b621e0"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/fixed-duration-calquence-approved-in-eu-for-1l-cll.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/fixed-duration-calquence-approved-in-eu-for-1l-cll",
      "id": "a53bbfe5a84a0c4fad728ed8cb2c02421eb1a6e7"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/fixed-duration-calquence-recommended-in-eu-for-cll.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/fixed-duration-calquence-recommended-in-eu-for-cll",
      "id": "86a4a922c5d98388d738daa81a324e6dcf9fcb7e"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/full-year-and-q4-2024-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/full-year-and-q4-2024-results",
      "id": "4104100f41d59871db55d166aff3470c598af216"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/gefurulimab-nanobody-met-phase-iii-endpoints.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/gefurulimab-nanobody-met-phase-iii-endpoints",
      "id": "cdd414dd0225b17b07e8bae2379bb199edac6aab"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/h1-and-q2-2025.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/h1-and-q2-2025",
      "id": "b7c5798a2f60c7a8b52e31f6a5834536a268abbd"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-approved-in-eu-for-aegean.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/imfinzi-approved-in-eu-for-aegean",
      "id": "26a00894e11878411a2abcf5ad4f7e867a5aadf2"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-approved-in-eu-for-limited-stage-sclc.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/imfinzi-approved-in-eu-for-limited-stage-sclc",
      "id": "2eb9ec774851b4d867ffa2c583c49a803a08af62"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-approved-in-the-eu-for-bladder-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/imfinzi-approved-in-the-eu-for-bladder-cancer",
      "id": "ebe1a3a7eb5c01a24dd07a0a4535cd4b7e261a84"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-approved-in-the-us-for-bladder-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/imfinzi-approved-in-the-us-for-bladder-cancer",
      "id": "7123b3d5edc27fcf935bd70e4b08e1f8db6cdbcc"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-granted-priority-review-and-breakthrough-therapy-designation-us-patients-with-resectable-early-stage-gastric-gastroesophageal-junction-cancers.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/imfinzi-granted-priority-review-and-breakthrough-therapy-designation-us-patients-with-resectable-early-stage-gastric-gastroesophageal-junction-cancers",
      "id": "4802256134dafe80d7d47df8fd756473195407bd"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-improved-dfs-in-early-bladder-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/imfinzi-improved-dfs-in-early-bladder-cancer",
      "id": "e6b48abee150575adef10405189649a84835be1c"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-improved-efs-in-early-stage-gastric-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/imfinzi-improved-efs-in-early-stage-gastric-cancer",
      "id": "e635144a847f283cd9ae09492ce50d756222fe18"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-perioperative-regimen-improved-event-free-survival-and-overall-survival-of-niagara-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/imfinzi-perioperative-regimen-improved-event-free-survival-and-overall-survival-of-niagara-phase-iii-trial",
      "id": "9fc790394ccbe10a6f3089211e63586de49a3a0a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-recommended-for-eu-approval-for-aegean.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/imfinzi-recommended-for-eu-approval-for-aegean",
      "id": "53265787fa07bd5d860631ca1abc5f9e08c07b57"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-recommended-for-eu-approval-for-ls-sclc.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/imfinzi-recommended-for-eu-approval-for-ls-sclc",
      "id": "b0b44de085972e0f9e83bb26a7e33f0eeb3b841a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-recommended-in-eu-for-bladder-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/imfinzi-recommended-in-eu-for-bladder-cancer",
      "id": "07454819e55d13637d5540679c3ba96ca01f9d4a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/imfinzi-regimen-reduced-risk-of-progression-recurrence-or-death-by-29-in-early-stage-gastric-cancer-vs-chemotherapy-alone-in-matterhorn-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/imfinzi-regimen-reduced-risk-of-progression-recurrence-or-death-by-29-in-early-stage-gastric-cancer-vs-chemotherapy-alone-in-matterhorn-phase-iii-trial",
      "id": "6b5949cb20abde222007c2afa22882a705fd8095"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/new-study-results-reinforce-tagrisso-as-the-backbone-therapy-for-egfr-mutated-lung-cancer-across-stages-and-settings.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/new-study-results-reinforce-tagrisso-as-the-backbone-therapy-for-egfr-mutated-lung-cancer-across-stages-and-settings",
      "id": "d653f6ead4b6168dddf9ec8a488c556cd168313f"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/positive-results-from-the-tezspire-phase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/positive-results-from-the-tezspire-phase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps",
      "id": "584e9e53785129038b89d608f7e952889d533068"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/q1-2025-results.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/q1-2025-results",
      "id": "f7db0a05954b820f672633627af0dd1a7e9fa6e6"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/saphnelo-met-primary-endpoint-in-tulip-sc.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/saphnelo-met-primary-endpoint-in-tulip-sc",
      "id": "63718cf1c020e9f52a6bb51d21f5c4e7e2591991"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/statistically-significant-clinically-meaningful-batura-phase-iii-trial-provide-evidence-airsupra-standard-care-as-needed-rescue-treatment-asthma.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/statistically-significant-clinically-meaningful-batura-phase-iii-trial-provide-evidence-airsupra-standard-care-as-needed-rescue-treatment-asthma",
      "id": "e4a1d258396315ea1d42cd6cc3fca05c4eadf1a5"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/tagrisso-plus-chemotherapy-demonstrated-a-median-overall-survival-of-nearly-four-years.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/tagrisso-plus-chemotherapy-demonstrated-a-median-overall-survival-of-nearly-four-years",
      "id": "ed36d1d50070101bd8d201fcff4658a4dce6d5d4"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/tagrisso-plus-chemotherapy-demonstrated-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-in-egfr-mutated-advanced-lung-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/tagrisso-plus-chemotherapy-demonstrated-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-in-egfr-mutated-advanced-lung-cancer",
      "id": "f62bd999b7b3bf2dbb91960939c333a1af265e28"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/trixeo-aerosphere-approved-in-the-uk-as-first-inhaled-respiratory-medicine-using-next-generation-propellant-with-near-zero-global-warming-potential.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/trixeo-aerosphere-approved-in-the-uk-as-first-inhaled-respiratory-medicine-using-next-generation-propellant-with-near-zero-global-warming-potential",
      "id": "8a38f4c8dc564b57a42c68d340449490bbd9596a"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/trixeo-aerosphere-receives-positive-eu-chmp-opinion-first-inhaled-medicine-using-next-generation-propellant-with-near-zero-global-warming-potential.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/trixeo-aerosphere-receives-positive-eu-chmp-opinion-first-inhaled-medicine-using-next-generation-propellant-with-near-zero-global-warming-potential",
      "id": "9447c7bc7a8c6fe5b6eac5bdc083d01438ff36e9"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/update-on-anselamimab-in-al-amyloidosis.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/update-on-anselamimab-in-al-amyloidosis",
      "id": "b660f7c5cd19a946525d5085c3f32bfd32fff5bc"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/update-on-capitello-280-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/update-on-capitello-280-phase-iii-trial",
      "id": "8922a70d9ef4f2d886c33b84eb332d311787e649"
    },
    {
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/update-on-resolute-phase-iii-trial.html",
      "source": "SITEMAPS",
      "targetPath": "/media-centre/press-releases/2025/update-on-resolute-phase-iii-trial",
      "id": "daf7262c44d484e23720d2fc28d78d68d5c0c9f0"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas",
      "id": "4b0869c5841c1eb4caf38510ae9beb2c1dcb220e"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/biopharmaceuticals.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/biopharmaceuticals",
      "id": "6b36adc4f20c2cdd0a5ce6a82de01a0b6b32a5b0"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/cardiovascular-renal-and-metabolism",
      "id": "23b21fafd78abec009abb524b851e21b01d1c11e"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism/cardiovascular-disease.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/cardiovascular-renal-and-metabolism/cardiovascular-disease",
      "id": "efc8da7750db7d0f208eab1e8c8e8d67926db80a"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism/heart-failure.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/cardiovascular-renal-and-metabolism/heart-failure",
      "id": "f68fbd436d0fc03c3950172608e344ee19ebb5ad"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism/metabolism.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/cardiovascular-renal-and-metabolism/metabolism",
      "id": "718cc55479afe9175958ad751f61a90727242bdd"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism/renal.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/cardiovascular-renal-and-metabolism/renal",
      "id": "cbe19d9f28a3913724122f3f2be63d099afdb04e"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/eosinophilic-inflammation.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/eosinophilic-inflammation",
      "id": "81de9d53dfb63b55f831694d0df2f3d88e2ed8d9"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/medicines.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/medicines",
      "id": "eba7ec1a12db4a61eb1ef2d76ae8d8857be9961e"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/oncology.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/oncology",
      "id": "1d6e28da4ac556c8af9dc7e400b85f197e7eaec9"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/oncology/at-the-forefront-of-lung-cancer-treatment.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/oncology/at-the-forefront-of-lung-cancer-treatment",
      "id": "1ad6c835cf4976afff5220f05bb1237f361324b8"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/oncology/breast-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/oncology/breast-cancer",
      "id": "4b29b959ba991c5c0b8f5097e56003e98b14a7f6"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/oncology/clinical-strategy.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/oncology/clinical-strategy",
      "id": "dbdf2685f5819326c86c8932547981eb98e565de"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/oncology/dna-damage-response.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/oncology/dna-damage-response",
      "id": "80cb5def3649cfd2d279f533e23af38af74ce105"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/oncology/haematology.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/oncology/haematology",
      "id": "9c6f967fcc249351fe57cf1aa5f605274043af4b"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/oncology/immuno-oncology.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/oncology/immuno-oncology",
      "id": "73b53f14d97d62ff3c8f29484755012c79a09083"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/oncology/leading-the-revolution-in-pancreatic-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/oncology/leading-the-revolution-in-pancreatic-cancer",
      "id": "6fd877f8f3e8ecde9c174362d79901bd328eb186"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/oncology/Liver-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/oncology/liver-cancer",
      "id": "f5d200178da7956b902723b27b676a5039c0ca72"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/oncology/medicines-portfolio-and-pipeline.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/oncology/medicines-portfolio-and-pipeline",
      "id": "f41e653cc122e6fcf2f827597f92677505c2945d"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/oncology/our-people-and-culture.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/oncology/our-people-and-culture",
      "id": "4b5952cc0a9e5f567d7298f920745767bfea8303"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/oncology/ovarian-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/oncology/ovarian-cancer",
      "id": "f9f4f84e8d794aae29bbef84cd7d2b063b886f13"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/oncology/patient-experience.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/oncology/patient-experience",
      "id": "6a560f8fac0709137753ea188308a840bd4d1394"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/oncology/prostate-cancer.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/oncology/prostate-cancer",
      "id": "2f8724153f342caeed21ef6311a4d8de714c236b"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/pipeline.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/pipeline",
      "id": "d28e079c71e83acd1bd205885d98ee40e8425379"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/rare-disease.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/rare-disease",
      "id": "faa62a469867993ad01d1e0a6bf390d1adc46379"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/respiratory-and-immunology.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/respiratory-and-immunology",
      "id": "7d1ac9e08ad208cb37bf7b0434dc250b5699bcfe"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/respiratory-and-immunology/epithelial-science.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/respiratory-and-immunology/epithelial-science",
      "id": "f18fe6c650973a5bdad20b4c3ea37069b63f6540"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/respiratory-and-immunology/lupus.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/respiratory-and-immunology/lupus",
      "id": "3a1713849c089cbbd660c1cb3d6285277d591344"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/vaccines-and-immune-therapies.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/vaccines-and-immune-therapies",
      "id": "744e73954e6676bf445dbe843e3bbfd5325d73ba"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/vaccines-and-immune-therapies/covid-19.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/vaccines-and-immune-therapies/covid-19",
      "id": "6c7c5210a03d1cdf8563234c35b981873bd606c2"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/vaccines-and-immune-therapies/hMPV.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/vaccines-and-immune-therapies/hmpv",
      "id": "aeb1b3286cf90b19bb841aec7a2114fdb034b3ef"
    },
    {
      "url": "https://www.astrazeneca.com/our-therapy-areas/vaccines-and-immune-therapies/respiratory-syncytial-virus.html",
      "source": "SITEMAPS",
      "targetPath": "/our-therapy-areas/vaccines-and-immune-therapies/respiratory-syncytial-virus",
      "id": "e226f875441c5c8be8520434a8f489b42ead05a1"
    },
    {
      "url": "https://www.astrazeneca.com/patient-reported-outcomes.html",
      "source": "SITEMAPS",
      "targetPath": "/patient-reported-outcomes",
      "id": "a70b827d4d441c82326210d1762cc0c716a781a0"
    },
    {
      "url": "https://www.astrazeneca.com/patient-reported-outcomes/cardiovascular.html",
      "source": "SITEMAPS",
      "targetPath": "/patient-reported-outcomes/cardiovascular",
      "id": "676941109a4b9360300e6d9b9515fc14b5d2462e"
    },
    {
      "url": "https://www.astrazeneca.com/patient-reported-outcomes/confirmation.html",
      "source": "SITEMAPS",
      "targetPath": "/patient-reported-outcomes/confirmation",
      "id": "867ef09ee11577de53aac0974a13f428f9636389"
    },
    {
      "url": "https://www.astrazeneca.com/patient-reported-outcomes/contact-us.html",
      "source": "SITEMAPS",
      "targetPath": "/patient-reported-outcomes/contact-us",
      "id": "c5064e5233f959e42bc64664ce312a118703095e"
    },
    {
      "url": "https://www.astrazeneca.com/patient-reported-outcomes/faqs.html",
      "source": "SITEMAPS",
      "targetPath": "/patient-reported-outcomes/faqs",
      "id": "31b48564b6b4eabf24f3284bcccc4218589c82cc"
    },
    {
      "url": "https://www.astrazeneca.com/patient-reported-outcomes/gastrointestinal.html",
      "source": "SITEMAPS",
      "targetPath": "/patient-reported-outcomes/gastrointestinal",
      "id": "168e3f3ee8646c554615b1184ef3689c2649061f"
    },
    {
      "url": "https://www.astrazeneca.com/patient-reported-outcomes/order-instrument.html",
      "source": "SITEMAPS",
      "targetPath": "/patient-reported-outcomes/order-instrument",
      "id": "714e8f0821ff8d9f6146f17834a0b271dbab62ea"
    },
    {
      "url": "https://www.astrazeneca.com/patient-reported-outcomes/respiratory.html",
      "source": "SITEMAPS",
      "targetPath": "/patient-reported-outcomes/respiratory",
      "id": "7be3f2117644743288dbc0ca4c33c3500103d58b"
    },
    {
      "url": "https://www.astrazeneca.com/publication.html",
      "source": "SITEMAPS",
      "targetPath": "/publication",
      "id": "837d98cf3d61dd82d352e2e5d932cfe3d626a21d"
    },
    {
      "url": "https://www.astrazeneca.com/r-d.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d",
      "id": "f13600bb5d4f7293dba39955ce6e1dd093f0d176"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/clinical-innovation.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/clinical-innovation",
      "id": "0f2bac583c11adbec8ecfebd76ee3a89f8391d01"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/data-science-and-ai.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/data-science-and-ai",
      "id": "661a70cb2fc16cfa857b262a2c1323820ff39ba4"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/digital-health-revolutionising-healthcare-for-patients.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/digital-health-revolutionising-healthcare-for-patients",
      "id": "bd91f519a266ab2c46d109fcc9c12fd542168de4"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/glossary.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/glossary",
      "id": "53a7468a012b819cb34ec621e3d6b0b8f6e05ae1"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/next-generation-therapeutics.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/next-generation-therapeutics",
      "id": "ec3046760900535f65102002632a5f47eede644f"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/next-generation-therapeutics/antibody-drug-conjugate.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/next-generation-therapeutics/antibody-drug-conjugate",
      "id": "8ab08aea896774b800b109fada0a8d8060c067f8"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/next-generation-therapeutics/anticalin-proteins.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/next-generation-therapeutics/anticalin-proteins",
      "id": "66bfcd779ba647a08249323015082fceeb738c88"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/next-generation-therapeutics/bicyclic-peptides.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/next-generation-therapeutics/bicyclic-peptides",
      "id": "de58e29b1c5bf9ec1907434cf133d3bd62fbeff2"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/next-generation-therapeutics/bispecific-antibody.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/next-generation-therapeutics/bispecific-antibody",
      "id": "469b40f0775dfe347431942aea6be52e3ffa0aa0"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/next-generation-therapeutics/cell-therapies.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/next-generation-therapeutics/cell-therapies",
      "id": "0b6a3ae410b760595dea04668cb5f8e71c692384"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/next-generation-therapeutics/fragment-antibody.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/next-generation-therapeutics/fragment-antibody",
      "id": "5805f00a7a149791ee80f4ca56cc81f21360b05c"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/next-generation-therapeutics/gene-therapy.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/next-generation-therapeutics/gene-therapy",
      "id": "0063a456dcbf4af1e293a0a579bb018d16290cfd"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/next-generation-therapeutics/in-vivo-expressed-biologics.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/next-generation-therapeutics/in-vivo-expressed-biologics",
      "id": "ee4346aa608bf4273546895f56e5868a7884e5f8"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/next-generation-therapeutics/monoclonal-antibodies.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/next-generation-therapeutics/monoclonal-antibodies",
      "id": "8fa3c9bdb4557d2ac7aaf9a15371bf42af9aefd7"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/next-generation-therapeutics/multispecifics.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/next-generation-therapeutics/multispecifics",
      "id": "6828ba42ba177dc1c1fb1cd9b89cd1dc892258bf"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/next-generation-therapeutics/nucleotide-based-therapeutics.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/next-generation-therapeutics/nucleotide-based-therapeutics",
      "id": "21b36cc5dc5e3a8bc5d6575a12e4eac9ebbe3cb3"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/next-generation-therapeutics/protacs.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/next-generation-therapeutics/protacs",
      "id": "fa4ee3a17931a9a663f1bac4c1d1de981ed6832d"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/next-generation-therapeutics/radioconjugates.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/next-generation-therapeutics/radioconjugates",
      "id": "4fffd55cd7d02c7739cc520117af2fcf41ce0e94"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/next-generation-therapeutics/small-molecule.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/next-generation-therapeutics/small-molecule",
      "id": "64190af049ebf2a5abc589c0f591911c8c5877b1"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/next-generation-therapeutics/sodium-zirconium-cyclosilicate.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/next-generation-therapeutics/sodium-zirconium-cyclosilicate",
      "id": "0d85af9ef74a5e19145d2eef8b72e4f1f4cdd1ba"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/next-generation-therapeutics/T-cell-engager.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/next-generation-therapeutics/t-cell-engager",
      "id": "54110a609eef621083b78be4f5a00cf7e518cfa5"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/next-generation-therapeutics/therapeutic-proteins.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/next-generation-therapeutics/therapeutic-proteins",
      "id": "2a4d51dee4031193a942287c68b41739e40eed6f"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/our-approach.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/our-approach",
      "id": "e8ee8b4820d486dae4dcea6f0587b3a1874f95bb"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/our-approach/stem-at-astrazeneca.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/our-approach/stem-at-astrazeneca",
      "id": "14690ceea5f2ce83147e54fd11ab53c28d506c65"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/our-strategic-r-d-centres.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/our-strategic-r-d-centres",
      "id": "60b1bfa1d05bd626934fa75d0c0deb2f3f70a4cd"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/our-technologies.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/our-technologies",
      "id": "e7845bef8eb895fc9590a19b4a53efd1bb0023fd"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/our-technologies/acoustic-tube-sample-management.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/our-technologies/acoustic-tube-sample-management",
      "id": "84d440feb3393987414eabb8d7f59bccad0a9c88"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/our-technologies/advanced-molecular-imaging.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/our-technologies/advanced-molecular-imaging",
      "id": "5278082bd9bd9e7f5a4ee3c4881b1e54f8815e79"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/our-technologies/cryo-em.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/our-technologies/cryo-em",
      "id": "3ab672f1401bee40f0d6b20c70dfbd7935168b6c"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/our-technologies/functional-genomics.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/our-technologies/functional-genomics",
      "id": "3dbd04c34305f96c3d6b6916b7c51d3570e72fec"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/our-technologies/genomics.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/our-technologies/genomics",
      "id": "acfaf77af74fd6f1ea802eb4237b22c537cfddcb"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/our-technologies/ilab.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/our-technologies/ilab",
      "id": "5f5132c8c22fb01cd0caaf57e64d312537d2c827"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/our-technologies/machine-learning-drug-discovery.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/our-technologies/machine-learning-drug-discovery",
      "id": "bc08861fa85a1bd51f6cb5f94debc7b51013577d"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/our-technologies/multi-omics.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/our-technologies/multi-omics",
      "id": "d0d1f9fccff6eb2d7eb974a76464764425385111"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/precision-medicine.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/precision-medicine",
      "id": "e705d71a7405a11282ddd5d21f85f0b4fc3aaa0e"
    },
    {
      "url": "https://www.astrazeneca.com/r-d/transformative-science.html",
      "source": "SITEMAPS",
      "targetPath": "/r-d/transformative-science",
      "id": "24a390fae35d9ba61784c8880696f493e00d2fd0"
    }
  ],
  "crawlOptions": {
    "timeout": 64800000,
    "inclusionPatterns": [],
    "exclusionPatterns": [],
    "limit": 1000,
    "sameDomain": true,
    "keepHash": false,
    "strategy": "sitemaps",
    "logger": {},
    "strategiesAttempted": [
      "SITEMAPS"
    ]
  },
  "extractionErrors": [
    {
      "url": "https://www.astrazeneca.com/az-suppliers.html",
      "status": "301 Moved Permanently Redirect: https://www.astrazeneca.com/partnering/az-suppliers.html"
    },
    {
      "url": "https://www.astrazeneca.com/sitemap.xml",
      "status": "parseSitemapFromUrl (https://www.astrazeneca.com/sitemap.xml): Error: Status: 400"
    }
  ],
  "errorCountMessage": "{\"E_301\":1,\"others\":1}",
  "error": null
}